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ABSTRACT 
Bacterial infection is a major cause of morbidity and mortality in sub-Saharan 
Africa especially among young children. Despite the high burden of disease 
caused by bacterial infection in Africa, there remains a significant paucity of 
data on the molecular epidemiology of most pathogens in the sub-region. 
Healthcare facilities are generally underfunded in West Africa and most 
facilities lack the basic capacity to perform standard microbiological 
identification of bacterial pathogens.  
Understanding the biology and epidemiology of pathogens is fundamental to 
a successful intervention strategy. Genomics offers unprecedented insights 
into the epidemiology and biology of infectious diseases, which dominate the 
public health agenda in West Africa. Here, I introduce a case study of three 
important pathogens in West Africa. I describe a unique scenario associated 
with each pathogen and present WGS as a solution to the problem.  
Firstly, whole genome sequencing has provided insights into the evolutionary 
origin of Staphylococcus aureus in monkeys from The Gambia and 
established that monkeys in The Gambia do not pose a threat of serving as 
reservoirs of highly virulent S. aureus that can infect humans. Secondly, 
genomics has unravelled the evolutionary mechanisms that led to the 
emergence of a novel clone of serotype 1 Streptococcus pneumoniae, which 
caused an outbreak of meningitis in Ghana following the introduction of the 
13-valent pneumococcal vaccine, PCV-13. Thirdly, through genomics we are 
beginning to build a deeper understanding of the epidemiology of 
Mycobacterium tuberculosis complex in West Africa. Genomics is unravelling 
the evolutionary mechanisms that are driving the emergence of multidrug 
resistant tuberculosis. Importantly, genomics has shown that lineages of 
MTBC that are endemic to West Africa are the principal proponents of 
multidrug resistance in this sub-region. 
The time has come for West Africa to embrace the genomics era and exploit 
the full potential of microbial genomics. I hope that my work will inspire West 
African scientists to embrace whole genome sequencing in the fight against 
infectious bacterial diseases.  
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1 CHAPTER ONE: INTRODUCTION 
1.1 Bacterial Infection 
1.1.1 The nature and discovery of bacteria 
The discovery of bacteria by Antonie van Leeuwenhoek is one of the most 
important discoveries in the field of microbiology. Armed with a simple 
microscope, Leeuwenhoek observed microscopic living organisms in 
specimens of water 1. In his 1667 letter to the Royal Society, Leeuwenhoek 
describes these microorganisms as "animalcules" 2.  
Bacteria are unicellular microorganisms that are characterized by the 
absence of a nucleus and membrane-bound cell organelles 3. Bacteria form a 
diverse group of organisms that are highly adaptable and occupy niches in all 
environments. Most bacteria can be considered harmless to humans or 
beneficial components of the human microbiome 4. 
In 1850, Ignaz Semmelweis delivered a lecture to the Vienna Medical Society 
detailing a link between puerperal fever (also known as childbed fever) and 
the re-absorption of noxious agents in decaying animal-organic matter 5. 
Semmelweis' observation that medical interns who performed autopsies were 
transmitting the disease to patients in the maternity ward contradicted the 
accepted scientific opinions of his time. Nonetheless, his observation led him 
to impose chlorine hand washing on medical personnel, which led to a 
decrease in puerperal fever mortality 6. 
The experiments of Louis Pasteur and Robert Koch were instrumental in 
establishing the proof that microorganisms can cause disease in healthy 
hosts. This proof led to the widespread acceptance of the germ theory that 
infectious diseases are caused by transmission of an infective organism from 
one host to another 7. Koch formulated what are now known as Koch's 
postulates, which were fundamental to the germ theory and establishing the 
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causative relationship between germs and diseases 7. Koch’s postulates 
state that in order to define a microorganism as the causal agent of infection 
it must: 
1. Be present in all diseased hosts but not be present in healthy hosts 
2. Be isolated from the diseased host and grown in a pure culture 
3. Be able to cause disease when the cultured microorganism is 
introduced into a healthy host 
4. Be re-isolated from the diseased experimental host and be identified 
as identical to the original specific causal agent 
It is important to note that Koch’s postulates are limited when it comes to 
defining a causal relation between disease and opportunistic bacteria, 
uncultivable bacteria or bacteria that elicit toxin-dependent pathogenesis 8. 
Bacterial infection involves a complex host-pathogen interaction, whose 
outcome is not solely dependent on the microbe. A number of factors 
contribute to disease outcome including but not restricted to 9: 
x A conducive environment for microbial replication 
x The microbe’s ability to cause disease 
x The immune status of the host 
x The ability of the microbe to penetrate the host's protective barriers 
and evade its innate defence mechanisms 
1.1.2  The global burden of bacterial infection 
Despite advances in sanitation, hygiene, medicine, healthcare and 
biotechnology, infectious diseases continue to be a major public health 
burden in all regions of the world 10. In 2012, the WHO ranked lower 
respiratory tract infections and diarrhoeal disease as the fourth and seventh 
most common causes of death globally respectively 11. Although the 2015 
global disease burden estimate reported a decline in the mortality due to 
communicable disease, diarrhoeal disease, lower respiratory tract infections 
and other infectious diseases continue to be a major cause of mortality 12. 
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Diarrhoea and pneumonia are the leading causes of death due to infection 
among children 13. The vast majority of these deaths occur in the first two 
years of life 13. Africa and South-East Asia bear the highest burden of severe 
pneumonia and severe diarrhoea globally 13. The Global Enteric Multisite 
Study reported that four species caused the majority of diarrhoeal infection in 
Africa and South-East Asia: Escherichia coli, Shigella, Cryptosporidium and 
rotavirus 14. Prior to the introduction of pneumococcal conjugate vaccines the 
bacterial species Streptococcus pneumoniae and Haemophilus influenzae 
were the leading causes of pneumonia, but the influenza virus and 
respiratory syncytial virus were also important causes of pulmonary disease 
11. 
The global burden of bacterial meningitis has remained relatively steady over 
the past decade 12 despite vaccine interventions in the African meningitis belt 
15. Healthcare-associated infections are a major public health concern 
globally and the highest burden exists in developing countries 16. It is 
worrying that healthcare-associated multidrug-resistant bacteria continue to 
emerge in different regions and spread across the globe 17.  
The WHO declared tuberculosis a global emergency in 1993 18. Mortality due 
to tuberculosis has been halved since 1990, but it remains one of the leading 
causes of death globally 19.Tuberculosis is the leading cause of death due to 
infection globally after HIV, despite the availability of effective treatment for 
both 12. HIV-infected individuals are at risk of developing bacterial sepsis, 
particularly from S. pneumoniae and non-typhoidal Salmonella 20.  
1.1.2.1 Infection is a disease of poverty 
In low-income countries, infectious diseases remain the most common cause 
of death: twenty species — principally viruses and bacteria — caused two-
thirds of the deaths from infectious diseases in low-income countries in 2010 
10. According to the 2010 global disease-burden study, lower-respiratory-tract 
infection was the leading cause of death in low- to middle-income countries 
11. The symbiotic relationship between poverty and infection breeds a vicious 
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cycle; the WHO estimates that infection forces 100 million people below the 
poverty line annually 21.  
Under-nutrition is a direct consequence of poverty 22. Children suffering from 
protein-calorie malnutrition are more susceptible to infection because they 
have a weakened innate immune response 23. Worryingly, the causal links 
run in both directions: malnutrition is a risk factor for diarrhoea and lower 
respiratory tract infection, but these infections also perpetuate malnutrition 
through decreased nutrient intake and energy loss 23,24. In adults, under-
nutrition leads to a weakened immune system, which increases the risk of 
progression from latent tuberculosis to active disease 25. 
Poor housing and suboptimal hygiene conditions have a negative impact on 
health. Poor housing leads to overcrowding and inadequate ventilation, 
which increases the risk of airborne disease such as tuberculosis 23. Lack of 
a clean water supply and poor sanitation are known risk factors for diarrhoea 
26. People living in the poorest regions of the world have limited access to 
healthcare. Those who are fortunate to make it hospital often cannot afford to 
pay for treatment and suffer from lost income 27. 
Infectious diseases disproportionately infect the most impoverished regions 
of the world, particularly sub-Saharan Africa 28,29. In the last decade mortality 
due to some neglected tropical diseases has risen: examples include Chagas 
disease, leishmaniasis, dengue and Ebola virus infection (mainly through the 
West African Ebola outbreak) 12. These infections (excluding Ebola) are 
largely treatable with existing drugs, but delivery is not always forthcoming 28. 
Intervention policies need to tackle the socio-economic causes and impacts 
of infectious diseases. 
1.1.3 Sources of bacterial infections 
The mechanisms for transmission of bacterial infection are well understood. 
Infectious disease are transmitted between individuals mainly though 
inoculation (coming into contact with the body fluids of an infected individual), 
airborne or waterborne transmission 30. Non-human vectors also play an 
important role in the life cycle and transmission of some pathogenic bacteria 
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31. Effective strategies exist for managing the spread of infectious diseases. 
These include clinical interventions such as vaccination and antibiotic 
therapy, as well as general measures like sanitation, chemical disinfection, 
hand washing and vector control 30. Despite these advances outbreaks of 
bacterial pathogens occur recurrently in the community and within healthcare 
facilities. 
Outbreaks of infectious disease are marked by a sudden increase in the 
incidence of a certain disease in a given locality. As little as two 
epidemiologically linked cases of a rare infectious disease may be 
considered as an outbreak 32. During an outbreak, individuals may have 
acquired the infection from a common source (e.g. a contaminated water 
source) or the outbreak may be propagated by inter-person transmission. 
When outbreaks spread to a large proportion of the population, they are 
referred to as epidemics. For example, the epidemic threshold for meningitis 
outbreaks is when more than 15 cases of meningitis per hundred thousand 
population are recorded averaged over two weeks 33. 
1.1.4 Zoonosis and emerging disease 
Zoonotic infections are infections that humans acquire from animals. 
Emerging infectious diseases can be described as the onset of a novel 
infection within a population or a rapid increase in the prevalence and/or 
geographical range of an existing infection 34. Emerging infectious diseases 
represent a major threat to public health globally 8. Unlike viruses that 
emerge mainly through rapid evolution, emerging bacterial infections are 
rarely due to novel pathogenic species/strains 8.  
The rise of virulent and antibiotic-resistant forms of known human-adapted 
bacterial pathogens may be considered as a source of emerging infectious 
diseases. Two of the best-known examples are methicillin-resistant 
Staphylococcus aureus (MRSA) and multidrug-resistant tuberculosis (MDR-
TB). Rapid dissemination of these strains within the community and among 
hospitalised patients justifies their consideration as emerging infectious 
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disease 8. Other notable examples are the vancomycin-resistant 
Enterococcus and extended-beta-lactamase-producing E. coli 8. 
Zoonoses are an important cause of emerging infections (Table 1.1) 8,34, with 
zoonotic transmission of bacterial infections to humans via routes including 
35: 
x Direct contact with infected animal material e.g. body fluids or faeces 
x Being bitten or scratched by an infected animal 
x Transmission through an arthropod vector 
x Eating contaminated animal products 
Table 1.1 Important zoonotic bacterial pathogens that are causes of emerging 
infection in humans. The list was adapted from 8 citing 36-43. 
Species Animal host Disease in humans 
Campylobacter spp Poultry and cattle Diarrhoea  
Streptococcus bovis Sheep, cattle and ruminants Endocarditis and colorectal cancer  
Capnocytophaga canimorsus Dogs and cats Sepsis, septic shock and meningitis  
Escherichia coli 0157:H7 Cattle and ruminants mainly Haemorrhagic colitis  
Neoehrlichia mikurensis Ticks and rats Neoehrlichiosis : Systemic inflammatory 
response; Vascular and thromboembolic 
events  
Anaplasma phagocytophilum Wild and domesticated mammals 
and in ticks 
Tick borne fever  
Spotted fever group 
Rickettsia spp. 
Ticks Spotted fever rickettsiosis  
Borrelia burgdorferi White-footed mouse and ticks Lyme disease  
 
Improved diagnostic techniques, both culture- and sequence-based, have 
been instrumental in the discovery of emerging bacterial infectious diseases 
44. To highlight a few examples: 
x Prolongation of culture duration led to the discovery of mycobacteria in 
blood 8 
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x Performing culture on media inoculated with antibiotics made it 
possible to grow Campylobacter and Helicobacter species 45,46 
x Culture with non-mammalian cell lines is a promising approach for 
culturing otherwise uncultivable bacteria 8 
x PCR is a useful tool for detecting emerging infections from sterile sites 
x 16S RNA sequencing has been useful in taxonomic classification of 
emerging infections 
1.1.4.1 Ecological factors 
The steady growth in human population and the consequent increase in 
population density aid the spread of bacterial infections among humans. 
Travelling has become easier over the years and international trade and 
tourism mean more and more people are travelling around the globe, which 
further aids the dissemination of infectious agents. Expanding communities 
continue to encroach deeper into natural habitats increasing the potential for 
zoonotic transmission of emerging infections. In North America, the re-
emergence of Lyme disease has been associated with deforestation and loss 
of habitat of its animal host 43. 
The deadliest emerging infection of our time is HIV/AIDS, with consequent 
bacterial infection as an emergent threat among HIV positive individuals 47. 
Ironically, advances in medicine have contributed to the emergence of new 
bacterial infections in vulnerable patients. When immunosuppression is 
employed due to organ transplants or autoimmune disease it renders 
patients vulnerable to infection. Patients being treated for chronic infections 
such as cancer, diabetes and renal insufficiencies are also prone to impaired 
immune systems and are vulnerable to infection. Urinary catheters have 
contributed to the emergence of bacterial urinary tract infections like 
Actinobaculum schaalii and Alloscardovia omnicolens 48. 
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1.2 Management of bacterial infection 
1.2.1 Prevention of bacterial infection: vaccination 
Vaccination is an important output from microbiology that embraces 
synergies between molecular biology, immunology, public health and 
biotechnology 49. The aim of vaccination is to induce long-term protection by 
priming the human immune system with a component of a pathogen 50. The 
general principle is that introduction of the vaccine leads to the production of 
an immune response against the antigenic component of the vaccine, which 
is protective when the body encounters the pathogenic microorganism. 
Classical vaccines are mostly comprised of attenuated organisms, 
inactivated whole-cell preparations or purified cellular components. 
The discovery of the smallpox vaccine by the physician Edward Jenner in the 
18th century paved the way for the eradication of smallpox 51. In the 19th 
century Pasteur discovered that the causative agent of chicken cholera 
Pasteurella multocida could be attenuated into less virulent forms 50. 
Although the true rationale behind attenuation would not become apparent 
until the latter part of the century, it formed the basis for Pasteur’s work on 
rabies and anthrax vaccines 50. The start of the 20th Century was marked by 
the discovery of the attenuated Mycobacterium bovis Bacille Calmette-Guérin 
vaccine, which is still the only licensed vaccine for tuberculosis 52. During this 
period, inactivated whole-cell vaccines were also produced against typhoid, 
cholera and the plague 50. 
Some bacteria secrete toxins that serve as important virulence factors 53. The 
discovery that sub-lethal doses of inactivated bacterial toxins (toxoids) could 
induce production of antitoxins in human serum, and thus confer protection, 
led to the development of the tetanus, pertussis and diphtheria vaccines 50. 
More recently, vaccines against Haemophilus influenzae type B, Neisseria 
meningitidis and Streptococcus pneumoniae have been developed by 
conjugating their capsular polysaccharide to protein molecules such as the 
diphtheria toxoid 54-56. 
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1.2.2 Diagnosis of bacterial infection 
Identifying the aetiological agent of infection facilitates the appropriate 
delivery of antibiotic therapy, which increases the chances of treatment 
success 57. Phenotypic methods for species identification, including 
microscopy, culture and biochemical assays, are still widely used as 
diagnostic tools. Classical taxonomy defined bacterial species as clusters of 
organisms sharing phenotypic traits (e.g. cell morphology, growth conditions 
and metabolic characteristics). This approach relies on being able to grow 
the bacteria in the lab, usually a pure culture, and therefore precludes the 
classification of uncultivable bacteria 58. Technological advances have made 
DNA-based molecular techniques for pathogen detection more accessible 
and affordable 57,59. 
1.2.2.1 Molecular diagnostic approaches 
Over time, species classification based on phenotypic traits was 
complemented with molecular indicators such as GC content and whole-
genome DNA-DNA hybridisation, where a cut-off of 70% DNA-DNA 
relatedness was recommended for classifying organisms into the same 
species (60 cited in 61). 
DNA-DNA hybridisation has now been replaced in most labs by the less 
arduous 16S ribosomal RNA sequencing, leading to an updated species 
definition which requires ≥97% sequence identity in the 16S rRNA gene 62. 
16S rRNA sequencing is a suitable marker for phylogenetic analysis and was 
instrumental in distinguishing Archaea as an independent domain of life 63. 
However, despite its usefulness, 16S rRNA fails to discriminate between 
some closely related species 63, even at a more stringent cut-off of 99% 
sequence similarity (e.g. species within the genus Acinetobacter) 61. 
PCR amplification of single gene loci is now the most widely used molecular 
technique for pathogen detection in research and diagnostics laboratories 57. 
The advantages of PCR-based detection include avoiding the onerous need 
for culture and the ability to detect specific pathogens at low concentrations 
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and even from non-viable cells 64,65. In addition, multiplex PCR assays can 
detect multiple pathogens in a single reaction 66,67. However, the chief 
disadvantage of PCR-based detection is that only known or expected 
species can be targeted. 
1.2.2.2 Rise of genomics and metagenomics 
Whole-genome sequencing (WGS) offers an opportunity to study the entire 
DNA of an organism. This has immense value beyond simply identifying the 
species—in addition, genomic data can be used for phylogenetic analysis 
and genotypic characterisation of strains 68.  
In the genome era, pairwise genomic comparisons have provided new 
insights into bacterial diversity, prompting a review of the boundaries of 
taxonomic classifications 69. In particular, measuring average nucleotide 
identity through pairwise comparison of shared sequences in the genome 
offers improved resolution at the species and sub-species level 70. An 
average nucleotide identity of 95% or more corresponds to 70% or more 
DNA-DNA re-association and strains with >94% average nucleotide identity 
show consistent phenotypes in the context of species designation 69. A 
similar metric based on amino acid identity is a useful measure for comparing 
distantly related genomes 70. 
Culture-free techniques like unbiased metagenomic sequencing are opening 
new frontiers in clinical microbiology 71, offering potential for detecting and 
characterising bacterial pathogens directly from clinical samples 72-74. 
Metagenomics also identifies uncultivable potentially pathogenic bacteria and 
offers a holistic snapshot of the microbiome 71. 
1.2.3 Treatment of bacterial infection: antibiotics 
The antibiotics era was ushered in by the discovery of naturally occurring 
compounds – penicillin, streptomycin, chloramphenicol and tetracycline – 
that have bactericidal properties 75. Antibiotics elicit bactericidal activity by 
inhibiting important cellular functions such as synthesis of the cell wall, of 
proteins, of DNA and of RNA 76. Despite the success of antibiotics as 
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therapeutic agents the antibiotics era has been marred by the widespread 
emergence of antibiotic resistance 77.  
Most antibiotics operate by binding to their target molecule with a high 
affinity. Antibiotic resistance can be conferred by a number of mechanisms 
such as 78: 
1. Preventing the antibiotic from reaching its target through: 
a. Decreased bacterial cell permeability by down-regulation of 
porin channels 79 
b. Increased removal of antibiotics from the bacterial cell through 
efflux pumps 
2. Modifying the drug target through: 
a. Point mutations in the gene encoding the drug target 
b. Homologous recombination with genes encoding insensitive 
drug targets e.g. penicillin binding proteins 
c. Modification of the target protein by methylation or binding of 
proteins 
3. Inactivating or modifying the antibiotic through: 
a. Enzyme-catalysed hydrolysis of the antibiotic e.g. β-
lactamases 
b. Chemical modification of the antibiotic e.g. aminoglycoside-
modifying-enzymes 80 
Although a crisis looms, the development of new antibiotics is no longer 
deemed economically viable 81. Instead pharmaceutical companies have 
turned their attention the development of more lucrative therapeutic agents 
for chronic non-communicable disorders 82. Antibiotic resistance is 
recognised as a global emergency 83. Scientists are exploring novel targets 
such as bacterial cell-division proteins as potential targets for future 
antibiotics 84. Bacteriophage therapy is also re-emerging as a promising 
alternative to antibiotics 85,86. Regulation, however, is a double-edged sword, 
because although it may be beneficial in controlling the rise of existing 
resistance, it can be an obstacle in pursuing the discovery of novel antibiotics 
82,87.  
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1.2.4 Epidemiological typing to monitor spread of 
bacterial infection 
Microbial typing allows us to track the emergence and spread of bacterial 
pathogens and in some cases can be used to retrace evolutionary history 88. 
Typing methods that discriminate between closely related strains are 
essential in identifying person-to-person transmission in an outbreak 89. 
1.2.4.1 Phenotypic typing approaches 
Phenotypic typing methods discriminate between strains on the basis of 
phenotypic traits. Serotyping is perhaps the most widespread phenotypic 
typing method. Serotyping exploits intra-species strain-specific differences in 
the expression of cell-surface antigens. For example, variation in the 
capsular polysaccharide of S. pneumoniae is used to classify strains into 
over 90 serotypes. The gold standard for this is the Quellung reaction, which 
detects a serotype-specific interaction between an antibody and the capsular 
antigen. However, molecular techniques are now available for serotyping S. 
pneumoniae based on detection of capsular genes 90,91.  
Salmonella isolates are serotyped according to the immunological profiles of 
their somatic (O) and flagellar (H) antigens. Serotyping has been the 
cornerstone of epidemiological studies of Salmonella. However, keeping 
stock of the antisera for all the antigenic variants is demanding. Molecular 
approaches for serotyping Salmonella are gradually replacing conventional 
techniques 92,93. 
1.2.4.2 Molecular typing: MLST 
The shortfall of the earliest typing methods was that they lacked a 
standardized nomenclature for clonal lineages and they showed poor 
reproducibility in unrelated datasets 94. Multilocus sequence typing (MLST) 
succeeded in providing a standardised format for documenting gene diversity 
to facilitate ease of inter-laboratory data comparison 95. MLST assigns a 
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sequence type (ST) based on the allelic combination of 7 housekeeping 
genes that are conserved in a given species 95.  
The nucleotide sequence for each of the seven housekeeping genes is 
compared to known allele sequences that are stored in a curated database. 
Each time a new sequence for a given gene is reported, it is designated a 
new allele number. Each unique combination of alleles is designated as a 
unique ST. STs are clustered into clonal complexes based on the sharing of 
at least 5 allelic loci with at least one other ST in the clonal complex 96. By 
convention the most abundant ST is designated as the founder of the clonal 
complexes.  
MLST is a robust tool for assessing population-based microbial diversity 57, 
as shown by a few key examples: 
x MLST has been instrumental in understanding the global population 
structure of Staphylococcus aureus 97,98  
x Through MLST, the impact of vaccine introduction on the genetic 
diversity of Streptococcus pneumoniae has been studied 99 
x MLST has been implemented in tracking the emergence and spread 
of antibiotic-resistant strains of Neisseria meningitidis 100 
x Associations between bacterial species and animal reservoirs have 
been revealed through MLST 101,102 
The ease of use and reproducibility of MLST make it the gold standard for 
typing most common bacterial pathogens 103,104. However, MLST does not 
offer enough discriminatory power to make it applicable for: 
x Detailed outbreak investigation in most species 89 
x Typing of genetically monomorphic bacteria like Mycobacterium 
tuberculosis (Mtb) 88  
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1.2.4.3 Molecular typing for Mycobacterium tuberculosis 
A wide range of molecular typing methods have been applied to Mtb, 
including: 
x IS6110-RFLP typing, which involves cleaving genomic DNA at 
specific sites and using electrophoresis to separate the IS6110 
fragments to yield a specific banding pattern 
x Spoligotyping, which characterizes strains based on the presence or 
absence of spacer units in the direct repeat locus 
x Mycobacterial interspersed repetitive unit variable number tandem 
repeat (MIRU-VNTR) analysis, which relies on the rapid rate of 
change in repetitive DNA elements, to distinguish between isolates 
with high-discriminatory power 
Although spoligotyping can distinguish between strains at the sub-species 
level it is limited by the fact that it uses less than 0.1% of the M. tuberculosis 
genome. MIRU-VNTR offers higher discriminatory power than spoligo typing 
but it lacks standardised laboratory protocols. IS6110-RFLP also offers high 
discriminatory power between strains, but it requires an expert technician 
and sophisticated hardware 105. 
1.2.4.4 Genomic epidemiology 
WGS using next-generation sequencing (see following section) has emerged 
as a useful tool for the detection and characterisation of outbreaks, as well as 
informing outbreak management 106,107. In fact, next-generation sequencing 
is now ready to contribute routine pathogen surveillance 108-111. This kind of 
digital surveillance twinned with effective data sharing will facilitate real time 
analysis of outbreaks in the context of the global phylogeny 108. However, 
whole-genome sequencing needs to be made accessible in low resource 
settings, where the burden of infection is highest.  
The problem with most existing genotyping methods is that they probe only a 
very small proportion of the genome 112. WGS has emerged as a superior 
technique for typing bacteria, since it can detect single nucleotide changes at 
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all genomic loci 113. WGS offers high-resolution inter-strain comparison, 
which has improved our understanding of geographic distribution of species 
and their evolutionary origins 114,115. Evolution within a species can be 
investigated by reconstructing a phylogeny from variant sites in the core 
genome 114,116. 
To establish WGS as the gold standard for microbial typing, standardised 
schemes for nomenclature and lineage assignment need to be devised. For 
some species like Mtb, a robust typing scheme exists for characterising 
strains based on a barcode of genome-wide single nucleotide variants 
(SNVs) 117. In other bacteria, like Staphylococcus aureus, nomenclature of 
clonal lineages inferred from MLST are still used to annotate whole-genome 
phylogenies 118. A ribosomal MLST scheme that probes 53 ribosomal 
proteins present in almost all bacteria has been proposed to ease the 
transition from working with MLST to working with whole genomes 119.  
1.3 DNA Sequencing 
1.3.1 Sanger sequencing  
The development of the DNA sequencing technique, now commonly known 
as Sanger sequencing, by Frederick Sanger and his colleagues in 1977 
remains a cornerstone of molecular biology 120. Sanger sequencing is based 
on a DNA synthesis polymerase reaction in the presence of 
dideoxynucleotide chain terminators 121. Initially, the reaction was run in 
quadruplicate with different base terminators (ddA, ddC, ddT or ddG) 
followed by gel separation in separate lanes. The user would then examine 
the gel to reconstruct the nucleotide sequence at each position based on the 
terminator base and fragment length 121. 
The advent of fluorescently labelled dideoxynucleotide chain terminators 
increased the throughput of Sanger sequencing and enabled automation. 
This meant that the sequencing could be performed in a single reaction and 
the strands could be separated through capillary electrophoresis 122. A 
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fluorescent detector connected to a computer was able to detect the 
nucleotides and reconstruct the sequence in real time 123. Sanger 
sequencing can generate reads up to a thousand base pairs long 124. 
1.3.2 Whole-genome sequencing 
The first bacterial genome sequences were published just over two decades 
ago 125,126. Since then, there has been an exponential increase in the number 
of bacterial genomes sequenced and our understanding of the bacterial 
genome has improved significantly. This development stems from 
technological advances in high-throughput sequencing, the decreased cost 
of sequencing and improved means of data sharing 127.  
Bacterial genome sequencing has evolved through three phases 128: 
1. The whole-genome shotgun sequencing era 
2. The next-generation sequencing era 
3. The single-molecule sequencing era 
The advent of shotgun cloning in WGS was the first breakthrough 128. In this 
three-step process, genomic DNA is randomly sheared, the fragments are 
cloned into E. coli and sequenced en masse by Sanger sequencing 128. 
Bioinformatics tools were developed to assemble the short reads into contigs 
(contiguous strings of bases). Shotgun cloning and subsequent whole-
genome sequencing provided novel insights into the biology of the deadly 
human pathogens Mycobacterium tuberculosis 129 and Yersinia pestis 130 and 
identified a myriad of novel genes in the model organism E. coli 131. Genome 
sequencing that relied on shotgun cloning, however, had its drawbacks: most 
notably that only clonable regions of the genome could be sequenced 128. 
The introduction of next-generation sequencing to bacterial genomics 
marked the second breakthrough. Next-generation sequencing involves 
preparing templates by tagging genomic fragments with chemical adapters, 
which are then amplified by PCR and undergo sequencing-by-synthesis on a 
solid surface 132. This technology ushered in the era of bench top sequencers 
like the Illumina MiSeq and the Roche 454 Jr 128. Bench top sequencers are 
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now commonplace in most research groups and for now Illumina dominate 
the field with short-read sequencing 109. 
Next-generation sequencing brought a massive improvement in throughput 
and volume of data but at the cost of significantly shorter read length 132. This 
meant that only draft assemblies could be generated, rather than complete 
genome sequences. Inadvertently, this influenced bacterial genomics by 
changing the emphasis from in depth analysis of single genomes to 
comparative genomics of large dataset of closely related strains 128. 
Single-molecule sequencing marks the third breakthrough in bacterial 
genome sequencing, while also reviving the study of complete genome 
sequences through long read lengths. Pacific Biosciences launched the first 
widely used single-molecule sequencing technology, the PacBio. The PacBio 
can generate high-quality finished genomes in combination with Illumina 
short reads, or even on its own 133,134. This makes PacBio ideal for structural 
genomics and plasmid analysis e.g. in multidrug resistant bacteria 135. 
Unfortunately the PacBio is mostly restricted to major sequencing centres 
due to the size of the instruments and its hefty price tag 128.  
Oxford Nanopore sequencing remains a work-in-progress, despite proof-of-
principle that it can generate reasonably good draft genomes 128. Palmtop 
sequencing with Oxford Nanopore’s Minion instrument has made on-site 
sequencing of samples possible in outbreak surveillance even in remote 
regions 136,137. 
1.3.3 Bacterial genome analysis 
Although most bacterial genomes consist of a single circular chromosome, a 
few species have evolved to harbour multiple chromosomes 138,139. Bacterial 
genomes are usually smaller than eukaryotic genomes and vary in size from 
112 kB to 14 MB 140,141. The nucleotide content of bacterial genomes varies 
markedly, e.g. the GC content of finished assemblies ranges from 15% to 
85%. Bacteria from complex environmental niches tend to have larger 
genomes and higher GC contents than host-associated bacteria 127. 
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1.3.3.1 Bacterial genome assembly and annotation 
Over the years, technological advances in sequencing have been paralleled 
by computational advances geared towards analysing sequence data. 
Genome assembly involves stitching together millions of short sequence 
fragments in an attempt to reconstruct the original genome. Reference-based 
assembly methods map short reads to a reference genome and overlapping 
fragments are assembled into contigs. However, reference-based mapping is 
limited by the fact the regions that do not map to the reference are excluded.  
De novo assemblers attempt to reconstruct the genome from scratch without 
the aid of external data. This eliminates the bias towards the reference, but 
the assemblies are generally more fragmented 124. De novo assembly is 
recommended for new pathogens or novel strains of well-studied pathogens 
142. Hybrid approaches that combine de novo assembly of long reads from 
single-molecule sequencing and error correction with high accuracy short 
reads have produced almost-complete genome assemblies 133,143. Contigs 
generated from de novo assembly with short reads can be improved by 
joining them into scaffolds using a reference guided approach 144,145. 
Bacterial genomes show a good correlation between genome size and 
number of genes and have low proportions of non-coding DNA 146. Automatic 
annotation pipelines are often employed for annotating new sequences of 
bacteria. The generic workflow of automated pipelines for annotating 
bacterial genomes includes the following steps 147: 
1. Predicting open reading frames from a FASTA sequence 
a. GLIMMER is the most common tool for this 148 
2. Comparing the predicted sequence to a reference genome or online 
databases e.g. Uniprot 
3. Search for a homologue 
a. If there is a match, assign annotation from the reference 
b. If there is no match, then annotate the coding sequence (CDS) 
as a hypothetical protein 
4. Predict functional domains for the protein and update annotation 
5. Predict other non-coding features e.g. non-coding RNAs 
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The exponential increase in the number of prokaryotic genomes available 
provides an amazing resource for comparative genomics. However, one 
must proceed with caution when transferring annotation from one genome to 
the next, as there are inconsistencies in the annotation protocols and 
pipelines implemented by different research groups 147. In addition, programs 
like Microsoft Excel have been shown to corrupt gene names 149, while 
spelling mistakes and use of inconsistent product names for the same gene 
compounds this problem 147. For all these reasons, to achieve high-quality 
annotation, the predicted annotation must be manually curated. 
1.3.3.2 Insights into pathogen biology 
Bacterial genomics has been instrumental in shaping our understanding of 
host-pathogen interactions. Knowing the sequence for all genes in the 
genome has given crucial insights into the biology of bacterial pathogens. 
Through the genome, we are able to study the full profile of virulence genes 
that mediate an organism’s pathogenesis 150. WGS has been instrumental in 
the detection and characterisation of novel variants of important virulence-
associated genes e.g. WGS has characterised diversity in the cagA gene, 
the most important virulence factor in Helicobacter pylori infection 151. 
Genome-wide association studies can be used to dissect the genetic basis 
for phenotypic traits in bacteria 152. A genome-wide association study of 
Campylobacter identified a seven-gene vitamin B5 biosynthesis region as a 
host-specificity factor 153. In the Campylobacter jejuni genome, the presence 
of imported genes has been linked with evolutionary relationships with 
specific host species 154,155. In Mycobacterium tuberculosis genome-wide 
association studies have been employed to detect antibiotic resistance 
mutations based on convergent evolution 156. Genome-wide associations in 
bacteria are confounded by the strong forces of natural selection that are 
exerted on bacterial populations 152. 
Advances in next generation sequencing have made it possible to sequence 
the entire bacterial transcriptome of a strain 157. The transcriptome is key to 
understanding how bacteria respond to changes in their environment. 
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Genomics has also provided insights into the role of regulatory non-coding 
RNA. Regulatory non-coding RNA’s can affect the physiology of bacteria by 
binding to messenger RNA in order to reduce translation efficiency 158.  
1.3.3.3 Discovery of novel targets 
Advances in genomics have led to the discovery of novel targets for 
diagnostics, antibiotic and vaccines 159. Comparative genomics can identify 
diagnostic targets that are conserved within a species, but are not found in 
other species. These targets can then be incorporated into real-time PCR 
diagnostic assays 160.  
In the genomics era, scientists have looked increasingly towards genomics 
solutions to the rising antibiotic resistance problem 161,162. To take just one 
example: in 2014, Mobegi et al published a genomic approach for 
systematically discovering novel antibiotic targets in three leading respiratory 
pathogens; Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis 163. Their approach exploited high-density transposon 
mutagenesis, high-throughput sequencing, and integrative genomics to 
identify essential genes that were conserved, but unlikely to interfere with 
host function or the microbiome. As proof of concept they identified four 
novel targets that were experimentally validated 163. Their approach 
overcame the shortfalls in specificity and throughput that held back previous 
attempts to discover novel targets from genomic data 164,165. As genomics 
screening for antibiotic targets circumvents the need for traditional laboratory 
screening, this can fast-track the discovery of novel antibiotics 163. 
The genomics era has also revolutionised vaccine development through 
“reverse vaccinology”, which mines bacterial genomes for proteins that can 
potentially elicit protective immunity as candidates for subunit vaccines 166-
168. Comparative genomics of multiple strains can predict the suitability of a 
candidate protein by determining how conserved it is across diverse strains 
169. Reverse vaccinology has the potential to lead to vaccines for bacteria 
where the conventional approaches have failed 167,169.  
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1.4 Bacterial genome evolution 
Bacterial evolution is driven by the accumulation of genetic variation in the 
bacterial genome. WGS has enhanced our understanding of the evolutionary 
mechanisms that shape major human pathogens, documenting 
unprecedented genomic diversity between and within bacterial species 127,170. 
Understanding microbial evolutionary mechanisms through the bacterial 
genome is central to refining intervention measures to counteract pathogenic 
bacteria.  
1.4.1 Processes shaping bacterial evolution 
1.4.1.1 Mutation, insertion, deletion 
Point mutations are the smallest units of evolution 171. Point mutations result 
from the substitution of a single nucleotide (referred to as SNV) or from the 
insertion or deletion of a single nucleotide. The convergence of point 
mutations in multiple independent lineages is an indication that the mutation 
is under positive natural selection 171. Point mutations may confer a selective 
advantage that leads them to become fixed in the population. 
SNVs that occur in protein-coding genes can yield synonymous mutations 
that code for the same amino acid or non-synonymous mutations that result 
in a change in the amino acid, potentially altering protein function. However, 
point mutations in non-coding regions can also affect gene function, 
especially if they occur in promoter regions 171. Deletions and insertions can 
introduce a frameshift mutation that leads to downstream sequences being 
translated in a different reading frame, with major effects on protein 
sequence, structure and function. Similarly, nonsense mutations result in 
premature stop codons that truncate proteins with severe consequences for 
function.  
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1.4.1.2 Rearrangement and homologous recombination 
Genome rearrangements are structural variations involving large chunks of 
DNA that can result from cellular process such as replication, DNA repair and 
DNA recombination 172. The impact of genome rearrangements on the 
evolution of eukaryotes has been widely studied and there is growing 
evidence that genome rearrangements are important evolutionary 
mechanisms in bacteria 172. Genome rearrangements can alter the order of 
genes as well as their orientation and copy number. These changes can 
affect the phenotype of an organism. Evidence shows the rearrangements 
can also influence gene expression 173,174.  
The bacterial genome is highly flexible and can undergo large sequence 
variation through insertions, deletions, inversions, translocations and 
duplications 171. 
1. Deletions can occur in intergenic regulatory regions and lead to gene 
inactivation. Deletions can also lead to loss of functional domains of 
proteins and altered gene function 172 
2. Duplications can have functional implications depending on the 
variation in the duplicated segment and how the segment is inserted 
172 
3. Insertions can introduce novel segments into the genome. The most 
well studied mechanism of insertion is horizontal gene transfer (HGT) 
175 . Mobile genetic elements (MGEs) can mediate the insertion of 
genomic segments from other loci within the genome. The functional 
implications of insertions are also governed by the genetic nature of 
the insert and context of the insertion loci 172 
4. Translocations involve the exchange of DNA segments within the 
same genome. They are important contributors to genome plasticity. 
Translocations can affect chromosome position, gene orientation and 
the distance between a target gene and its transcription factors 176 
5. Inversions flip the orientation of genomic segments 
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1.4.1.3 Recombination and horizontal gene transfer 
Plasticity within the bacterial genome allows bacteria to adapt to selective 
pressures from the environment and their hosts 177. Understanding the 
evolutionary mechanisms that confer genome plasticity in bacteria can yield 
valuable insights into their pathogenesis and adaptive mechanisms. Bacteria 
are able to acquire foreign DNA through HGT 175. HGT is the largest source 
of variation in the genome. Uptake of foreign DNA by bacteria is mediated 
mainly through three processes: 
1. Transformation involves the incorporation of exogenous DNA from 
the surroundings into the host 
2. Conjugation results from direct cell-to-cell contact between cells and 
transfer of DNA via a sex pilus 
3. Transduction is mediated by bacteriophages – viruses that infect 
bacterial cells 
Recombination is a DNA repair process in bacteria that facilitates the 
incorporation of foreign DNA into the bacterial genome 178. Recombination 
maintains genetic diversity in bacterial populations while preventing the build-
up of unfavourable changes 171. Homologous recombination classically 
involves the interaction of two strands of DNA with high sequence similarity. 
However, recombination can also account for HGT wherein highly divergent 
sequences are incorporated into the genome 171. Moreover, recombination 
can mediate the incorporation of DNA acquired through phage mediated 
transduction as well as conjugation 171. 
1.4.1.4 Mobile Genetic Elements 
MGEs shape the evolution of bacterial pathogens by mediating movement of 
DNA within the genome and between species 179. MGEs introduce diversity 
in the accessory genome mainly through plasmids, bacteriophages and 
genomic islands 180. Plasmids are large extra chromosomal strands of DNA, 
linear or circular, that replicate independently and carry a wide range of 
genes 180. Plasmids can carry a large number of genes that introduce 
complex phenotypic traits and lead to quantum leaps in evolution 181,182. 
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Plasmids can be transferred, mainly by conjugation, between distantly 
related species and even between bacteria and some eukaryotes 183.  
Bacteriophages are viruses that infect bacteria. Bacteriophages can replicate 
within a bacterial cell and kill the cell within minutes of contact when the lytic 
cycle is activated 184. However, in the lysogenic cycle the lytic cycle is not 
activated and the phage genome can be integrated into the host 
chromosome 184 to become a prophage 171. Prophages can remain dormant 
in the chromosome until they are reactivated. In the pseudolysogenic cycle, 
the phage genome remains in the cytoplasm as an episomal plasmid 184. 
Bacteriophage genomes may encode genes that can greatly enhance 
virulence and transmissibility such as exotoxins 185. In some cases phages 
are involved in the transfer of toxins as well as their activation 186. Phages 
can alter the microbiome by killing off competitors 187. 
Genomic islands are regions of the genomes that are believed to have 
evolved through the interchange of plasmids and bacteriophages 180. 
Genomic islands are present in some strains but are not conserved across a 
species. Genomic islands can carry genes that mediate genetic mobility but 
also frequently carry virulence-associated genes 180. Pathogenicity islands 
are genomic islands that carry one or more virulence genes and are present 
in the genomes of pathogenic strains but absent in non-pathogenic strains 
from the same or closely related species 188. Pathogenicity islands play an 
important role in mediating the virulence of bacterial pathogens in a range of 
host organisms 188.  
1.4.1.5 Genome degradation and deletion bias 
Genome degradation is believed to be an important evolutionary mechanism 
that sometimes contributes to the evolution of bacterial pathogenicity 189,190. 
Comparing the genomes of some ancient human pathogens (Yersinia pestis, 
Salmonella enterica serovar Typhi CT18 and Mycobacterium leprae) with 
genomes from closely related species reveals extensive genome degradation 
and gene loss 191-193. The observed genome degradation in these species is 
believed to mark a “change in lifestyle” for these organisms towards 
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occupying a simpler host niche 190. Gene loss may also contribute to 
diminished virulence: the Salmonella species S. bongori has multiple deletion 
regions compared to its more virulent close relative S. enterica 194. 
Conversely the loss of the antivirulence cadA gene in Shigella flexeneri 
increases the invasiveness of the species 195. cadA deactivates the enzyme 
lysine decarboxylase, whose product inhibits the organisms plasma-encoded 
virulence factors 195.  
Comparative genomics has revealed that some species show an 
evolutionary bias towards gene deletion 196. Studying the dynamics of 
genome degradation can provide insights into the mechanisms bacterial 
pathogens employ in host specialisation. The smallest bacterial genomes 
occur in intracellular pathogens and symbionts 197. The constant supply of 
nutrients from the host allows these bacteria to survive with a shrunken 
genome and reduced functionality 197. 
1.4.2 Pan-genomes 
All of the genes within a bacterial species make up its pan-genome, which is 
comprised of a conserved core genome and a flexible accessory genome 
198,199. The bacterial core genome largely consists of housekeeping genes 
that are conserved across the entire species 177. Accessory genome 
elements mediate important evolutionary mechanisms such as host 
adaptation, virulence and antibiotic resistance 200. Bacterial species that live 
in highly specialised niches tend to have closed pan genomes that are finite 
201. More generalist species possess open pan-genomes that increase with 
the addition of more strains, and are characterised by high rates of HGT 201.  
The unprecedentedly high rates of HGT in bacterial genomes have led 
scientists to question the existence of bacterial species 62, particularly as one 
might suppose that it would not be possible for a bacterial species to 
maintain its identity in such a genetically promiscuous environment. 
However, the existence of phenotypically stable clusters despite the 
observed genome fluidity is explained by the core genome hypothesis. The 
core genome hypothesis attributes the stability of phenotypic clusters to a 
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repository of core genes (the core genome) that maintain the identity of a 
species, despite rampant changes in the accessory/flexible genome 62. 
The core genome hypothesis predicts that core genes are primarily under 
purifying selection as a mechanism to maintain existing function 62. Core 
genomes are believed, on average, to express a neutral rate of evolution 
while a variety of selective pressures are levied on accessory genes 62. The 
core genome hypothesis is, however, challenged by the existence of open 
pan genomes in some species and the high rates of homologous 
recombination between closely related bacteria 202.  
1.4.3 Bacterial evolution in monomorphic lineages 
Genetically monomorphic lineages are bacterial taxa that are characterised 
by very low sequence diversity to such an extent that sequencing 
housekeeping genes from divergent strains yields few if any SNVs 88. This 
trait precludes the use of standard genotyping techniques such as MLST to 
discriminate between strains from monomorphic lineages, and, thus, the 
evolutionary history of monomorphic lineages remained unclear until the 
widespread application of whole-genome sequencing 88. 
Some of the deadliest human pathogens form genetically monomorphic 
lineages that have emerged from species with greater diversity. But why do 
monomorphic lineages occur? One explanation is that this kind of evolution 
intensifies disease transmission 203. Often the population dynamics of 
genetically monomorphic lineages are distinct from those of the supra-
species 88 e.g.: 
x Y. pestis (causes plague, including the Black Death), is a recently 
emerged clone of the species Yersinia pseudotuberculosis 204 
x Mycobacterium tuberculosis (causes tuberculosis, the white plague) is 
part of a much more diverse Mycobacterium tuberculosis complex 205 
x Bacillus anthracis (causes anthrax) is part of the Bacillus cereus 
group of soil-dwelling saprophytes 206 
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Similarly, highly virulent monomorphic clades can exist within genetically 
diverse species e.g.:  
x The O157:H7 clade of E. coli, which infects cattle and can sometimes 
infect humans inducing haemorrhagic colitis and the haemolytic–
uremic syndrome 207 
x  The serovar Typhi of Salmonella enterica the cause of typhoid fever 
208 
x The O1 or O139 clade of Vibrio cholerae, the cause of pandemic 
cholera 209 
There is evidence to suggest that Darwinian selection is a leading contributor 
to the evolution of bacterial pathogens 210. Darwinian selection has been 
demonstrated in laboratory experiments 211 as well as in nature. For 
example, the widespread use of fluoroquinolones over more than twenty 
years has resulted in decreased susceptibility in all lineages of serovar Typhi 
due to accumulation of mutations in the gyrA gene 208. However, Darwinian 
selection for a single trait sometimes leads to only transient selection, 
because the selected variants may prove less fit than their progenitors in the 
absence of the selective pressure 212. This might explain why susceptible 
clones of serovar Typhi have co-evolved with the resistant clones.  
Comparative genomics suggests that genetically monomorphic lineages are 
under neutral selection, with mild purifying selection 203. Comparative 
genomics shows that synonymous and non-synonymous mutations are 
accumulated at similar rates in these lineages 115,205,213. Moreover there is 
limited evidence of convergent evolution in these lineages since they exhibit 
almost negligible levels of homoplasy, with the exception of antibiotic-
resistant genes 203.  
Although monomorphic lineages are devoid of traces of recent homologous 
recombination, genomic evidence suggests the occurrence of recombination 
events that predated the emergence of some lineages 214,215. The absence of 
HGT makes genomic deletions useful phylogenetic markers in monomorphic 
lineages like M. tuberculosis 216. 
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1.4.4 Phylogenetic dating 
In 1962, Linus Pauling and Emile Zuckerkandl noted a linear correlation 
between the number of amino acid differences in haemoglobin and time, as 
determined by fossil evidence 217. This formed the basis of the molecular 
clock theory, which states that the rate of evolutionary change in a given 
protein is constant over time and across different lineages 218.  
The assumption that mutation rates are constant in lineages has been known 
to obscure phylogenetic inference. To overcome this barrier statistical 
methods like maximum likelihood and Bayesian inference have been 
employed. These methods use a “relaxed molecular clock” that assumes an 
independent mutation rate in each lineage 219.  
In order to infer dates using a molecular clock, the mutation rate must be 
calibrated with independent dating evidence from sources such as fossils or 
ancient DNA 220. Once a mutation rate is established for a species, it can be 
employed to estimate the time since divergence of closely related or distant 
strains. 
1.4.5 Population genomics and evolution 
1.4.5.1 Within-host evolution and transmission history 
Classical genotyping techniques can identify the existence of mixed infection 
due to different lineages 221,222. However, they lack the resolution to trace the 
minute evolutionary changes that occur within a single lineage during 
colonisation. Advances in WGS continue to shed light on the evolution of 
single bacterial strains within a host 223. Microevolution is driven mainly by 
point mutations and in a number of species the short-term evolution rates are 
much higher than the long-term evolution rates 224-226. Clouds of diversity can 
result from microevolution; within these clouds, variants with different 
phenotypic traits can potentially co-exist 227. Changes in the host immune 
system or antibiotic treatment introduce selection bias that selects for the 
most favourable trait 227. 
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Most transmission studies rely on single genomes isolated from patients and 
do not take into consideration the effect of microevolution, which is a 
problem, as cloud diversity potentially hinders the ability to accurately infer 
transmission networks 228. To understand cloud diversity within a host, 
multiple genomes need to be sampled—at different time points and/or at a 
single time point but from multiple colonies 229. Moreover, heterogeneous 
transmission from one host to another may occur whereby multiple 
genotypes are transmitted 228,229. Co-colonisation of multiple species that are 
part of the normal flora can lead to recombination which further complicates 
efforts to detect transmission chains 229. 
1.4.5.2 Selection for antibiotic resistance 
As noted previously, the world is going through a crisis in antibiotic 
resistance driven largely by overuse and inappropriate prescription of 
antibiotics 82. The natural environment is replete with antibiotic resistance 
genes, which when transferred to pathogenic bacteria, render them resistant 
230. On top of that, bacteria can spontaneously accumulate mutations that 
confer antibiotic resistance. Resistant variants typically form minority 
populations because they are often less fit than their susceptible 
counterparts. However, in the presence of antibiotic treatment, a selection 
sweep occurs within the host-associated bacterial population so that 
antibiotic-resistant variants become dominant 229. WGS has documented 
microevolution within a single host leading to the emergence of drug-
resistant bacteria 231-233.  
The large-scale use of antibiotics has rendered antibiotic resistance a 
selective advantage leading to the emergence of almost impossible to treat 
superbugs 234. Relaxed stewardship of antibiotics in hospitals means that 
vulnerable patients are at an increased risk of nosocomial antibiotic-resistant 
infection 81. Widespread use of antibiotics in agriculture and animal 
husbandry, particularly in developed countries, has also contributed to the 
rise in antibiotic resistance 81,235.  
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1.4.5.3 Vaccine-induced selective pressure 
Vaccines have proven to be an effective means of eradicating or 
substantially reducing the prevalence of infectious diseases. However, 
occasionally some infections persist despite the availability of a vaccine and 
some vaccinated individuals remain susceptible. This may arise due to the 
selection of adaptive features that counteract the impact of the vaccine 221. 
Adaptive features include evasion and virulence evolution 221. Evasion arises 
through the emergence of novel mutants that can escape the immune 
response induced by the vaccine 221. An example of this is the serotype 
replacement phenomenon that occurs in S. pneumoniae in response to 
conjugate vaccines 236,237. 
Bacteria can alter their virulence mechanisms as an evolutionary mechanism 
to escape the effect of a vaccine. A classical example is the diphtheria 
antitoxin vaccine, which primes the immune system against the diphtheria 
toxin, the main virulence agent of Corynebacterium diphtheriae 238. However, 
despite vaccination, a resurgence of diphtheria has been observed in Russia 
and surrounding territories. Genomic analysis showed that this resurgence 
was driven by the persistent circulation of non-toxinogenic strains 239. 
Worryingly there is evidence that these strains are evolving into toxinogenic 
forms and driving a re-emergence 239. In the UK, vaccine pressure led to an 
increase in the prevalence of diphtheria due to the closely related species C. 
ulcerans 240. 
1.5 Bacterial infection in West Africa: three 
case studies 
1.5.1  West Africa: geography and demographics 
Africa is comprised of five regions: Northern Africa, Eastern Africa, Southern 
Africa, Central Africa and Western Africa. Despite being replete with natural 
resources, Africa is home to some of the poorest communities in the world 
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241. The WHO reports that children born in Africa are more likely to die within 
their first year of life than children born elsewhere. Pneumonia, diarrhoea and 
malaria are the principal causes of death among children under 5 years of 
age 242.  
West Africa is comprised of 16 countries with a landmass of approximately 
6.1 million square kilometres (Figure 1.1). The estimated population of West 
Africa in 2015 was 340 million, 55% of whom are estimated to live in rural 
areas with limited access to good quality healthcare 243. 
 
 
Figure 1.1 A map of West Africa highlighting the 15 countries on the mainland. The 
geographic position of West Africa is highlighted in the thumbnail map of Africa.  
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West African countries, with the exception of Mauritania, form the Economic 
Community of West African States (ECOWAS), an economic partnership that 
mandates free movement of people and goods between member states 244. 
This union has obvious economic benefits for the region, but it presents a 
unique public health challenge: the mass movement of people and goods 
can facilitate the spread of human infectious diseases. Cross-border cattle 
trading also presents an opportunity for the spread of zoonotic pathogens 
across the region 245. 
Traditionally, government spending on healthcare has been low in West 
Africa. The recent Ebola outbreak in West Africa highlighted the fragility of 
healthcare infrastructure in the region 246. Neighbouring countries could do 
little more than close their borders and watch as this deadly disease ravaged 
through parts of Sierra Leone, Liberia and Guinea.  
Understanding the biology and epidemiology of pathogens is fundamental to 
a successful intervention strategy. Here, I introduce a case study of three 
important pathogens in West Africa. I describe a unique scenario associated 
with each pathogen and present WGS as a solution to the problem.  
1.5.2 Staphylococcus aureus 
1.5.2.1 Clinical features and pathogenesis 
S. aureus is a Gram-positive commensal that can cause infection in humans. 
It is estimated that 50-60% of the human population are intermittently or 
persistently colonized with S. aureus 247. The most common site of 
colonisation is the anterior nares, but other sites such as the skin, perineum 
and pharynx are also commonly colonised by S. aureus 248. Colonisation with 
S. aureus places humans at risk of subsequent infection with the colonizing 
strain 249,250. S. aureus can cause superficial skin and soft tissue infections, 
as well as more invasive life threatening infections such as sepsis, 
endocarditis, meningitis and pneumonia 251,252. S. aureus is a leading cause 
of bacteraemia and skin and soft tissues infection globally 252-255.  
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Neutrophils are the host’s first line of defence against S. aureus infection 247. 
Once engulfed in neutrophils, S. aureus can avert apoptosis through the 
release of leukotoxins such as Panton-Valentine leukocidin, which promote 
the direct lysis of neutrophils by permeating the plasma membrane 256. S. 
aureus employs other mechanisms to evade the host immune system and 
invade host tissue, which include 251: 
x Surface proteins, which mediate the adhesion to and invasion of host 
cells as well as biofilm formation. Variation of the surface proteins 
allows S. aureus to evade the host immune system 
x α-Hemolysin, which causes host cell cytolysis and induces neutrophil 
recruitment. α-Hemolysin plays an important role in the pathogenesis 
of S. aureus in skin and soft tissue infection 
x Coagulases, which interfere with the host defences by promoting 
coagulation 
Worryingly, drug resistance has emerged for virtually all antibiotics used to 
treat S. aureus including the “last-line” methicillin and vancomycin 257. 
Hospital-associated MRSA levies a significant economic burden on health 
care services and can lead to loss of life 258. The rise in morbidity and 
mortality due to community-associated MRSA is a growing public health 
problem 259. 
1.5.2.2 The burden of staphylococcal infection in West Africa 
Population-based studies, mainly in developed countries, estimate the 
burden of S. aureus bacteraemia to be approximately 15–40 per 100,000 
population per year 260. S. aureus is the fourth commonest cause of invasive 
disease in sub-Saharan Africa and, in The Gambia, it is the second 
commonest pathogen isolated from patients with bacteraemia 261-263. Despite 
the importance of this pathogen, serious knowledge gaps still exist regarding 
the epidemiology of S. aureus in sub-Saharan Africa. Studies in Ghana, 
Senegal and Nigeria show that a higher proportion of urinary tract infections 
are due to S. aureus compared to Europe 264,265. It is likely that the burden of 
S. aureus in West Africa is underestimated since the majority of cases are 
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likely to go undetected or treated empirically without laboratory confirmation. 
Moreover in West Africa research efforts are more concentrated on other 
infectious agents such as HIV, tuberculosis and malaria that are greater 
threats to public health. 
1.5.2.3 Potential for animal reservoirs in West Africa 
S. aureus colonises a wide range of hosts including domestic animals 266 and 
wild animals 267. The epidemiology of S. aureus in non-human primates has 
been studied in remote regions of West Africa using MLST 268. Although 
these studies describe the population structure of S. aureus in non-human 
primates, they do not investigate the molecular mechanisms that govern host 
adaptation. Moreover, these genotyping techniques cannot ascertain whether 
the non-human primates can serve as a reservoir for highly virulent S. aureus 
that can infect humans. 
Humans come into frequent contact with Green Vervet Monkeys in The 
Gambia. This interaction provides opportunities for the exchange of 
pathogenic bacteria between humans and monkeys. In 2011 The Vervet 
Consortium partnered with the MRC Unit The Gambia to investigate the 
epidemiology of Simian Immunodeficiency Virus in Green Vervet monkeys in 
The Gambia. Speculatively, nasopharyngeal swabs were collected from the 
monkeys and ~30% of the monkeys were asymptomatic carriers of S. 
aureus. 
My task was to employ WGS to infer the evolutionary origin of S. aureus in 
monkeys in The Gambia. This involved investigating the existence of inter-
species transmission of S. aureus and attempting to elucidate the 
mechanisms that govern host adaptation. Through this analysis, I sought to 
establish whether monkeys posed a threat as a reservoir of highly virulent S. 
aureus in The Gambia. 
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1.5.3 Streptococcus pneumoniae 
1.5.3.1 Clinical features and pathogenesis 
S. pneumoniae has a propensity to colonise the young, the elderly and the 
immunocompromised 269. Successful colonisation by S. pneumoniae is a 
prerequisite to infection, which usually occurs within a month of colonisation 
270. The carriage rates of S. pneumoniae are higher in children under 5 
compared to older children and adolescents 270. Carriage of S. pneumoniae 
can lead to transmission through respiratory droplets and children are the 
main source of transmission 270.  
From the upper respiratory tract, S. pneumoniae can invade the lungs 
through aspiration to cause pneumonia (by invading the alveoli) or empyema 
(by invading the pleura or the pericardium) 269. S. pneumoniae can also enter 
the bloodstream and cause bacteraemia/sepsis 271. Bloodstream invasion by 
S. pneumoniae can lead to this pathogen crossing the blood-brain barrier to 
cause meningitis; pneumococcal meningitis is associated with a high case-
fatality rate and long-term neurological damage 271. S. pneumoniae can also 
spread locally from the upper respiratory tract to cause otitis media and 
sinusitis 269. 
The pneumococcal capsule, which is the main virulence factor of S. 
pneumoniae, is important for nasal colonisation 272. Adhesion to epithelial 
cells is a pre-requisite for colonisation. Adhesion is mediated through the 
binding of pneumococcal surface proteins such as pneumococcal surface 
adhesin A and choline-binding protein A to cell surface carbohydrates on 
epithelial cells 273. The enzyme neuraminidase reduces the viscosity of the 
mucosal layer making the epithelial surface more accessible for adhesion 274. 
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1.5.3.2 The burden of pneumococcal infection in sub-Saharan 
Africa 
In sub-Saharan Africa, rates of pneumococcal carriage are generally high, 
but there is a paucity of data from most countries 275. Rates of invasive 
pneumococcal disease are higher among younger children and 
immunocompromised individuals, due to higher rates of carriage 276. Other 
risk factors for invasive disease include respiratory viral co-infection, 
overcrowding and lack of vaccination 270. S. pneumoniae is the most 
common cause of pneumoniae among children and is one of the major killers 
among HIV infected individuals in sub-Saharan Africa 277. In West Africa, 
lethal outbreaks of pneumococcal meningitis have been reported across the 
so-called African meningitis belt 278,279. 
1.5.3.3 Vaccination and genomic outbreak surveillance 
Pneumococcal conjugate vaccines are efficient intervention tools for 
preventing pneumococcal infection. They reduce nasopharyngeal carriage in 
both vaccinated and unvaccinated individuals and reduce the burden of 
invasive disease due to vaccine serotypes 280-282. However, throughout most 
of West Africa the impact of vaccination on the molecular epidemiology of S. 
pneumoniae is unknown due to the lack of carriage surveillance or extensive 
disease surveillance.  
The pneumococcal meningitis outbreak that broke out in the Brong-Ahafo 
region of Ghana in December 2015 was a reminder that vaccination is not 
always the end of the story. This outbreak occurred two years after the 
introduction of the 13-valent pneumococcal conjugate vaccine, PCV-13.  
During the outbreak sample integrity was a major shortfall and the majority of 
samples were not viable for culture. The cause of the meningitis outbreak in 
Ghana would thus have remained unknown without the use of the 
quantitative PCR assay for detection of bacterial pathogens from human 
cerebrospinal fluid 283. Quantitative PCR identified serotype 1 S. 
pneumoniae, a vaccine serotype, as the main etiological agent from the 
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outbreak 283. But how could this happen in a country where PCV-13 had 
been administered to over 80% of the children under five years of age? 
Fortunately, a handful of viable isolates of S. pneumoniae were salvaged 
from the outbreak and as described in a subsequent chapter, were analysed 
using WGS. Previously sequenced serotype 1 genomes from West Africa 
served as a baseline for comparing the outbreak strains. This made it 
possible to identify evolutionary changes that distinguished the outbreak 
strains. This analysis demonstrated the power of genomics in outbreak 
surveillance and reiterated the fact that to characterise an outbreak properly, 
it must be analysed in the context of the global phylogeny 108. 
1.5.4 Mycobacterium tuberculosis 
1.5.4.1 Clinical features and pathogenesis 
Tuberculosis is caused by a group of closely related ecotypes that form the 
Mycobacterium tuberculosis complex 284. Mycobacteria are slow growing, 
intracellular, non-motile, non-sporulating, acid-fast bacilli. Mycobacteria have 
a very thick cell wall, uniquely multi-layered, with varied hydrophobicity. The 
inner layer consists of hydrophilic peptidoglycan sacculus and 
arabinogalactan layers, covalently linked to a hydrophobic outer layer of 
mycolic acids that form a waxy mesh of long chain fatty acids 285,286. 
A hallmark of the cell-mediated immune response to tuberculosis infection is 
the formation of granulomas 287. Granulomas can suppress the spread of 
bacteria within tissues by trapping the bacilli within macrophages in a mesh 
of immune cells 288. However, mycobacteria can survive in an encapsulated 
form in lung granulomas for several years in a state of latency 288. In a tenth 
of cases, the tubercle bacilli will escape from the granuloma and spread 
through the body to cause active disease.  
The most common site of tuberculous infection is the lungs, but other extra-
pulmonary sites including the bones, brain and kidneys can also become 
infected 289. Tuberculosis is transmitted by aerosol from patients with active 
disease through coughing, sneezing, laughing or even talking 289. Symptoms 
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of tuberculosis may include persistent cough, productive cough, malaise, 
night sweats, weight loss, loss of appetite and fever 289. 
Treatment of tuberculosis is complicated by the emergence of resistance to 
anti-TB drugs. Efforts to eradicate tuberculosis have been set back by the 
emergence of MDR-TB and extensively drug resistant (XDR-TB) forms of 
tuberculosis. MDR-TB is defined as resistance to at least isoniazid and 
rifampicin, the two most powerful first-line anti-TB drugs 290. XDR-TB are 
MDR-TB that are also resistant to a fluoroquinolone and one of the second-
line injectable drugs (amikacin, kanamycin or capreomycin) 291.  
1.5.4.2 The burden of mycobacterial infection in West Africa 
Tuberculosis is a major cause of death globally and the highest-burden 
regions are Africa and Southeast Asia. In 2015, over 1.3 million cases of 
tuberculosis were notified in Africa 292. However, among the notified cases of 
pulmonary tuberculosis, only 64% were bacteriologically confirmed 292. Most 
health facilities in the continent lack the facilities for bacteriological 
confirmation of tuberculosis and rely on expert opinion based on clinical 
symptoms. This highlights an urgent need to strengthen diagnostic capacities 
in Africa. 
In 2015, there were an estimated 480,000 new cases of MDR-TB 292. 
Estimating the burden of MDR-TB in Africa is challenging due to lack of 
accurate surveillance data. In 2015, the reported treatment success rates 
among MDR-TB and XDR-TB patients were 54% and 24% respectively 292. 
Poor adherence due to lack of awareness among patients and shortages of 
medication are a major factor is treatment failure. However it is worth 
considering the impact of misdiagnosis at primary health care facilities on the 
treatment outcomes of MDR-TB and XDR-TB. Most primary health facilities 
will not be able to perform drug susceptibility testing and are likely to place 
patients with MDR-TB on an inadequate treatment regimen before they are 
referred to the tertiary referral centres for retreatment. 
Between 2009 and 2013, the West African Nodes of Excellence for 
Tuberculosis AIDS and Malaria (WANETAM) carried out surveys in eight 
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West African countries to estimate the true burden of drug-resistant 
tuberculosis 293. At the time, only Senegal, Gambia and Nigeria had 
performed drug-resistance surveys in the sub-region. The estimates of drug 
resistance from WANETAM were higher than WHO estimates, suggesting 
that the burden of MDR-TB in West Africa could be underestimated 293. In 
particular, the prevalence of MDR-TB among retreatment cases in Mali 
(59%) and Nigeria, Ibadan and Lagos (39 % and 66 %), was significantly 
higher than WHO estimate for prevalence of MDR-TB among retreatment 
cases in the African region (20%) 293. 
1.5.4.3 Knowledge gaps for tuberculosis in West Africa 
Molecular epidemiology studies that employ classical genotyping techniques 
have been carried out across West Africa. These studies involve a range 
sampling strategies and isolated communities, making it challenging to 
compare the epidemiology across countries 294. MTBC in West Africa is 
highly diverse, with six of the seven global lineages present in the region 294. 
Despite this rich diversity very little is known about the evolutionary history of 
MTBC in West Africa, especially of the lineages and genotypes that are 
exclusively endemic to this region. Moreover, classical genotyping 
techniques do not have the resolution to distinguish between closely related 
strains and to infer  on going transmission. 
The WANETAM dataset of over 900 archived MTBC isolates presents an 
ideal platform through which we can begin to understand the evolution of 
MTBC in this region. WGS holds the potential to offer novel insights into the 
phylogeography of MTBC in West Africa. WGS has the power to unearth  on 
going chains of transmission and even detect microevolution of MTBC within 
the host over the duration of treatment. With the phenotypic drug-resistance 
profiles already known, the genome can be studied to understand the 
molecular mechanisms that are driving drug resistance in this setting.  
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1.6 Aims and objectives 
The time has come for West Africa to embrace the genomics era and exploit 
the full potential of microbial genomics. Genomics offers unprecedented 
insights into the epidemiology and biology of infectious diseases, which 
dominate the public health agenda in West Africa. In this thesis, I aim to 
exploit the sequencing and analysis of whole bacterial genomes to 
understand the evolution and spread of bacterial infection and antimicrobial 
resistance in West Africa. My work focuses on three important human 
pathogens in different contexts. 
1. In Chapter 3, I will evaluate the use of whole genomic sequencing to 
study the molecular epidemiology of S. aureus from humans and 
monkeys in The Gambia. I aim to determine whether transmission has 
occurred between hosts and, if it has, I aim to identify the underlying 
evolutionary mechanisms that accompany host adaptation. Through 
this work, I hope to demonstrate the applicability of genomics to 
investigate animal reservoirs for deadly human pathogens in West 
Africa 
2. In Chapter 4, I will assess the value of WGS in unravelling the 
genomic epidemiology of a pneumococcal meningitis outbreak that 
occurred in Ghana after the introduction of the pneumococcal 
conjugate vaccine. Here, I aim to identify the factors that led to the 
outbreak and to demonstrate the benefits of genomics in outbreak 
surveillance 
3. In Chapter 5, I will explore the genomic epidemiology of tuberculosis 
in West Africa. I employ pilot datasets from two West African countries, 
Mali and Nigeria. Through genomics, I investigate the phylogenetic 
relationships of strains causing tuberculosis in West Africa and the 
molecular mechanisms that are driving drug resistance in this setting. 
Through this work I hope to showcase the applicability of genome-
scale monitoring to the evolution and the spread of antibiotic 
resistance in a major pathogen in West Africa. 
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2 CHAPTER TWO: METHODS 
2.1 Bacterial cultures 
Colleagues at the MRC Unit The Gambia (MRCG) performed identification, 
characterisation and antimicrobial susceptibility testing for S. aureus, S. 
pneumoniae and MTBC. 
2.1.1 Staphylococcal culture and identification 
S. aureus strains were isolated from archived clinical specimens (venous 
blood pleural fluid, cerebrospinal fluid, joint aspirate, lung aspirate, ascitic 
fluid, and lymph node aspirates) and from nasopharyngeal and 
oropharyngeal swabs collected from healthy humans and monkeys using 
sterile calcium alginate swabs. Swabs were inoculated into chilled skim-milk 
tryptone glucose glycerol transport medium immediately after collection. All 
swabs were vortexed for fifteen seconds and stored at -70ºC within eight 
hours of collection. Specimens were plated on Mannitol Salt Agar and 5% 
sheep blood agar for 48 hours and 24 hours respectively under aerobic 
conditions (Oxoid, Basingstoke, UK). Suspected S. aureus colonies were 
sub-cultured on blood agar and confirmed using the Slidex Staph kit 
(Biomerieux, Basingstoke, Hampshire, UK).  
S. aureus isolates were characterised by MLST, targeting seven 
housekeeping genes, aroE, ptA, glp, arcC, gmK, tpi, and yqiL as described 
previously 97. Sequence types (STs) were grouped into clonal complexes 
(CCs) by performing an eBURST analysis 295 of all STs in the MLST 
database (http://saureus.mlst.net) (Appendix 2.1). Occasionally eBURST 
grouped two or more previously described CCs into one eBURST group. In 
such cases, the known CC designations were retained in order to maintain 
consistency with the existing literature. 
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2.1.2 Pneumococcal culture and identification 
Cerebrospinal fluid specimens were collected from suspected meningitis 
cases in the Brong-Ahafo region by performing a lumbar puncture. 
Specimens were plated on Columbia blood agar and chocolate agar for 
overnight incubation. Suspected pneumococcal colonies were confirmed 
based on growth characteristics, Gram stain and the optochin test (5µg 
optochin disks; Oxoid Basingstoke, UK). Serotyping using latex agglutination 
was performed on all confirmed pneumococcus isolates as previously 
described 296. Nucleic acid extraction was performed using the Qiagen DNA 
Mini kit (Qiagen, UK) following manufacturer’s instructions. Serotyping was 
confirmed by qPCR at the World Health Organization Regional Reference 
Laboratory for Invasive Bacterial Diseases hosted at the MRCG. 
2.1.3 Mycobacterial culture and identification 
Mycobacterial isolates on Löwenstein–Jensen media were sent to the MRCG 
from WANETAM collaboration sites 293. Isolates were sub-cultured in the 
MGIT 960 system (Becton Dickinson, Oxford Science Park, Oxford, UK) to 
maintain viability. Positive cultures were tested for purity by inoculation on 
blood agar, and followed up only if there was no growth after 24 hours 
incubation. The presence of MTBC was confirmed by Ziehl–Neelsen staining. 
In order to extract whole-genome DNA I sub-cultured isolates from the MGIT 
tubes into Middlebrooks 7H9 liquid medium (Sigma Aldrich, Gillingham, 
Dorset, UK). Middlebrook 7H9 medium was prepared according to 
manufacturer’s instructions: 
1. 4.9g of broth stock dried medium was dissolved in 900ml of distilled 
water with stirring at room temperature 
2. The media was autoclaved 
3. 2ml of glycerol was added to the hot media before cooling to 5ºC 
4. 100ml of Oleic Albumin Dextrose Catalase enrichment medium 
(Sigma Aldrich, Gilling, Dorset, UK) was added in a safety cabinet and 
mixed by pipetting up and down with a 25 ml pipette 
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5. 10-15ml of the enriched 7H9 medium was aliquoted into 25ml tissue 
culture flasks (ThermoFisher Scientific, MA, USA) 
6. The top of the flasks were sealed with tape to prevent the media from 
drying 
7. Flasks were incubated at 37ºC for 48 hours to check for purity 
(contamination would lead to turbidity) 
8. Flasks were stored at 5ºC 
Isolates were grown on 7H9 for 3-8 weeks and the presence of cells at the 
bottom of the culture flask confirmed growth. MTBC was confirmed by the 
rapid test CapiliaTM TB-Neo (Sigma Aldrich, Gillingham, Dorset, UK) and BD 
MGIT™ TBc (Becton, Dickinson and Company, Oxford Science Park, 
Oxford, UK). To test for purity the culture medium was streaked onto blood 
agar and incubated at 37ºC for 48 hours. Blood agar plates were checked for 
growth and referred to the senior laboratory microbiologists for confirmation. 
Contaminated samples were decontaminated by: 
1. Transferring the sample to a 50 ml falcon tube and adding an equal 
amount N-Acetyl-L-Cysteine Sodium Hydroxide solution and vortexing 
2. Incubating at room temperature for 15 minutes 
3. Adding phosphate buffer up to the 50 ml mark 
4. Centrifuging at 3000 x g for 15 minutes 
5. Decanting the supernatant in 5% Hycolin 
6. Re-suspending pellet in 1ml phosphate buffer 
7. Inoculating decontaminated isolates into a fresh 7H9 culture flask 
2.1.4 Antimicrobial susceptibility testing 
S. aureus isolates were screened for antimicrobial resistance by disc 
diffusion with penicillin, cotrimoxazole, tetracycline, chloramphenicol, 
gentamicin, cloxacillin, erythromycin and cefoxitin (Oxoid, Basingstoke, UK) 
according to Clinical and Laboratory Standards Institute guidelines 297. For 
pneumococcal isolates, antimicrobial susceptibility testing was done for 
clindamycin, vancomycin, trimethoprim-sulfamethoxazole, erythromycin, 
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chloramphenicol and rifampicin using disc and E-test diffusion testing 
following CSLI guidelines. 
For MTBC, susceptibility testing for the first-line drugs streptomycin (STR, 1 
µg/mL), isoniazid (INH, 0.1 µg/mL), rifampicin (RIF, 1µg/mL), and ethambutol 
(EMB, 4.5 µg/mL) was performed on the MGIT 960 system (Becton 
Dickinson, Oxford Science Park, Oxford, UK) according to manufacturer’s 
instructions 298. Multidrug-resistant strains (resistant to isoniazid and 
rifampicin) were further tested for susceptibility to the second-line drugs 
capreomycin (CAP, 2.5 µg/mL), ofloxacin (OFX, 2 µg/mL), and ethionamide 
(ETH, 5 µg/mL) (Sigma-Aldrich, St. Louis, Mo, USA) 293. 
2.2 Sequencing 
2.2.1 Attribution of effort 
Colleagues at the MRCG performed DNA extractions for S. aureus and S. 
pneumoniae strains. I performed the DNA extractions for all MTBC strains. 
All the S. aureus and MTBC strains as well as eight of the outbreak S. 
pneumoniae strains were sequenced at the University of Warwick on the 
Illumina MiSeq following Nextera XT library preparation. Seven outbreak 
strains were sent to the Crick Institute, UK for sequencing after failing to 
sequence in Warwick. At the Crick the libraries were prepared with the 
TruSeq library preparation kit and sequenced on the Illumina MiSeq. 
Contributions to library preparation and sequencing were as follows: 
x S. aureus: Madikay Senghore (50%) and Emma Doughty (50%) 
x S. pneumoniae: Madikay Senghore (30%), Gemma Kay (25%) and 
Crick Institute (45%) 
x MTBC (Nigeria): Madikay Senghore (70%) and Emma Doughty (30%) 
x MTBC (Mali): Madikay Senghore (80%) and Gemma Kay (20%) 
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2.2.2 DNA extraction 
For S. pneumoniae and S. aureus strains, genomic DNA was extracted from 
fresh overnight cultures using the Qiagen DNA Mini kit and Qiagen Genomic 
DNA extraction Kit (Qiagen, UK) respectively, following manufacturer’s 
instructions. Briefly, following lysis, the lysate suspension was aliquoted into 
the Qiagen separation column. The lysate was washed with manufacturer’s 
wash buffers before being eluted as pure genomic DNA. 
For the MTBC, I performed genomic DNA extraction from 3-8 weeks cultures 
using the cetyl trimethylammonium bromide (CTAB) method 299. Briefly: 
1. The culture flasks were slanted against the safety cabinet to 
concentrate cells at the bottom of the flask 
2. 1.5 ml of cell suspension was transferred into a 2mL Safe-Lock 
Eppendorf tube 
3. 1.5 ml of cell suspension was mixed with 1.5 ml Tryptone soya broth 
and aliquoted into two barcode labelled 2 ml cryovials (ThermoFisher) 
for storage at -70ºC 
4. The cells were heat killed at 80ºC for at least 20 minutes 
5. The suspension was spun for 5 min at 9000rpm and the supernatant 
was decanted in a 5% Hycolin waste bucket 
6. Cells were suspended in 450μL Tris/EDTA (TE) buffer (Sigma Aldrich, 
Gillingham, Dorset, UK) 
7. Cells were lysed by adding 50μL of 10mg/ml lysozyme and shaking 
overnight at 37ºC 
8. Proteins were denatured by adding 100μL of 20% Sodium dodecyl 
sulphate and 10μL proteinase K then incubating at 60ºC for 40 
minutes 
9. The DNA was released by adding 100μL of 5M NaCl (Sigma Aldrich, 
Gillingham, Dorset, UK) and then adding 100μL of NaCl/CTAB 
solution and vortexing 
10. The DNA was separated by adding chloroform/Isoamyl alcohol (24:1) 
(Sigma Aldrich, Gillingham, Dorset, UK) and spinning for 8 minutes at 
11000 rpm 
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11. The aqueous layer containing the DNA was carefully transferred to a 
fresh 1.5 mL Eppendorf tube using a P200 pipette 
12. Finally, the DNA was stained with Glycoblue (ThermoFisher Scientific, 
MA, USA) and resuspended by adding cold Isopropanol stored at -
20ºC (Sigma Aldrich, Gillingham, Dorset, UK) 
13. The DNA was washed with cold 70% ethanol and resuspended in 
200μL TE buffer for storage at -70ºC 
2.2.3 Library preparation and sequencing 
Genomic DNA libraries were prepared for whole genome sequencing using 
the Nextera XT library prep kit according to manufacturer’s instructions 
(Illumina, Little Chesterford, UK). Briefly, input DNA was fragmented using a 
tagmentation step at 55qC. The fragmented DNA was tagged with adapters 
and indexed for multiplex sequencing. The tagged DNA fragments were then 
amplified by PCR and the PCR products were purified using Ampure beads. 
Purified PCR products were quantified using the Qubit® fluorometer 
(ThermoFisher, MA, USA). Libraries were typically diluted to 4ng/μl. To 
ensure an equal representation of all samples, a volume representing 40ng 
of each PCR product (typically 10μl of a 4ng/μl dilution) was added to the 
pool. Samples were sequenced on an Illumina MiSeq following the 
manufacturer’s instructions (Illumina, Little Chesterford, UK).  
2.3 Sequence analysis 
The bioinformatics and sequence analysis was performed on a LINUX server 
at the University of Warwick and on an Ubuntu instance running the 
Genomics Virtual Lab on the Cloud Infrastructure for Microbial Genomics 
(CLIMB) 300. Andrew Millard administers the Pallen group server. The CLIMB 
instance came preloaded with numerous bioinformatics tools including the 
Nullarbor pipeline for clinical microbiologists. My collaborators at the 
University of Bath and at St George’s University of London performed 
analyses on their own servers. 
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2.3.1 Genome assembly and annotation 
For each strain de novo contigs were generated from the paired-end 
sequencing reads using SPAdes (kmers: 21, 33, 55, 77, 99 and 127) 301. 
Draft assemblies were annotated with prokka 302. S. aureus genomes were 
filtered to remove contigs that were likely to be contaminants. This was 
achieved by removing short contigs (< 300 bp) that had a low coverage 
(kmer coverage < 2). This information was retrieved from the headers of 
each contig generated by SPAdes.  
2.3.2 MLST and antibiotic resistance prediction from 
whole genome for S. aureus 
The MLST profile of each S. aureus strain was inferred from the genome 
sequence. Initially, I used an assembly approach whereby each draft 
assembly was compared to all alleles in the MLST database 
(http://saureus.mlst.net) using BLAST with default parameters. Alleles were 
called based on 100% sequence coverage and 100% nucleotide identity. 
Some strains had unresolved profiles either due to partial coverage of an 
allele or less than 100% nucleotide identity with a given allele (Appendix 2.2).  
My collaborators at the University of Bath repeated this analysis using the 
SRST2 tool to map raw sequence reads from each strain to all MLST alleles 
and call alleles based on the best match 303 (Appendix 2.3). The results from 
the mapping approach were compared to the results from the BLAST 
approach and they agreed in most instances. The alleles that could not be 
resolved by the BLAST comparison were assigned based on the results of 
the mapping approach. Genomic MLST profiles were compared to MLST 
profiles reported from the laboratory as a quality control. Eleven isolates that 
showed discordance between genomic and laboratory MLST profiles were 
excluded from further analysis. 
The antibiotic resistance profiles for S. aureus strains were predicted by 
uploading sequencing reads onto the Mykrobe predictor tool 304. Mykrobe 
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predicted antibiotic resistance to the main antibiotics: Beta-lactams 
(methicillin, penicillin), quinolones (ciprofloxacin), macrolides/lincosamides 
(erythromycin, clindamycin), tetracycline, aminoglycosides (gentamicin), 
glycopeptides (vancomycin), rifampicin, mupirocin, fusidic acid and 
trimethoprim based on the presence of whole genes as well as point 
mutations. 
2.3.3 In silico serotyping for S. pneumoniae 
Sequencing reads from each isolate were mapped to a multiFASTA file 
containing the sequences of the capsular region for 95 pneumococcal 
serotypes 305 using SMALT. Each capsular type was concatenated into a 
single contig in the multiFASTA file. Samtools version 0.1.18 was used to 
convert the SAM file to a BAM file and to sort the BAM file. The depth utility 
on samtools calculated the depth coverage for each site from the sorted bam 
file. I wrote a Perl script to calculate the average coverage depth and the 
proportion of the sequence covered by at least one read for each capsular 
type (averagecoverage_cps.pl). The average coverage was calculated as the 
sum of depth coverage at all sites divided by the number of sites. Serotype 
was assigned based on the capsular type with the highest proportion of its 
sequence covered by at least one read. 
2.3.4 Analysis using Nullarbor 
S. pneumoniae strains were analysed using the Nullarbor pipeline 306 , which 
performed a number of steps: 
x Sequencing reads were trimmed and filtered for low quality bases and 
reads by trimmomatic 307  
x The species of each isolate was determined by a kmer analysis of a 
database of known genomes using kraken version 0.10.5-beta 308 
x De novo assemblies were generated using MEGA-HIT 309 and 
annotated with prokka 302. Although Nullarbor has an option to 
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generate assemblies using SPAdes, this option proved too memory-
intensive and caused the program to crash 
x MLST profiles 310 were inferred from the assemblies using Seeman’s 
MLST program 311 
x Resistance genes were detected from the assembled genomes using 
abricate, which BLASTs contigs against a database of known 
antimicrobial resistance genes 312 
2.3.5 Lineage assignment and drug resistance 
prediction for MTBC 
Three tools were used to infer phylogenetic lineage and antibiotic resistance 
profiles from MTBC genomes: 
x Kvarq run locally, which predicted drug resistance based on canonical 
mutations 313. However, kvarq predicted resistance in only 66% of the 
phenotypically isoniazid resistant isolates. Kvarq placed strains into 
the seven global lineages, but did not offer phylogenetic placement of 
strains into the sub-lineages 
x PhyResSe and TBProfiler were web-based applications that also 
predicted drug resistance and placed strains into phylogenetic 
lineages 314,315. PhyResSe and TBProfiler provided improved 
resistance prediction for isoniazid resistance, as they scanned through 
a wider repository of resistance mutations. Both tools placed strains 
into the sub-lineages of the Euro-American super-lineage  
2.4 Phylogenetic analyses 
2.4.1 Staphylococcus aureus  
SNVs in the core genome of S. aureus were identified using a customized 
pipeline built by our collaborators at the University of Bath 316. Briefly, paired-
end reads from each genome were mapped against the well-annotated 
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EMRSA15 reference genome (Accession number: HE681097) using SMALT 
317. Known repeat regions, insertion sequences and mobile genetic elements 
(identified by our collaborators at Bath) were excluded and SNVs were called 
using Samtools (version 0.1.18), the GATK toolbox and custom Perl scripts 
318,319. A maximum-likelihood phylogeny was reconstructed using FastTree 
on default parameters 320. 
In line with published estimates, the intra-clonal mutation rate for S. aureus 
was assumed to be ~ 2 x 10-6 per site per year, with a core genome size of 
~2.5 Mb, and was assumed to be constant across lineages and over time 321. 
This equates to a short-term mutation rate of 5 SNVs per year, therefore 
dividing the number of SNVs between two strains by ten gives an estimate of 
the number of years since divergence from a most recent common ancestor 
(MRCA). 
𝑇𝑖𝑚𝑒 𝑠𝑖𝑛𝑐𝑒 𝑀𝑅𝐶𝐴 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑆𝑁𝑉𝑠
𝑀𝑢𝑡𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑖𝑡𝑒𝑠 ×2
 
2.4.2 Streptococcus pneumoniae  
Sequencing reads of S. pneumoniae strains from the meningitis outbreak in 
Ghana were mapped onto the spn1041 reference genome (Accession 
number: PRJNA50807) using Snippy and Snippy-Core within the Nullarbor 
suite to create a multiple sequence alignment of SNVs in the core genome 
322. Nullarbor then created a phylogenetic tree using FastTree. This 
phylogenetic tree was visualised in the context of the geographic origin of the 
strains. The Nullarbor suite also calculated a distance matrix based on the 
pairwise SNV difference between strains. 
In a subsequent analysis, draft assemblies were generated from S. 
pneumoniae serotype 1 isolates using MEGA-HIT. A quality check was 
performed by self-mapping sequencing reads from each strain to its draft 
assembly to ensure that each base in the assembly was supported by at 
least four reads. These assemblies, together with 108 archived draft 
genomes from West African serotype 1 isolates (68 from ST303 and 44 from 
ST217), were mapped against the spn1041 reference genome and SNVs in 
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the core genome were called using core.ope, an assembly-based SNV-
calling pipeline created by Dr Zhemin Zhou (University of Warwick) 323. 
The core.ope method initially aligned each assembly to the spn1041 
reference genome using the nucmer function in MUMmer 324 and placed all 
aligned query genomes in a multiple sequence alignment with the reference 
genome. Custom Perl scripts drawing on a user-generated table with the 
start and stop positions of all insertion sequences in the reference genome 
were used to remove insertions. The mobile genetic elements in the spn1041 
reference genome were listed in the annotation provided by the Sanger 
institute (Appendix 2.4). I searched the CRISPR database for CRISPRs in 
the spn1041 reference genome but none were listed. The core genome was 
assigned as the regions that were conserved in all genomes that were not 
insertion sequences. (A folder with the core.ope source code is available in 
the Appendix folder) 
Variants were called from the core genome and recorded in a SNV table 
listing variant calls in each strain at every polymorphic site in the core 
genome. The SNV table was converted into a multiple sequence alignment, 
which was then loaded into RAxML: Randomized Axelerated Maximum 
Likelihood to reconstruct a maximum likelihood phylogeny using a general 
time reversible model for substitution 325. 
The multiple sequence alignment of the outbreak serotype 1 strains and 108 
West African serotype 1 strains was inputted into Gubbins and recombination 
events were inferred with default parameters 326. The drawing tools in 
Gubbins were used to present recombination events as a heatmap adjacent 
to a phylogenetic tree reconstructed by Gubbins. 
Genotypic diversity indices for serotype 1 strains were computed using R 
(3.3.1) statistics tools and R packages (poppr 2.2, adegenet 2.1). The SNV 
table inferred from the core genome of the outbreak serotype 1 strains and 
108 West African serotype 1 strains was inputted into R. Strains were 
clustered into three groups:  
x West African ST303 clade 
x Novel ST303 clade  
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x West African ST217 clade.  
Allele frequencies and the Simpson diversity index were calculated for each 
variable site. As a quality control, uninformative sites that did not distinguish 
between the three clusters and sites that had a Simpson’s index < 0.1 were 
not considered. The Shannon diversity index for each cluster was calculated 
to determine the level of diversity within the cluster 327. The index of 
association (IA) and the standardized index of association, rÂ¯ d were 
computed for each cluster to determine the level of clonality within each 
cluster 328.  
2.4.3 Mycobacterium tuberculosis complex 
The phylogeny of MTBC isolates from Nigeria was reconstructed using a 
custom pipeline built by Dr Adam Witney (St George’s University of London) 
329. Sequencing reads were mapped on to the H37Rv reference genome and 
variants were called using Samtools and custom Perl scripts. Variants were 
called from sites that were covered by at least two reads in either direction, 
were supported by at least 75% of reads and had a quality score of at least 
30. An alignment of variants in the core genome from all strains was 
generated and the maximum likelihood phylogeny was reconstructed using 
RAxML with a general time reversible model for substitution.  
The core.ope pipeline was employed to reconstruct the phylogeny of MTBC 
isolates from Mali. Draft assemblies generated with SPAdes were mapped to 
the H37Rv reference genome and SNVs were called from the core genome 
as described above. The repeat regions in the H37Rv genome, which were 
excluded from the core genome were identified by Dr Martin Sergeant 
(University of Warwick) as part of his work on tuberculosis in ancient 
mummies 330. A distance matrix was generated by uploading the multiFASTA 
alignment of core genome SNVs onto MEGA7: Molecular Evolutionary 
Genetics Analysis version 7.0 331, which computed the number of differences 
between strains. The maximum likelihood phylogeny with RAxML using a 
general time-reversible model of substitution was reconstructed.  
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2.4.4 Tree visualisation and annotation  
Phylogenetic trees were visualised with their associated metadata using 
FigTree 1.4.2 and were annotated on inkscape. The following context-
specific colouring approaches were used: 
x For S. aureus, tips were coloured based on the source of the isolate 
(i.e. invasive disease, carriage, reference or monkey) and the 
branches were coloured to represent the major clades in the 
phylogeny 
x Outbreak S. pneumoniae strains were placed into three groups: Novel 
ST303, West African ST303 and non-serotype 1. Unique tip colours 
were assigned to each group 
x For the broader serotype 1 phylogeny, branches were coloured to 
show three major clades (1) West African ST303 clade, (2) Novel 
ST303 clade and (3) West African ST217 clade and tips were 
coloured based on the country of origin of the strain. The novel clade 
was highlighted on the phylogenetic tree 
x For MTBC, the branches were coloured according to major lineage 
(lineage 1-7) and the tips were coloured according to sub-lineage 
2.5 Accessory genome analysis 
An accessory genome analysis for the S. aureus dataset was performed 
using SPINE and AGEnt 332. To infer a core genome from our dataset, a 
representative genome was selected from each clade or clonal complex in 
our phylogeny. The best quality assemblies were identified according to 
assembly size, number of contigs and n50. Where possible, a published 
closed genome was used to represent major clonal complexes. The 
representative dataset included 35 genomes. SPINE used Mummer to align 
the genomes and then extracted the core genome by identifying genes that 
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were conserved in all 35 genomes. AGEnt inferred the accessory genome of 
each query genome by removing the representative set of core genes.  
A Bio Perl script authored by Dr Sion Bayliss (University of Bath) was used 
iteratively to identify orthologous groups of coding sequences (CDSs) 
between the accessory genomes (FindSharedGeneContent.pl). The scripts 
iteratively took each CDS in the accessory genome of each strain and 
searched the accessory genome of all other strains for a homolog using 
BLAST. To prevent redundancy, CDSs that already had a match were not 
compared in subsequent queries. For each CDS, presence or absence of an 
orthologue was scored based on 85% sequence identity at the protein level, 
while CDSs generating multiple hits in any genome were ignored. A pairwise 
matrix was generated showing the proportion of shared accessory genome 
(PercentID.pl). An R script authored by Dr Sion Bayliss plotted the proportion 
of shared accessory genome as a heatmap linked to the phylogenetic tree 
(Plot_Gambia.R).
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3 CHAPTER THREE: HUMAN TO MONKEY 
TRANSMISSION OF STAPHYLOCOCCUS AUREUS 
IN THE GAMBIA 
3.1 Introduction 
3.1.1 Genome evolution in S. aureus 
The Staphylococcus aureus genome consists of a circular chromosome of 
approximately 2.8 Mb 333 together with, in some strains, one or more extra-
chromosomal plasmids that can carry virulence and antibiotic resistance 
genes 334. S. aureus is characterised by high rates of horizontal gene transfer 
(HGT). This leads to marked strain-to-strain diversity in the repertoire of 
mobile genetic elements (MGEs) and, consequently, in repertoires of 
virulence and resistance genes 335,336. MGE content can vary remarkably 
even between strains within the same clonal lineage 337. MGEs make up 15-
20% of the S. aureus genome 337,338 and include: 
x Transposons 
x Bacteriophages 
x Plasmids 
x S. aureus pathogenicity islands (SaPIs) 
x The staphylococcal cassette chromosome mec (SCCmec), which 
encodes methicillin-resistance  
The S. aureus core genome makes up ~75% of the genome content in any 
particular strain 335,339. There is marked diversity at the core genome level 
between the independently evolving clonal lineages of S. aureus 340. 
Diversity within the core genome is driven mainly by accumulation of point 
mutations 341. Core genome transfer is also a source of diversity in the core 
genome 340. However, although rates of core genome transfer between 
closely related strains are low 97, for basal branches of the species tree, there 
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is strong evidence for high rates of recombination between clonal complexes 
340. 
3.1.2 Genomic Islands 
Genomic islands (GIs) are regions of the genome, 10–200 kb in length, that 
have an atypical nucleotide composition and contain clusters of genes 
acquired through HGT 342. GIs can carry a wide variety of genes that often 
confer mechanisms for microbial adaptation to the host and environment 342. 
Most S. aureus strains carry a diverse array of GIs, including three highly 
polymorphic genomic islands (νSaα, νSaβ and νSaγ) that carry genes for 
superantigens, lipoproteins and proteases 339,343. Diversity of vSas is driven 
by gene loss, high recombination rates and transferability by transducing 
phage particles 339,344.  
3.1.3 Evolution of drug resistance 
Shortly after the introduction of penicillin in the early 1940s, penicillin-
resistant S. aureus emerged 345. Early penicillin resistance was conferred 
through acquisition of the blaZ gene. blaZ encodes for the production of β-
lactamase, which hydrolyses the beta-lactam ring 346. Since then, drug 
resistance has emerged for virtually all antibiotics used to treat S. aureus, 
even including drugs such as methicillin and vancomycin 257. 
Methicillin resistance is conferred by the mecA gene, which is carried by the 
Staphylococcal chromosome cassette mec (SCCmec). mecA encodes an 
altered penicillin binding protein that has a low affinity for all beta-lactam 
antimicrobials and their derivatives 347,348. Methicillin-resistant S. aureus 
(MRSA) spread mainly through clonal inheritance, but the SCCmec can also 
be transferred between strains 349. MRSA was originally associated with 
hospital infection, but over the past three decades a remarkable increase has 
been observed in the prevalence of community-associated MRSA 345.  
The unprecedented rise of antibiotic resistance in S. aureus has led to 
increased use of vancomycin for treatment 350. The selective pressure due to 
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widespread vancomycin usage has led to the emergence of vancomycin 
resistant strains of S. aureus 351. 
3.1.4 Population structure of human S. aureus 
Staphylococcus aureus is a largely clonal organism, which means that 
strains cluster into several widespread clonal complexes (CCs) 97,352. Aside 
from similar sequence alleles among core genes, each clonal complex is 
defined by possession of a common set of lineage-specific variable genes 
335,337. However, some variable genes are shared between lineages through 
vertical transfer and subsequent sequence divergence 335. 
Globally ten dominant lineages (CC1, CC5, CC8, CC12, CC15, CC22, CC25, 
CC30, CC45 and CC51) are believed to cause the majority of human 
infection 97. Occasionally localised lineages of S. aureus emerge that are 
predominant in particular regions. For example, CC152 is uncommon in 
Europe, but is dominant in Mali, in Ghana and probably throughout much of 
sub-Saharan Africa 118,353,354. In Japan, the predominant community-
associated methicillin resistant lineage CC89 is believed to have emerged 
locally and evolved under strong selective pressure from antibiotics 355.  
3.1.5 Genomic epidemiology of S. aureus infections 
When the first S. aureus genome was sequenced 15 years ago it revealed a 
vast repository of virulence genes and the contribution of HGT to genome 
diversity 356. Whole genome sequencing (WGS) offered a new perspective on 
the population structure and evolution of S. aureus, which built on knowledge 
from phenotypic methods and genotyping techniques 357 (Table 3.1). WGS 
has enhanced our understanding of the transmission and spread of MRSA 
both in the community and in hospital settings 266,321,358. During an outbreak 
of S. aureus chains of transmission can be identified through WGS 359,360. 
Longitudinal studies have revealed fluctuations in gene diversity that occur 
within the host during asymptomatic carriage and subsequent invasive 
disease 236,361. Routine WGS of S. aureus in Europe has provided insights 
into the transmission dynamics of S .aureus and served as an early warning 
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for the emergence of highly virulent clones 118. In sub-Saharan Africa major 
knowledge gaps exist in the molecular epidemiology of S. aureus highlighting 
the need for genomic surveillance 362. 
Table 3.1 Use of genomic epidemiology to track the evolution of S. aureus infection. 
Important citations are listed and a brief summary is provided for each study. 
Citation Region Major findings 
360 
Global Global epidemiology of the hospital associated MRSA lineage 
ST239. Evidence for intercontinental spread of the lineage. 
Convergent evolution on antibiotic resistance genes 
363 
Oxfordshire, 
UK 
Sequential strains sequenced from asymptomatic carriers of S. 
aureus. Evidence of evolution in asymptomatic carriage 
dominated by purifying selection. 
358 
South 
England, UK 
Genome analysis used to infer the routes of transmission of 
MRSA in a hospital setting. Evidence that patient-to-patient 
transmission is not the main source of infection. Importantly 
WGS disproved patient-to-patient transmission inferred by 
inferior genotyping techniques and detected unsuspected 
cases of transmission. 
321 
United States The evolution of the community-acquired MRSA lineage ST8 
(USA300) driven by household reservoir. The expansion of the 
clone is also driven by emergence of fluoroquinolone resistance 
359 
Thailand Diversity of ST239 MRSA lineage in a low resource setting 
hospital. Remarkable level of diversity in a single hospital. 
Nosocomial spread and microevolution within a single patient. 
364 
Denmark, 
Copenhagen 
Monitoring MRSA through routine WGS and epidemiological 
data. MRSA genome database enhances understanding of 
transmission.  
304 
- Mykrobe predictor, a milestone in genomic epidemiology of S. 
aureus. Prediction of antibiotic resistance from sequencing 
reads within minutes on a laptop. Error rates comparable to 
gold standard phenotypic test. 
365 
England and 
Ireland 
Whole genome sequencing of MRSA isolates from long term 
care facilities. Major lineage ST22. Evidence of transmission of 
MRSA between patients in the facility. 
366 
East of 
England, UK 
Genomic analysis of USA300 MRSA strains isolated from 
patients with sequenced USA300 strains from USA. Evidence 
of multiple introductions of USA300 in the region and 
household transmission. 
118 
Europe Snapshot of the European invasive S. aureus population 
structure: “high-risk clones can be identified on the basis of 
population level properties such as clonal relatedness, 
abundance, and spatial structuring and by inferring virulence 
and resistance properties on the basis of gene content”. 
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3.1.6 Evidence for host switching 
S. aureus colonises a wide range of non-human hosts including livestock, 
companion animals 266 and wild animals 267. Some clonal lineages of S. 
aureus have a strong association with specific hosts 367, but occasionally 
bacteria will adapt to a new host and spread through a new host population 
352. For example, some livestock-associated lineages of MRSA lineages, 
most notably CC97 and CC398, have overcome the species barrier to infect 
humans 368,369. Similarly MRSA clones from human-associated lineages, 
such as CC5, CC9 and ST88, have been reported in livestock 370. A study 
based on MLST across multiple host species showed that anthroponotic 
(human-to-animal) transmission of S. aureus occurs more frequently than 
zoonosis (animal-to-human transmission) 101. Whole-genome sequencing 
has been used to detect and analyse transmission of S. aureus within and 
between various host species, including anthroponotic and zoonotic events 
368,371,372. 
3.1.7 S. aureus among non-human primates 
Recent data shows that human-associated S. aureus lineages can infect 
great apes that come into contact with humans in captivity and in the wild 
373,374. These infections can be fatal and this poses a threat to some 
endangered great apes species 373,374. African monkeys in remote regions 
are colonized by S. aureus from uncharacterized clonal complexes that rarely 
colonize or infect humans 268. One highly divergent clade of coagulase-
positive staphylococci is known to infect monkeys in sub-Saharan Africa, but 
has never been recovered from humans so far; this clade has recently been 
classified as a new species, S. schweitzeri 268,375. However, such monkeys 
are also often colonized by human-associated genotypes of S. aureus, which 
they are likely to have acquired from humans 268. Previously S. aureus in 
monkeys was only studied through MLST, which does not have the 
resolution to infer inter-species transmission and cannot elucidate the 
evolutionary mechanisms that drive host adaptation. Our study was the first 
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comparative genomics study on S. aureus from humans and monkeys in 
sub-Saharan Africa 316. 
3.1.8 Objectives and study rationale 
Here, I describe the use whole-genome sequencing of S. aureus isolates 
from humans and monkeys in The Gambia with the following goals: 
x To determine whether transmission of S. aureus has occurred 
between humans and non-human primates in The Gambia through 
a phylogenetic analysis of S. aureus isolates from monkeys alongside 
human S. aureus from carriage and invasive disease 
x To estimate the timescale of any inter-host transmission events 
using a published mutation rate to estimate the time since the most 
recent common ancestor based on the number of mutations 
accumulated in the core genome 
x To investigate the genetic changes accompanying host 
adaptation by studying the patterns of gene presence and absence in 
the accessory genome   
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3.2 Materials and Methods 
3.2.1 Bacterial isolates 
Prior to this study, staff at the MRC Unit in The Gambia had compiled an 
initial dataset of MLST profiles from 298 S. aureus isolates from The Gambia. 
This set of isolates included: 
1. Monkey isolates cultured from nasopharyngeal and oropharyngeal 
swabs taken from African Green Monkeys (Chlorocebus sabaeus) 
in 2011 by the International Vervet Research Consortium during a 
study on Simian Immunodeficiency Virus in The Gambia 376. 
2. Human invasive disease isolates (unpublished data), recovered 
from archived clinical specimens including venous blood, pleural 
fluid, cerebrospinal fluid, joint aspirate, lung aspirate, ascetic fluid, 
and lymph node aspirates 
3. Human carriage isolates were recovered from nasopharyngeal and 
oropharyngeal swabs from healthy humans  
For this study, a subset of 90 human and monkey isolates of S. aureus was 
selected. These strains had been previously characterised by MLST and 
antimicrobial susceptibility testing by staff at the MRC Unit in The Gambia 
(Table 3.2). This subset included 46 human invasive disease, 13 human 
carriage and 31 monkey pharyngeal carriage isolates (Table 3.2) This subset 
included at least one strain from each clonal complex present in the full 
MLST dataset and 20 reference genomes were included to represent as 
many of the major clonal complexes as possible.   
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Table 3.2 Metadata for 90 S. aureus isolates analysed by WGS. 
ID
 
Ep
id
em
io
lo
gy
 
ST
 
CC
  
Pe
n 
Sx
t 
Te
t C Cn
 
O
b E 
M
et
h 
Da
te
 
A2 Invasive 1 CC1 R S S S S S S S 25/05/02 
C11 Invasive 852 CC1 R S S S S S S S 11/08/07 
C12 Invasive 852 CC1 R S S S S S S S 28/10/09 
SA9 Carriage 1* CC1 S S S S S S S S 29/03/04 
B12 Invasive 101 CC101 S S I S S S S S 19/09/02 
C1 Invasive 101 CC101 R S S S S S S S 24/11/05 
C3 Invasive 121 CC121 R S S S S S S S 04/04/03 
SA32 Invasive 121 CC121 R S R S S S S S 27/04/06 
SA33 Invasive 121 CC121 R S R S S S S S 24/12/02 
D11 Invasive 2433 CC121 R S S S S S S S 01/03/03 
SA2 Carriage 15 CC15 S S S S R S S S 13/01/04 
A8 Invasive 15 CC15 R S S S S S S S 11/01/08 
A9 Invasive 15 CC15 R S R S S S S S 18/11/05 
A10 Invasive 15 CC15 R S R S S S S S 02/09/04 
A11 Invasive 15 CC15 R S S S S S S S 23/02/09 
B1 Invasive 15 CC15 R S S S S S S S 14/07/09 
B3 Invasive 15 CC15 R S R S S S S S 18/07/02 
B4 Invasive 15 CC15 R S R S S S S S 30/08/06 
SA23 Invasive 15 CC15 R S R S S S S S 04/08/10 
SA24 Invasive 15 CC15 R S R S S S S S 19/05/09 
SA26 Invasive 15 CC15 R S S S S S S S 11/10/05 
SA31 Invasive 15 CC15 R S R S S S S S 07/07/05 
SA29 Monkey 15 CC15 S S S S S S S S 01/04/11 
D12 Invasive 2434 CC15 R S S S S S R S 26/08/08 
C4 Invasive 152 CC152 R S S S S S S S 10/02/09 
C6 Invasive 152 CC152 R S S S S S S S 24/04/08 
C7 Invasive 152 CC152 R S R S S S S S 24/08/09 
C8 Invasive 152 CC152 R S S S S S S S 12/09/05 
SA34 Invasive 152 CC152 R S R S S S S S 25/09/07 
F5 Monkey  CC152 S S S S S S I S 01/04/11 
D10 Invasive 2432 CC2432 S S S S S S S S 20/02/07 
B5 Invasive 25 CC25 R R R S S S S S 31/07/09 
B6 Invasive 25 CC25 R R S S S S S S 04/11/08 
F7 Monkey Novel CC2531 S S S S S S S S 01/04/11 
F8 Monkey Novel CC2531 S S S S S S S S 01/04/11 
SA22 Monkey Novel CC2531 S S S S S S S S 01/04/11 
F9 Monkey 2532 CC2532 S S S S S S S S 01/04/11 
G2 Monkey 2532 CC2532 S S S S S S S S 01/04/11 
F11 Monkey 2533 CC2533 S S S S S S S S 01/04/11 
F12 Monkey 2533 CC2533 S S S S S S S S 01/04/11 
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SA27 Monkey 2533 CC2533 S S S S S S S S 01/04/11 
H4 Monkey Novel CC2565 S S S S S S I S 01/04/11 
H5 Monkey Novel CC2565 S S S S S S S S 01/04/11 
H6 Monkey Novel CC2565 S S S S S S S S 01/04/11 
H7 Monkey Novel CC2565 S S S S S S I S 01/04/11 
H8 Monkey Novel CC2565 S S S S S S S S 01/04/11 
G5 Monkey 2566 CC2566 S S S S S S I S 01/04/11 
H9 Monkey 2569 CC2566 S S I S S S I S 01/04/11 
H10 Monkey 2569 CC2566 S S S S S S S S 01/04/11 
G8 Monkey 2567 CC2567 S R S S R R I R 01/04/11 
G9 Monkey 2567 CC2567 S S S S S S S S 01/04/11 
G10 Monkey 2567 CC2567 S S S S S S S S 01/04/11 
G11 Monkey 2567 CC2567 S S S S S S S S 01/04/11 
G12 Monkey 2567 CC2567 S S S S S S S S 01/04/11 
H2 Monkey 2567 CC2567 S S S S S S S S 01/04/11 
SA18 Carriage 30 CC30 S S S S I R S S 25/02/04 
B8 Invasive 30 CC30 R S S S S S S S 19/02/02 
SA35 Invasive 30 CC30 R S R S S S S S 20/02/07 
D1 Invasive 1472 CC30 R S S S S S S S 19/02/02 
D2 Invasive 1472 CC30 R S S S S S S S 12/08/05 
D4 Invasive 1472 CC30 R S S S S S S S 09/09/08 
D5 Invasive 1472 CC30 R S S S S S S S 08/11/02 
D6 Invasive 1472 CC30 R S S S S S S S 08/11/02 
C9 Invasive 508 CC45 S S S S S S S S 22/04/10 
SA21 Carriage Novel CC45 S S S S S S S S 11/03/04 
A3 Invasive 5 CC5 R S R S S S S R 28/01/09 
A5 Invasive 5 CC5                   
SA17 Invasive 5 CC5 R S S S S S S S 12/08/05 
E1 Monkey 6 CC5 S S S S S S S S 01/04/11 
E2 Monkey 6 CC5 S S S S S S S S 01/04/11 
E3 Monkey 6 CC5 S S S S S S S S 01/04/11 
E4 Monkey 6 CC5 S S S S S S S S 01/04/11 
E5 Monkey 6 CC5 S S S S S S S S 01/04/11 
E6 Monkey 6 CC5 S S S S S S I S 01/04/11 
E8 Monkey 6 CC5 S S S S S S S S 01/04/11 
SA6 Carriage 72 CC5 S S S S S R S S 20/01/04 
B9 Invasive 72 CC5 R S R S S S S S 20/08/05 
B10 Invasive 72 CC5 R S R S S S S S 21/09/04 
SA3 Carriage 730 CC5 S S S S S S S S 05/04/04 
SA14 Carriage 730 CC5 S S S S S S S S 23/03/04 
SA15 Carriage 730 CC5 S S S S S S S S 23/03/04 
SA16 Carriage 5* CC5 S               27/03/04 
A6 Invasive 8 CC8 R R R S S S S S 27/02/07 
A7 Invasive 8 CC8 R S S S S S S S 13/03/08 
D8 Invasive 239 CC8 R R R S R R R R 01/06/07 
SA7 Carriage 509 CC89 S S S S S S S S 10/12/03 
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SA13 Carriage 509 CC89 S S S S S S S S 16/03/04 
SA19 Carriage 509 CC89 S S S S S S S S 14/01/04 
SA20 Carriage 509 CC89 S S S S S S S S 21/04/04 
B11 Invasive 97 CC97 S S R S S S S S 16/05/07 
Footnote: Isolates metadata showing genomic ID, Lab ID, Epidemiology (human carriage, human 
invasive disease or Monkey carriage), sequence type ST, clonal complex CC, antibiotic resistance 
(penicillin Pen, trimethroprim Sxt, tetracycline Tet, Chloramphenicol C, Gentamycin Cn, Cloxacillin Ob, 
Erythromycin E and methicillin Meth) and date of sample collection. Table sorted by CC then ST then 
Epidemiology to make it more easily intelligible. * In ST represents a single nucleotide variant. 
 
3.2.2 Geography and demographics of study area 
The Gambia is a small West African country with a population of 
approximately 1.8 million. The Gambia is partitioned across its breadth by the 
river Gambia, which forms an estuary with the Atlantic Ocean. The most 
developed region of The Gambia is the Western region, the coastal region 
south of the River Gambia. My dataset combines isolates from three studies 
that were carried out in the Western region of The Gambia.  
The majority of monkeys sampled had been trapped within a 10km radius of 
the MRC camp in Fajara, either at the Bijilo Forest Park or the Abuko nature 
reserve 376 (Figure 3.1). The monkeys were habituated to humans as a result 
of urbanisation and tourism. The Bijilo Forest Park is a tourist attraction 
where locals and tourists go to visit the monkeys. Visitors get a chance to get 
up close to the monkeys, taking pictures with them and on some occasions 
illegally feeding them peanuts. This interaction presents an opportunity for 
inter-host transmission of potential pathogens.  
The human carriage survey was performed in Sibanor, a village ~80km from 
the MRC camp in Fajara, between Dec-04 and Apr-05 (Table 3.3) 377. This 
study was carried out to document the prevalence and diversity of S. aureus 
colonising humans prior to the introduction of pneumococcal conjugate 
vaccines in The Gambia. The invasive disease isolates were recovered from 
patients that reported to the MRC clinic in Fajara. Strains from these two 
datasets were genotyped in order to provide a baseline for comparing the S. 
aureus strains isolated from monkeys and human S. aureus. 
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 Figure 3.1 A Google map screen shot showing the spatial distribution of the study 
sites where the S. aureus isolates were sampled. Red stars indicate monkeys sampling 
sites and blue star indicates the site for the carriage study. 
 
Table 3.3 A summary of the three studies that formed the basis of the S. aureus 
analysis. For each study the distance from the MRC camp to the study sampling site and 
the period of sampling was listed. The number of samples analysed by MLST and the 
number of samples analysed by WGS are indicated. 
Epidemiology Study site Distance 
from MRC 
(km) 
Start 
date 
End 
date 
MLST 
analysis 
(n) 
WGS 
analysis 
(n) 
Invasive 
disease 
MRC Clinic 
Fajara 
0 2002 2010 116 46 
Human 
carriage 
Sibanor, Foni 83 Dec-04 Apr-05 100 13 
Monkey 
carriage 
Mainly Abuko 
nature reserve 
and Bijilo forest 
park 
10 km radius Apr-11 May-11 82 31 
3.2.3 Workflow for bioinformatics and sequence 
analysis 
A detailed explanation of the methods is provided in the methods section 
(section 2). Below I present a flow chart that summarises the steps that were 
taken as part of the analysis (Figure 3.2). 
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Figure 3.2 A flowchart summarizing the workflow for the bioinformatics analysis of the 
S. aureus dataset.  
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3.3 Results 
3.3.1 Genome sequences 
Draft assemblies ranged from 2,701,991 to 3,048,160 nucleotides in length 
(average 2,793,864.9, median 2,786,149), with an average GC content of 
32.7 % (range: 32.5 to 32.9%). The genomes were annotated with an 
average of 2593 coding sequences (CDSs) (range 2462 to 2921). When 
mapped to the EMRSA15 reference genome, the mean genome-wide 
coverage was 61.5 fold (range 12.5 to 126.2).  
3.3.2 Population structure of S. aureus in The Gambia 
Single nucleotide variants (SNVs) were called from 232,276 variable sites in 
the core genome after excluding all known repeat regions and transposable 
mobile elements. These SNVs were used to create a maximum-likelihood 
phylogenetic tree linking isolates with reference strains (See the multiple 
sequence alignment of core genome SNVs and the core SNV distance matrix 
in Appendices 3.1 & 3.2 respectively). This phylogenetic tree revealed the 
clonal population structure of S. aureus. Strains belonging to the same clonal 
complex clustered on monophyletic branches on the phylogenetic tree. The 
tree resolved five major S. aureus clades that were consistent with previous 
species-wide phylogenetic analyses (Figure 3.3): 
x Clade 1 encompassed pandemic clonal lineages CCs 1, 5, 6, 8, 15 
and 25, and closely related genotypes. Clade 1 encompassed both 
human carriage and human invasive disease strains including two 
MRSA invasive disease strains from the ST5 and ST339. Within clade 
1 there was also a cluster of ST6 isolates from monkeys and a ST15 
isolate from a monkey that clustered with the human ST15 isolates 
x Clade 2 represented a monkey-specific clade that contained most of 
the S. aureus isolates recovered from monkeys. This clade was 
comprised of lineages bearing (at the time) novel STs that were only 
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isolated from monkeys. Clade 2 was characterised by deep branches 
that resolved into clusters of unique CCs inferred by eBURST 
x Clade 3 included the EMRASA15 reference genome; human carriage 
and human invasive disease strains belonging to the globally 
disseminated lineages CC30 and CC45; and a cluster of ST509 
carriage strains, which were single locus variants of the Japanese 
MRSA lineage ST89 
x Clade 4 housed the pandemic lineage CC121 alongside animal-
associated reference genomes. All the CC121 strains were recovered 
from human invasive disease 
x Clade 5 included the dominant West African lineage ST152 and 
closely related genotypes. All human strains in clade 5 were 
recovered from invasive disease specimens. In clade 5 we also 
recovered a single novel variant from monkeys (F5), which was 
related to, but still distinct from, ST152 
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Figure 3.3 Maximum likelihood phylogenetic tree of all S. aureus study isolates and 
reference genomes. Tips coloured by epidemiology and branches coloured based on 
arbitrary nomenclature (clade 1-5). Branches are also annotated with the major human 
clonal complexes (CCs) that are described in the literature and CCs for clade 2 strains 
assigned by eBURST. 
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3.3.3 Anthroponotic transmission of S. aureus  
This dataset provided a rare insight into the contemporaneous population 
structure of S. aureus in humans and monkeys. Assuming a constant 
mutation rate, the timescales for inter-host transmission of S. aureus 
between humans and monkeys in The Gambia were estimated (Table 3.4). 
Current estimates of intra-clonal mutation rates are consistent in S. aureus 
321. Based on the intra-clonal mutation rate for S. aureus of ~ 2 x 10-6 per site 
per year 321, and a core genome size of ~2.5 Mb, it was possible to estimate 
an upper bound date for the transmission events. The short-term mutation 
rate equates to about 5 SNPs per year. Thus simply dividing the total number 
of SNPs between any pair of contemporary S. aureus isolates by ten gives 
the approximate number of years since they shared a common ancestor. 
The phylogenetic placement of clade 2 – nested between human-associated 
clades – suggests this clade has human ancestry. The most divergent pair of 
clade 2 isolates differed by 26,464 SNVs. Similarly, the closest pairwise 
distance to an isolate outside clade 2 (The MSSA476 reference genome) 
was 26,968 SNVs. Thus, clade 2 was likely to have emerged from a host 
jump that occurred ~2700 years ago. There were no clear examples of 
zoonotic transmission (from monkeys to humans), as no human-derived 
isolates fell within the novel monkey-associated clade 2. 
The ST6 monkey isolates in clade 1 formed a tight cluster, within which the 
furthest distance between two ST6 monkey isolates was 270 SNVs. The 
lowest divergence between a ST6 isolate from a monkey and the reference 
ST6 isolate from a human in Europe was just 311 SNVs. These observations 
suggest that ST6 was transmitted from humans to monkeys a little under 
three decades ago.  
The single ST15 isolated from a monkey in clade 1 differed from an invasive 
disease isolate by 71 SNVs. This most likely represents an anthroponotic 
host switch that occurred approximately less than 7 years ago. This estimate 
was not attempted for the monkey isolate in clade 5 due to lack of a closely 
related human isolate. 
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Table 3.4 The estimated time-scales for the anthroponotic transmission events. 
Monkey 
Genotype 
Closest Human 
isolates (SNVs) 
Estimated time 
of host jump 
(years) 
Furthest within-
clade monkey 
isolate (SNVs) 
Estimated time 
of divergence 
(years) 
ST15 71 7 - - 
ST6 311 31 270 27 
Clade 2 26968 2700 26464 2700 
 
3.3.4 Proportion of shared accessory genome  
The core genome was inferred from a representative dataset of 35 genomes, 
including reference genomes, using SPINE. The accessory genome for each 
strain was inferred using AGENT, which excluded the representative core 
genome 332. Using a custom Perl script, the pairwise proportion of accessory 
genome shared between strains was calculated based on 85% sequence 
homology. A heatmap showing pairwise shared proportion of accessory 
genome was plotted with the phylogenetic tree (Figure 3.4). The gene 
presence and absence list is presented in Appendix 3.3. 
Isolates within the same clonal complexes shared similar accessory genome 
content. Similarly, the related CCs that formed distinct clades shared more 
similar accessory genome content than unrelated CCs. For example, in clade 
1 CC15/1/8/97/6/25/5 share more accessory genome content with each other 
that other clades (Figure 3.4). The same trend was observed in the monkey-
associated clade 2: CCs within the clade had similar accessory genome 
content and the accessory genome was highly conserved between strains 
within the same CCs. The CC152 monkey strain F5 had a unique accessory 
genome that consisted of 365 CDSs. F5 shared less that 40% of its 
accessory genome with any other genome. 38% of the accessory genes 
present in F5 were present in clade5 isolates while 31% were present in 
CC2566 isolates in clade2. The conservation of accessory genome content 
within CCs supports the concept of a “core variable” genome 335. 
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Figure 3.4 A heatmap showing the proportion of accessory genes between S. aureus 
linked to the phylogenetic tree. The nodes on the phylogenetic tree are coloured to 
represent their respective CCs. The list of tips in the key corresponds to the order of CCs in 
the vertical tree on the left from top to bottom. 
3.3.5 Gene loss in clade 2 and host adaptation 
The BLAST Ring Image Generator (BRIG) highlighted genome erosion 
based on an 85% sequence similarity threshold with the USA300 reference 
genome. BRIG compared six monkey-derived isolates representing the 
different CCs within clade 2. Genome erosion was observed among clade 2 
isolates on mobile genetic elements such as; the genomic islands νSaα and 
νSaβ; the SCCmec cassette; the phage element ϕSa2USA; the pathogenicity 
Island SaPI5; and the Immune evasion cluster (IEC) (Figure 3.5).  
The SCCmec cassette and the pathogenicity Island SaPI5 were absent in all 
of the representative strains from the clade 2 sub-clusters. The genomic 
islands νSaα and νSaβ were consistently partially eroded in all strains. There 
was variation within the different clade 2 subgroups, notably isolates H10 
(CC2569) and G11 (CC2567) contain a more intact phage φSA2USA than 
the other clade 2 subgroups. The ϕSa3USA phage element and the IEC 
were only intact in isolates SA27 (CC2533) and F7 (CC2531) respectively.
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Figure 3.5 Genome-wide BLAST comparison of isolates representing the CCs of clade 2 against the USA300 reference genome showing regions of 
genome erosion. (A) The inner ring represents the reference genome and each of the outer rings represents a unique strain. Annotations represent mobile 
genetic elements and Genomic Islands. (B) A schematic of clade 2 wherein each CC is coloured uniquely.  
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3.3.6 Antibiotic resistance 
The Mykrobe predictor was employed to predict antimicrobial resistance from 
the genome sequence data 304. Mykrobe predicted antibiotic resistance 
based on the presence of whole genes as well as point mutations. The 
Mykrobe predictor also determined the presence of the Panton-Valentine 
leukocidin toxin genes in the strains. 
Based on phenotypic antimicrobial susceptibility testing high levels of 
penicillin resistance were observed among invasive disease isolates (89%). 
Penicillin resistance was conferred by presence of the blaZ gene in most 
cases. Among invasive disease isolates 19 were resistant to tetracycline. 
The tetL, tetM and/or tetK genes mediated tetracycline resistance. 
Two invasive disease isolates were confirmed to be methicillin resistant and 
both isolates bore the mecA gene. The MRSA invasive disease strains 
belonged to the globally disseminated genotypes ST239 and ST5. These 
represented the first published reports of MRSA causing invasive disease in 
The Gambia 316. 
None of the carriage strains were classified as penicillin or tetracycline 
resistant based on disc diffusion antimicrobial susceptibility testing. However, 
based on the genome Mykrobe predicted that 12/13 and 4/13 carriage strains 
were resistant to penicillin and tetracycline respectively. This indicates that 
the burden of antimicrobial resistance among S. aureus carriage strains in 
The Gambia is likely to be underestimated by disc diffusion. 
This dataset does not confirm drug resistance among S. aureus isolates from 
monkeys in The Gambia. Initially one isolate from a monkey had been 
characterised as methicillin resistant based on cefotoxin disc diffusion. 
However, when the antibiotic resistance test was repeated with eTest the 
isolate was reclassified as methicillin sensitive. Furthermore there was no 
genetic evidence of MRSA in this isolate based on a Mykrobe prediction 304.  
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3.4 Discussion 
3.4.1 Anthroponotic transmission  
We posit that clade 2 represents an ancient human-to-monkey transmission 
event that occurred a minimum of 2700 years ago. Clade 2 has undergone 
clonal expansion and diversified into at least six sub-clades within the 
monkey population. Whilst this can be largely explained in terms of common 
clonal inheritance (descent with modification), it is also possible that some of 
the differences in gene content between clade 2 and the other clades in the 
tree underlie adaptation to the monkey host. The presence of the monkey-
associated isolates in both Clade 2 and ST6 provides an opportunity to 
detect any genes that may have been acquired independently in two 
unrelated monkey-adapted lineages. 
Human-associated genotypes have been previously isolated from monkeys 
in West Africa: ST1, ST6 and ST15 268. We report the presence of ST6 and 
ST15 in monkeys raising the possibility that these genotypes may be prone 
to human-to-monkey transmission. The fact that ST15 was only recovered 
once from monkeys is also consistent with a recent transmission event. The 
cluster of monkey-derived ST6 isolates is consistent with onward 
transmission within the monkey population. However, the upper-bound 
estimate for time since transmission of ST6 to monkeys may be spuriously 
high since we were unable to sequence the closest human ST6 isolate. 
Furthermore, the ST6 cluster may have emerged as a result of multiple host 
switching events. In this case, the within-clade diversity would also represent 
a high upper-bound estimate for the time since the host switch occurred. 
The evolutionary origin of the CC152 monkey isolate F5 is unclear given its 
unique accessory genome composition and the similarity to ST152 strains at 
the core genome level. A likely scenario is that a ST152 isolate was 
transmitted to monkeys then subsequently lost some of its accessory 
genomes and acquired some accessory content from monkey specific 
lineages through recombination. ST152 strains are able to adapt to multiple 
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host niches and have been detected among domestic animals in Africa 268. 
Moreover, an overhaul of the accessory genome is not uncommon in S. 
aureus. It has previously been described that ST239 is a product of 
recombination of a large block of DNA from a CC30 donor into a CC8 
background 378. 
3.4.2 Gene loss as a contributor to host adaptation 
The loss of genes harboured on the genomic islands νSaα and νSaβ in clade 
2 isolates may have enhanced adaptation to the monkey host. The spl 
operon (spl A-F) is harboured on νSaβ and it encodes serine proteases as 
well as lytN, which is essential for bacterial growth and cell wall synthesis 
379,380. All clade 2 isolates harboured novel variants of spl genes that were 
not present in human isolates or reference genomes highlighting a potential 
role in host adaptation. 
The immune evasion cluster IEC1 harbours the immune evasion genes (chp, 
sak and scn) and enterotoxin genes such as sea, sep, sek, and seq 381,382. 
These genes elicit human-specific immune modulation using different 
mechanisms including the blockage of neutrophil chemotaxis 383. Thus it is 
not surprising that the IEC1 was lost in the vast majority of isolates recovered 
from monkeys. Similarly the Panton-Valentine leukocidin genes (lukF-PV and 
lukS-PV) were absent from all isolates recovered from monkeys. Panton-
Valentine leukocidin is a potent human neutrophil cytotoxic factor that does 
not work on monkeys 384.  
Genes carried on MGEs play an important role in host adaptation 343. 
However, our data suggests that in addition to gene acquisition, gene loss 
may play an important role in adaptation to non-human hosts. If gene loss is 
assumed to occur more readily than gene acquisition, then this relationship 
might explain why anthroponotic transmission of S. aureus is more common 
than zoonotic transmission. Protein-truncating mutations in S. aureus have 
been previously implicated in the progression from carriage to invasive 
disease 361.  
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3.4.3 Risk of monkeys serving as reservoirs for highly 
virulent S. aureus 
Our data supports previous suggestions that anthroponotic transmission 
events may be relatively frequent, while zoonotic transmission is much less 
common 101. Although human-to-monkey transmission has been documented 
in West Africa there is no evidence of zoonotic transmission from monkeys 
268. From a public health perspective, this is reassuring as it suggests that 
monkeys do not constitute a serious risk of S. aureus infection in humans. 
Related to this, we also note that none of the monkey isolates were MRSA. 
Furthermore, although there were high levels of resistance to penicillin 
among invasive disease isolates, the isolates from monkeys were all 
susceptible to penicillin. 
3.4.4 Limitations 
The main limitation of this study is that the samples from the three 
epidemiological classes were collected over different timescales and from 
different regions. De novo sample collection over a standard harmonized 
timeframe would have enabled us to make more accurate inferences on the 
direction of transmission. A longitudinal study would also be required to 
confidently determine the dynamic of the inferred host switching events. 
Finally, our study lacked precise demographic information that could link 
each isolates to the location where the monkey bearing it was trapped and 
sampled. This information would have facilitated a more in depth 
understanding of the dynamic of S. aureus in monkeys in The Gambia.
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4 GENOMIC EPIDEMIOLOGY OF A 
PNEUMOCOCCAL MENINGITIS OUTBREAK IN 
GHANA, 2016 
4.1 Introduction 
4.1.1 The African meningitis belt 
The African meningitis belt spans a region from Senegal to Ethiopia, a region 
home to ~300 million people 385,386 (Figure 4.1). Globally, the highest 
incidence rates of meningitis occur in the African meningitis belt 386. The 
main cause of meningitis in the belt is Neisseria meningitidis, the 
meningococcus, but Streptococcus pneumoniae or Haemophilus influenzae 
type B are also known to cause localised outbreaks 386,387. Across the belt, 
incidence levels peak during the cold dry season, from October to April, 
causing thousands of deaths annually and large epidemic outbreaks 
periodically 386,387. 
 
Figure 4.1 A map showing of part of Africa highlighting the African meningitis belt 
(red line) and the Brong-Ahafo region (red highlight) adapted from 283. 
 79 
 
The dynamics behind the seasonality of meningitis outbreaks are unclear, 
but climate is believed to be the strongest driving force 388,389. During the dry 
season, the Harmattan winds blow from the Northeast, carrying high levels of 
atmospheric mineral dust 390. The persistent dust and low humidity are 
believed to damage the mucosal epithelium leading to an increased risk of 
progression from asymptomatic carriage to invasive disease 386,391. Similarly, 
viral respiratory tract infections such as the flu weaken the immune system 
enhancing transmission and invasion of bacteria 392. 
4.1.2 Molecular epidemiology of meningitis in West 
Africa 
Since the 1990s, meningococcal ST5 complex strains belonging to 
serogroup A have been the most common causes of meningitis outbreaks 
393. In 2000, the serogroup W NmW135 strain emerged as the cause of a 
major meningitis outbreak during the annual Hajj pilgrimage in Mecca, Saudi 
Arabia 387. Shortly afterwards, in 2002, NmW135 was responsible for a major 
meningitis outbreak in Burkina Faso 394. NmW135 reached epidemic status 
due to high incidence rates among children but for unknown reasons the 
prevalence of NmW135 decreased significantly within a short space of time 
395. The year 2003 saw the emergence of a new serogroup A strain from the 
ST2859 complex, which demonstrated the potential to cause epidemics in 
the future 387.  
Since the 2000s, lethal community-based pneumococcal meningitis 
outbreaks have been reported in northern Ghana, Burkina Faso and Togo, 
affecting all age groups 278,279,396. S. pneumoniae serotype 1 is the leading 
cause of pneumococcal meningitis in the meningitis belt 397. Serotype 1 can 
cause lethal outbreaks of meningitis in high-burden settings 396,398. Serotype 
1 is highly virulent and has a high invasiveness index, since it is rarely 
detected in asymptomatic carriage 397. The sequence type (ST) 217 clonal 
complex (CC) and closely related genotypes ST303 and ST618 have been 
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implicated in previous outbreaks of pneumococcal meningitis in West Africa 
396,398,399. 
4.1.3 Vaccine intervention in the African meningitis 
belt 
The MenAfriVac® campaign was launched in 2010 in a bid to eradicate 
serogroup A. MenAfriVac® has been a success story, since it led to 
elimination of serogroup A carriage and to herd immunity that protected even 
unvaccinated individuals 15. MenAfriVac vaccination in Burkina Faso led to 
the eradication of serogroup A strains among carriage and diseased 
individuals. However, following vaccination the serogroup X strains have 
become the dominant genotype isolated from carriage and invasive disease 
400. Worryingly the serogroup W strains, which have demonstrated the ability 
to cause lethal outbreaks in the past 394, have re-emerged in Burkina Faso 
post-vaccination 15,400. 
The need for mass vaccination campaigns against S. pneumoniae, especially 
serotype 1, in the meningitis belt cannot be stressed enough. In The Gambia 
the introduction of the pneumococcal conjugate vaccine PCV-13, which 
includes serotype 1, has led to a marked decrease in the prevalence of 
vaccine serotypes causing invasive pneumococcal disease 280. A study 
showed that across Burkina Faso, Ghana, Nigeria, Mali, Senegal, and The 
Gambia 65-87% of pneumococcal isolates had serotypes covered by PCV-
13 401. Evidence shows that pneumococcal vaccination campaigns should 
also be extended to cover older children and adults in order to boost efficacy 
278. 
4.1.4 Evolution of the pneumococcal genome 
Variation is introduced into the pneumococcal core genome primarily through 
homologous recombination (uptake and incorporation of exogenous DNA) 
and point mutations 178. Pneumococcal genomes undergo very high rates of 
recombination; rates are influenced by capsular type and carriage rates 
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across lineages 402. Clinical interventions such as vaccination and antibiotic 
therapy rapidly select for novel pneumococcal genotypes that arise through 
homologous recombination 116,403. In addition, S. pneumoniae can acquire 
novel genes that mediate virulence and antimicrobial resistance from other 
species by horizontal gene transfer (HGT) 403,404.  
4.1.5 Evolution of drug resistance 
The emergence of drug resistance in S. pneumoniae is a major public health 
concern driven by the emergence of multidrug-resistant strains 405. 
Antimicrobial resistance can be spread by clonal dissemination of resistant 
strains or emergence of resistance in susceptible strains 405. Pneumococcal 
strains can acquire antibiotic resistance through target modification, efflux 
pump and/or enzyme inactivation of the drug 406.  
β-lactam resistance is acquired through modification of the penicillin binding 
protein (PBP). Modifications of PBP occur primarily through point mutations 
but the mosaic structure of PBP suggests that the PBP may have been 
modified in other Streptococci before being transformed into S. pneumoniae 
through recombination 178,405. Fluoroquinolone resistance is driven primarily 
by spontaneous mutations in the quinolone resistance determinant region 405. 
Genes carried on transposable mobile genetic elements confer resistance to 
a broad range of antibiotics 407. For example, the Tn916 family transposons 
carry: 
x Macrolide resistance determinants ermB and mef,  
o ermB encodes a protein product that induces resistance by 
methylating the 23S ribosomal binding site and the  
o mef genes, which encode an active efflux pump 408 
x Accessory genes catQ and tetM that confer chloramphenicol and 
tetracycline resistance through enzymatic inactivation and target 
alteration respectively 405,409 
A new antibiotic called teixobactin, which inhibits cell wall biosynthesis has 
recently been discovered 410. Teixobactin has shown efficacy in mice infected 
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with S. pneumoniae and a wide range of gram-positive bacteria 410. 
Encouragingly it is expected that this compound will avoid the development 
of resistance that is common to most antibiotics 410. Perhaps teixobactin and 
similar compounds that will emerge from this discovery may influence the 
future of therapeutic intervention for S. pneumoniae. 
4.1.6 The Brong-Ahafo meningitis outbreak 
A meningitis outbreak broke out in the Brong-Ahafo region of Ghana during 
the peak of the 2015-2016 dry season. The WHO Regional Reference 
Laboratory hosted at the MRC Unit The Gambia (MRCG) played a crucial 
role in providing laboratory and data management support to the local health 
authorities in Brong-Ahafo region in response to the outbreak. A team of 
scientists and a database manager were dispatched from MRCG to work 
with the WHO and Ghana Ministry of Health in the Brong-Ahafo region.  
There were 886 suspected cases of meningitis in the Brong-Ahafo region 
between 2nd December 2015 and 26th February 2016. The mortality rate 
among suspected cases whose outcome was known was 10%. Over 95% of 
the confirmed cases occurred in children over 5 years and adults. All 
available cerebrospinal fluid specimens from suspected cases were tested by 
rapid test, qPCR and/or culture. 135 cases of meningitis were confirmed by 
identification of a pathogen: 
x Streptococcus pneumoniae (77%, 104/135) 
x Neisseria meningitidis (22%, 30/135)  
x Group B streptococcus (GBS) (1%, 1/135). 
49 pneumococcal strains were successfully serotyped by PCR of which, 40 
(78%) were serotype 1 and five (12%) were serotype 12F. Other serotypes 
detected included 35B, 6A/6B, 7F and 3. 
It was surprising that serotype 1 S. pneumoniae was the main pathogen 
identified during the outbreak, as PCV-13 was included in the Ghanaian 
expanded program of immunization in 2012. Although nationwide coverage 
of PCV-13 was below 50% in 2012, it rose steadily and by 2014 had reached 
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81%. PCVs usually induce herd immunity leading to a decrease in the 
prevalence of vaccine serotypes even in non-vaccinated individuals 281,282,411. 
However recent estimates suggests that conjugate vaccines may take up to 
a decade to induce herd immunity among the unvaccinated population 412.  
4.1.7 Objectives and study rationale 
To understand the molecular epidemiology of the outbreak we set out to 
perform whole genome sequencing (WGS) on stored pneumococcal isolates 
from outbreak patients with the following objectives: 
x To confirm the serotype and determine the MLST profile of the 
outbreak S. pneumoniae strains by comparing their genome 
sequence to the sequences of the known pneumococcal serotypes 
and MLST alleles respectively 
x To reconstruct the phylogeny of the outbreak strains based on 
single nucleotide variants in the core genome 
x To study the evolutionary events that led to the emergence of 
serotype 1 outbreak following the introduction of PCV-13 by 
gleaning the genome for evidence of capsular switching and changes 
in the core and accessory genome that could have led to enhanced 
fitness or virulence 
x To compare the serotype 1 strains from the outbreak with 
previously sequenced serotype 1 strains from West Africa. These 
strains were sequenced as part of a previous collaboration through 
the Pneumococcal African Genomics Consortium (PAGe)  
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4.2 Methods 
4.2.1 Geography and demographics of the study area 
The Brong-Ahafo region lies at heart of Ghana, midway up the North-South 
axis but below the African meningitis belt (Figure 4.2). The region consists of 
27 districts and has a population of 2.4 million. Like much of West Africa, the 
Brong-Ahafo region has a tropical climate, with a dry season that lasts from 
November to March and two rainy seasons in between. Prior to the outbreak 
the WHO did not have standard guidelines for containing a pneumococcal 
meningitis outbreak. Moreover, such outbreaks were not expected to occur in 
the Brong-Ahafo region because it lies outside the meningitis belt. As a 
result, regional health authorities were caught off guard and initially struggled 
to contain the outbreak. After helping to contain the outbreak the MRCG 
team made important recommendations to the WHO for dealing with 
pneumococcal meningitis outbreaks. 
 
 
Figure 4.2 A district map of the Brong-Ahafo region of Ghana (source: 
http://www.maphill.com). 
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4.2.2 Bacterial isolates 
During the outbreak meningitis, the primary method for confirmation of 
meningitis cases was the Pastorex meningitis kit (Biorad, Hemel Hempstead, 
Hertfordshire, UK). When the WHO RRL was called in, qPCR assays were 
performed at the MRCG to identify the aetiological pathogen from 
cerebrospinal fluid. S. pneumoniae serotyping was performed using latex 
agglutination 296. Culture facilities were not available at most health centres, 
so samples had to be sent to the regional hospital in Sunyani for culture. 
However, sub-optimal storage and transportation conditions meant that most 
samples were not viable for culture. Consequently out of 104 laboratory-
confirmed cases of pneumococcal meningitis, we recovered just sixteen 
isolates. These isolates were characterised by antibiotic susceptibility testing 
to Clindamycin, Optochin, Vancomycin, Trimetoprim-sulfamethoxazole, 
Erythromycin, Chloramphenicol, Rifampin, Ceftriaxone, Penicillin and 
Tetracycline. WGS was performed on 15 isolates of S. pneumoniae that were 
stored from the outbreak (Figure 4.3). These included 12 serotype 1 and one 
each of serotype 35B, serotype 7A and serotype 3. 
The majority of the strains analysed by WGS were isolated from 
cerebrospinal fluid specimens that were sampled from patients during the 
outbreak (14/15). We analysed one strain that was recovered from a throat 
swab of a healthy carrier in Wenchi district. Unfortunately we were unable to 
retrieve the patient information for the throat swab and the exact time of 
sample collection. The majority of isolates were recovered between the 6th 
and 9th week of 2016 inclusive. Patients’ age ranged from 9 to 45 years 
(mean 21, median 19) and the ratio of male to female was 3:4 (Table 4.1). 
The antibiotic susceptibility profiles to commonly used antibiotics are 
presented in table 4.1 but the antibiogram for the throat swab isolate 
(BAR_19) was not reported. Staff at the MRCG reported high rates of 
resistance to tetracycline and trimethoprim-sulfamethoxazole (commonly 
known as co-trimoxazole) among these isolates. One serotype 1 isolate was 
also resistant to penicillin in addition to tetracycline and co-trimoxazole 
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resistance. The serotype 35B strain was susceptible to all antibiotics that 
were tested. 
Table 4.1 The antibiotic susceptibility profiles for the outbreak S. pneumoniae strains 
to commonly used antibiotics in the sub region.  
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BAR_19 
   
                    
BAR_15 20 M ALIVE S S S I S S S S S R 
BAR_16 11 M DEAD S S S R S S S S S R 
BAR_3 45 F DEAD S S S S S S S S S S 
BAR_11 10 F ALIVE S S S I S S S S S R 
BAR_10 9 M ALIVE S S S R S S S S S R 
BAR_17 13 F ALIVE S S S I S S S S S S 
BAR_7 22 F ALIVE S S S I S S S S S R 
BAR_5 35 M DEAD S S S R S S S S S R 
BAR_9 14 F ALIVE S S S R S S S S S R 
BAR_6 17 F ALIVE S S S I S S S S S R 
BAR_14 30 F DEAD S S S I S S S S S R 
BAR_13 24 M ALIVE S S S S S S S S S R 
BAR_18 35 M DEAD S S S R S S S S S R 
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4.2.3 Outbreak summary and workflow for sequence 
analysis 
 
Figure 4.3 A summary of the pneumococcal meningitis outbreak and the workflow for 
the bioinformatics analysis. 
Suspected casesn = 886
CSF collectedn = 795
Pathogen detectedn = 135
N. meningitidisn= 30 S. pneumoniaen = 104
WGSn = 14 + 1
SpeciationKRAKEN AssemblyMEGA-HIT
MLSTBLAST AntibiogramAbricate
SerotypingMapping
Serotype 1n= 12
West Africa serotype 1n = 108
Phylogenycore.ope ClonalityR packages RecombinationGUBBINS
PhylogenySnippy
GBSn = 1
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4.3 Results 
4.3.1 Genome analysis 
The 15 outbreak strains were initially characterised using the nullarbor 
pipeline (Section 2.3.4). The statistics for read mapping and genome 
assemblies are summarized in table 4.2. The sequencing reads were 
mapped to the spn1041 reference genome using snippy. The median depth 
of coverage was 107 (range 44 to 446). The average GC content for all 
strains was 40%. Draft assemblies generated by MEGA-HIT ranged in size 
from 1978923 to 2151432 base pairs. The number of contigs per genome 
ranged from 90 to 852.  
Table 4.2 Summary of statistics for whole genome sequence mapping to spn1041 
reference genome and genome assembly. 
 
Read Mapping Genome assembly 
BAR_ID Reads GeeCee Depth Contigs bp N50 
BAR_12 3171580 39.8 414 742 2088168 4899 
BAR_19 2746326 39.8 375 480 2093176 9511 
BAR_15 3263496 39.8 428 852 2059204 3736 
BAR_16 499400 40.3 56 123 2083942 41179 
BAR_3 2608300 39.5 356 429 2151432 11081 
BAR_11 343746 40.6 44 90 1978923 54852 
BAR_10 451008 40.4 55 128 2084361 35741 
BAR_17 701526 40.4 83 116 2080555 43628 
BAR_7 471882 40.4 61 125 2118549 41387 
BAR_5 387734 40.1 44 124 2055102 39459 
BAR_9 3267338 39.8 446 762 2079240 4967 
BAR_6 2453604 39.8 336 386 2093558 11772 
BAR_14 436534 40.3 55 131 2118859 41265 
BAR_13 935610 40.4 114 123 2078016 43265 
BAR_18 869786 40.2 107 133 2077163 38302 
 
Sequence data has been submitted to the European Nucleotide Archives 
under the study accession number PRJEB15437.   
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4.3.2 Characterisation of strain genotypes 
All 15 strains were confirmed to be S. pneumoniae by uploading sequencing 
reads onto kraken through the nullarbor pipeline. By mapping the sequencing 
reads to the capsular region for 95 pneumococcal serotypes in silico 
serotyping was performed. Serotypes were assigned based on percentage 
coverage of the capsular region and average coverage depth. In total 12 
strains were serotype 1 and the remaining three were serotype 3, 7A and 
35B respectively. MLST profiles were inferred by a BLAST comparison of the 
assemblies to known MLST alleles. Serotype 1 isolates all belonged to 
ST303 while serotypes 3 7A and 35B strains belonged to the genotypes 
ST700, ST2833 and ST373 respectively (Table 4.1). 
Table 4.3 The genomic characterisation of the S. pneumoniae strains by MLST and 
serotyping.  
 
In silico serotyping MLST 
ID Serotype 
Average 
coverage Percentage Coverage ST 
BAR_12 1 360.51 99.93% 303 
BAR_19 1 342.17 100.00% 303 
BAR_15 1 370.68 100.00% 303 
BAR_16 1 48.97 100.00% 303 
BAR_3 35B 290.75 100.00% 373 
BAR_11 7A 17.99 95.51% 2833 
BAR_10 1 46.76 100.00% 303 
BAR_17 1 64.40 99.98% 303 
BAR_7 1 47.26 100.00% 303 
BAR_5 3 27.41 54.45% 700 
BAR_9 1 413.94 100.00% 303 
BAR_6 1 306.04 100.00% 303 
BAR_14 1 45.69 100.00% 303 
BAR_13 1 85.91 100.00% 303 
BAR_18 1 94.98 100.00% 303 
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4.3.3 Phylogeography of outbreak strains 
The sequencing reads from all outbreak strains were mapped to the spn1041 
reference genome with snippy and variants were called from the core 
genome using snippy-core (Alignment in Appendix 4.1). The maximum 
likelihood was reconstructed using FastTree.  
The phylogenetic tree resolved the serotype 1 strains into two clades (Figure 
4.4A). Eight serotype 1 strains formed a novel clade that was distinct from 
the spn1041 reference genome. Isolates within the novel clade were closely 
related with a within-clade average pairwise distance of 16 core genome 
single nucleotide variants (SNVs) (Table 4.4). The most similar strains within 
the novel clade differed at four core genome loci and the most divergent pair 
differed by 27 SNVs. Four other outbreak serotype 1 strains clustered in a 
clade with the ST303 reference genome spn1041 (henceforth referred to as 
reference-type ST303). Strains within the reference-type ST303 clade 
differed by an average of 91 core genome SNVs (Table 4.4). The strains 
belonging to other serotypes differed from serotype strains by at least 16,000 
SNVs and formed outliers on individual long branches of the phylogenetic 
tree.  
A phylogeography analysis was attempted by linking the annotated 
phylogenetic tree to a district map showing the incidence rates of confirmed 
cases in the respective districts of the Brong-Ahafo region. Seven strains in 
the novel clade were isolated from patients in Techiman, Wenchi or Tain; 
districts within the epicentre of the outbreak (Figure 4.4B). During the 
outbreak the incidents rates in the epicentre rose above the epidemic 
threshold for meningitis outbreaks 283. The eighth strain from the novel clade 
was isolated from a patient in Tano South, south of the epicentre. Two 
reference type ST303 strains were isolated from patients in Nkoranza South 
and one from Techiman while the origin of the fourth was unknown (on 
Figure 4.4 this strain was assigned to Sunyani where the regional hospital is 
located). The non-serotype 1 strains were isolated from the fringe districts, 
Jaman South, Dorma and Tano South, where the number of confirmed cases 
was relatively low.
 91 
 
Figure 4.4 A phylogeographic analysis of S. pneumoniae strains from the meningitis outbreak. (A) The phylogeny of the outbreak strains was coloured 
based genotype: novel clade, ST303 and non-serotype 1. (B) The map of Brong-Ahafo shaded to represent the number of confirmed cases per 100,000 in 
each district during the outbreak. Pie chart shows the prevalence of each genotype in each district. 
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Table 4.4 A distance matrix showing the number of core SNV differences between pairwise comparisons of the meningitis outbreak S. pneumoniae 
strains. Values are colour coded based on a scale of magnitude: dark blue = 0, white = medium and red = highest value. 
ID BAR_12 BAR_19 BAR_15 BAR_10 BAR_17 BAR_14 BAR_13 BAR_9 Ref BAR_16 BAR_7 BAR_6 BAR_18 BAR_3 BAR_11 BAR_5 
BAR_12 0 6 18 23 11 15 10 18 247 307 298 310 274 17173 16950 16105 
BAR_19 6 0 12 17 7 13 4 12 245 305 296 308 272 17171 16948 16103 
BAR_15 18 12 0 27 17 23 14 22 257 317 308 320 284 17181 16960 16113 
BAR_10 23 17 27 0 22 28 19 23 236 296 287 299 263 17164 16965 16094 
BAR_17 11 7 17 22 0 16 7 17 250 310 301 313 277 17176 16953 16106 
BAR_14 15 13 23 28 16 0 15 23 250 310 301 313 277 17178 16955 16110 
BAR_13 10 4 14 19 7 15 0 14 249 309 300 312 276 17175 16952 16105 
BAR_9 18 12 22 23 17 23 14 0 257 317 308 320 284 17183 16960 16115 
Reference 247 245 257 236 250 250 249 257 0 80 71 83 47 17138 16900 16050 
BAR_16 307 305 317 296 310 310 309 317 80 0 127 73 103 17180 16936 16094 
BAR_7 298 296 308 287 301 301 300 308 71 127 0 130 90 17186 16947 16100 
BAR_6 310 308 320 299 313 313 312 320 83 73 130 0 106 17183 16939 16091 
BAR_18 274 272 284 263 277 277 276 284 47 103 90 106 0 17163 16922 16077 
BAR_3 17173 17171 17181 17164 17176 17178 17175 17183 17138 17180 17186 17183 17163 0 17918 17565 
BAR_11 16950 16948 16960 16965 16953 16955 16952 16960 16900 16936 16947 16939 16922 17918 0 17048 
BAR_5 16105 16103 16113 16094 16106 16110 16105 16115 16050 16094 16100 16091 16077 17565 17048 0 
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4.3.4 Comparison with West African ST303 and ST217 
An assembly based pipeline was employed to reconstruct the phylogeny of 
the outbreak serotype 1 strains alongside 108 West African serotype 1 
archived genomes: 68 from ST303 and 44 from ST217 (full methods in 
Section 2.4.2). The phylogeny was reconstructed from 9389 variable core 
genome sites (Alignment in Appendix 4.2). The novel clade from the 
outbreak was placed on a divergent branch that stemmed from the West 
African ST303 cluster (Figure 4.5). The ST303 and ST217 clades clustered 
strains from the same country together. The reference type ST303 strains 
from the outbreak clustered with Ghanaian ST303 strains within the West 
African ST303 clade. The phylogenetic placement of ST217 strains highlights 
that ST217 is the ancestral founder of the ST303 lineage. 
Based on the topology of the phylogenetic tree strains were classified into 
three clusters: West African ST217, West African ST303 and the novel clade. 
Diversity indexes were computed for each of the clusters using R statistical 
packages. The Shannon diversity index was computed for each cluster and it 
confirmed a low level of sequence diversity in the novel clade compared to 
the West African clades. Similarly, the index of association (IA) and the 
standardised index of association (rÂ¯ d) were computed for each cluster and 
both showed that the novel clade had a higher degree of clonality than the 
West African clades (Table 4.5).  
Table 4.5 The clonal diversity indexes of West African and outbreak serotype 1 
strains.  
Cluster 
name 
Number of 
strains 
Shannon-
Weiner Index 
Index of 
association (IA) 
Standardized 
index of 
association 
(rÂ¯ d) 
ST303 68 4.22 1157.25 0.19 
Novel clade  8 2.08 1582.16 0.35 
ST217  44 3.78 314.79 0.11 
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Figure 4.5 The phylogeny of the outbreak serotype 1 strains and the West African 
serotype 1 genotypes ST303 and ST217. Tips without labels are strains with new STs. 
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4.3.5 Recombination events that define the novel 
clade 
Recombination regions were predicted from an alignment of 120 serotype 1 
strains including the outbreak strains and the West African genotypes ST303 
and ST217 using Gubbins (Predicted recombination regions are listed in 
Appendix 4.3). It appears that the West African ST303 strains evolved from 
the ST217 ancestral clade through a series of recombination events. Several 
recombination blocks were conserved in all ST303 strains, including the 
novel clade, but were absent in ST217 strains (Figure 4.7).  
The novel clade was placed on a long branch that had accumulated 271 
SNVs: 222 SNVs occurred in recombination regions and 49 SNVs occurred 
outside of recombination regions. The evolution of the novel clade from the 
West African ST303 clade was driven by recombination events that were 
unique to the novel clade. Seven recombination blocks, which varied in size 
from 349 to 15406 base pairs (median 5091 bp), were conserved in all 
strains within the novel clade but absent in the West African clades. 
The largest recombination block (i) overlapped with a region flanking the 
fucose metabolism operon (Figure 4.6). This region encompassed numerous 
regulatory genes most notably the dltABCD operon, the zinc uptake 
regulatory protein acdA and a MarR-family regulatory protein (Table 4.6). 
Other recombination blocks overlapped with numerous metabolism proteins, 
putative proteins, ATP transporter proteins, the regulatory protein recX and a 
DNA repair system protein C (Table 4.7).  
 
Figure 4.6 An Artemis window snapshot showing the largest recombination region (i) 
(misc_feature) overlapping with a region flanking the fucose metabolism operon. 
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Figure 4.7 A heatmap showing the presence/absence of recombination blocks next to the phylogeny of serotype 1 reconstructed by Gubbins. Red 
blocks are present in multiple strains and blue blocks are present in one strain. The three genotypic clusters are highlighted. 
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Table 4.6 Table showing the genes that overlap with the recombination regions that characterise the novel clade (blocks I - iii). The start and stop 
positions show where the recombination starts and stops on the reference genome. The sizes of the recombination blocks are listed. 
Region Start Stop Size (b.p.) 
Gene name /locus 
tag Description 
i 2037275 2052681 15406 
fucK putative fuculokinase 
INV10418720 putative fucose phosphotransferase system repressor 
adcA Zinc-binding protein AdcA precursor 
INV10418740 ABC transporter permease protein 
INV10418750 ABC transporter ATP-binding protein 
INV10418760 MarR-family regulatory protein 
dltD putative D-alanyl-lipoteichoic acid biosynthesis protein 
dltC D-alanyl carrier protein 
dltB putative activated D-alanine transport protein 
dltA D-alanine--poly(phosphoribitol) ligase subunit 1 
INV10418820 major facilitator family transport protein 
INV10418830 putative reverse transcriptase - Group II intron (pseudogene) 
INV10402910 Group II intron maturase 
ii 2025618 2026848 1230 fucI putative L-fucose isomerase 
iii 1933663 1938754 5091 
gltX glutamyl-tRNA synthetase 
pgi glucose-6-phosphate isomerase 
INV10417860 putative peptidase 
INV10417870 ABC transporter ATP-binding membrane protein 
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Table 4.7 A continuation of table 4.6 showing the genes that overlap with recombination regions (blocks iv – vii). 
Region Start Stop 
Size 
(b.p.) 
Gene name /locus 
tag Description 
iv 208670 209752 1082 INV10401540 putative metallopeptidase.  
v 575174 581949 6775 
uvrC UvrABC DNA repair system protein C 
INV10405190 nitroreductase family protein 
 
Oxygen-insensitive NAD(P)H nitroreductase  
pepV putative Xaa-His dipeptidase 
INV10405210 uracil DNA glycosylase superfamily protein 
INV10405180 putative extracellular solute-binding protein 
brnQ putative branched-chain amino acid transport system carrier protein 
vi 1781679 1782028 349 recX Regulatory protein recX 
vii 1852685 1858834 6149 
INV10417140 putative surface anchored protein (pseudogene) 
INV10417170 putative aminotransferase 
INV10417180 putative membrane protein 
INV10417190 putative universal stress protein 
INV10417200 haloacid dehalogenase-like hydrolase 
asnB putative L-asparaginase 
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4.4 Discussion 
4.4.1 Novel clade drove the outbreak 
Novel lineages of serotype 1 can emerge through clonal expansion and in 
some cases they can progress to become the dominant clone 413. It is highly 
likely that the novel clade was the dominant clone in the meningitis outbreak 
since it was the most prevalent genotype among the genome-sequenced 
isolates and it was predominantly isolated from the epicentre of the outbreak. 
Additionally, the close genetic relationship between the strains suggests that 
the strains in the novel clade were undergoing clonal expansion and 
spreading through the community. The other strains isolated from patients 
during the outbreak such as the reference-type ST303 strains were 
genetically more diverse, which suggested they were not being transmitted or 
undergoing clonal expansion. These strains are likely to represent sporadic 
cases of meningitis that occurred during the time of the outbreak. 
4.4.2 Evolution of the novel clade 
The evolution of novel clones due to selective pressure from the host is an  
on going phenomenon for S. pneumoniae 414. However, due to homologous 
recombination, most novel clonal clusters are transient and get reabsorbed 
into the main clonal lineages 415. There is evidence that the novel clade 
underwent substantial sequence diversity, primarily through homologous 
recombination, to form a distinct cluster. Recombination blocks overlapped 
with genes responsible for important cellular functions that could impact on 
fitness and virulence: 
x The dltABCD operon mediates D-alanylation of lipoteichoic acids, a 
mechanism for evasion of host innate immune response through 
repulsion of cationic antimicrobial peptides 416. Thus, modification of 
the dlt operon through recombination could have enhanced host 
immune evasion in the novel clade 
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x MarR-family proteins regulate expression of virulence factors and 
responses to antibiotic and oxidative stress 417. Mutations in MarR-
family genes have been associated with increased virulence and 
invasiveness in a number of bacterial species 418. In the novel clade, 
modification of the MarR family protein could have led to increased 
virulence and invasiveness 
x ATP transporter proteins play an important role in bacterial virulence 
through uptake of nutrients and metal ions as well as in host cell 
attachment 419. ATP transporters are highly immunogenic and have 
been considered as potential vaccine targets for S. pneumoniae 419 
x The zinc-uptake regulatory protein adcA is highly immunogenic and 
plays an important role in S. pneumoniae infection 417. Modification of 
the adcA gene by recombination could enhance immune evasion 
4.4.3 Vaccine-induced selective pressure 
The introduction of vaccines can induce selective pressures that favour 
serotype replacement through capsular switching or the rise of low 
prevalence non-vaccine serotypes 116,420. The very small sample size that we 
had showed 5 cases due to 12F. This could have represented a substantial 
transmission network supported by the same conditions that drove the 
overall outbreak. Alternatively they might all have been sporadic, and just at 
the usual background level. There was no evidence of capsular switching 
through the alteration of cps genes in the novel clade. However, it cannot be 
ruled out that vaccine-induced selective pressure may have contributed to 
the emergence of this novel clone. 
Conjugate vaccines alter the nasopharyngeal microbiome by eliminating the 
most prevalent serotypes 421. This provides new opportunities for S. 
pneumoniae to acquire novel DNA by recombination within the modified 
microbial ecology of the nasopharnyx 414. It is known that vaccine 
intervention selects for S. pneumoniae lineages that have undergone 
recombination 116,403. It can be hypothesized that the ancestral clone of the 
novel clade underwent rapid evolution through recombination and then was 
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selected for by the introduction of PCV-13. The recombination events are 
likely to have conferred a selective advantage through enhanced virulence 
and potential host immune evasion mechanisms.  
4.4.4 Potential reasons for outbreak 
A likely scenario is that at the time of the outbreak, the strains from the novel 
clade were already disseminated in the population. The most divergent 
strains within the novel clade differed by as many as 28 core genome SNVs 
(without excluding recombination). This is an indication that the novel clade 
has been undergoing clonal expansion for some time, perhaps a few years. 
The dust and low humidity that characterises the dry season favoured a 
switch from carriage to invasiveness, leading to disease. This hypothesis is 
supported by the emergence of sporadic cases of meningitis due to other 
serotypes and other genotypes of ST303 serotype 1. 
Once the new clade emerged with potentially superior fitness, it could have 
easily spread among the older unvaccinated population in the community. 
This is supported by the fact that overall over 95% of confirmed cases 
occurred among children over 5 and adults. Similarly, the novel clade strains 
were isolated from patients aged 9 years and above. A strain isolated from a 
healthy individual was also part of the novel clade, which suggests that strain 
from the novel clade may have been disseminated in the community prior to 
the outbreak. Unfortunately this cannot be confirmed since there is no 
information on when this isolate was collected. 
4.4.5 Need for carriage surveillance 
A carriage study needs to be carried out in Ghana in order to provide 
baseline data on the molecular epidemiology of S. pneumoniae after the 
introduction of PCV-13. This is important since the altered dynamics of 
competition and collaboration between pneumococcal strains and with 
bacterial species can drive the evolution of novel clones of S. pneumoniae 
414. A carriage study would identify the emergence of novel clones and the 
dissemination of genotypes that have the potential to cause lethal outbreaks. 
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4.4.6 Limitations 
The main limitation of this paper is the small sample size. This highlights the 
vital need to strengthen laboratory services across West Africa to a level 
where they can perform bacterial culture and identification. The lack of 
longitudinal carriage data makes it difficult to predict when the novel clade 
emerged. A Bayesian estimate phylogenetic dating approach could have 
shed light on the potential timeline for the emergence of the novel clade. 
Unfortunately I was unable to attempt phylogenetic dating on the novel clade 
because the samples were collected within a short time frame. The paucity of 
patient metadata and small sample size ruled out the feasibility of a risk 
factor analysis using regression models. The use of wider reference datasets 
would support more solid inference on the origin of the clade. 
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5 CHAPTER FIVE: GENOMIC EPIDEMIOLOGY OF 
TUBERCULOSIS IN WEST AFRICA 
5.1 Introduction 
5.1.1 Global population structure of M. tuberculosis 
The Mycobacterium tuberculosis complex (MTBC) consists of several 
ecotypes that are genetically distinct yet closely related. The complex is 
characterised by identical 16S ribosomal RNA sequences and 99.9% 
nucleotide identity at the whole genome level 284. Ecotypes within MTBC are 
adapted to infect a wide range of hosts. Strains belonging to the same 
ecotype are differentiated by means of genotyping techniques into lineages 
and families 422.  
The main etiological agents of tuberculosis (TB) in humans are 
Mycobacterium tuberculosis sensu stricto and Mycobacterium africanum 284. 
M. tuberculosis and M. africanum form seven distinct phylogenetic lineages 
that are believed to have co-evolved with humans over millennia 423-425 
(Figure 5.1). The global diversity of the MTBC may be explained by recent 
patterns of migration, trade and conquest 426. It has been proposed that 
MTBC originated in East Africa 426 before spreading out of Africa with human 
migration. Certain lineages (e.g. the Euro-American lineage) were later re-
introduced into Africa by travellers, traders and through conquest 423. The 
Out-of-Africa scenario estimates on the age of the MTBC is 40,000 – 70,000 
years 423. However studies that relied on MTBC genomes recovered from 
ancient DNA estimate that the complex is approximately 6000 years old 
424,427. 
Comparative genomics of MTBC has revealed that significant genetic 
variation exists between different lineages of MTBC, which can impact the 
pathogenicity of and transmissibility strains 428. 
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Some lineages of the MTBC are more prevalent in certain geographical 
regions than others and this is reflected in the nomenclature of the lineages 
429 (Figure 5.1): 
x The East Asian, East-African-Indian and Euro-American lineages 
(Lineages 2,3 and 4 respectively) form the so-called “modern clade” of 
the MTBC, characterised by the absence of the TbD1 region 429 
x Lineages 2 (including Beijing strains) and 4 are more widespread than 
other MTBC lineages and are more pathogenic and virulent 428 
x The Indo-Oceanic (lineage 1) and the M. africanum lineages West 
Africa 1 and 2 (also called Lineages 5 and 6 or MAF1 and MAF2) are 
among the ancient lineages of the MTBC. The ancient lineages are 
more geographically restricted that lineages 2 and 4 
x Lineage 7 (Ethiopian) was recently discovered around the horn of 
Africa: phylogenetically lineage 7 is placed between the modern clade 
of the MTBC and other lineages 430 
 
Figure 5.1 A schematic representation summarizing the phylogenetic relationships of 
the major the MTBC lineages that cause human tuberculosis. Tips are labelled by 
lineage. Tree topology and nomenclature adapted from 423 and 429 respectively.  
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5.1.2 Population structure of TB in West Africa 
A unique feature of TB in West Africa is the presence of all six major lineages 
of the MTBC (Lineages 1-6). However, the Euro-American and the two M. 
africanum lineages cause most human pulmonary TB in West Africa 294.  
M. africanum is almost exclusive to West Africa and sporadic cases in other 
regions are generally linked to West African migrants 431. Geographic 
clustering is observed within the two M. africanum lineages:  
x MAF1 is more prevalent around the Gulf of Guinea  
x MAF2 is more prevalent in the western regions of West Africa 431 
The restriction of M. africanum to West Africa may be driven by an unknown 
animal reservoir. This hypothesis is supported by the close phylogenetic 
relationship that exists between M. africanum and other animal lineages 
428,432. An alternative hypothesis is that due to its inferior fitness, M. 
africanum cannot compete with other M. tuberculosis lineages in other 
regions 433. However, this does not explain why M. africanum remains an 
important cause of disease in West Africa, despite the presence of “fitter” 
lineages in the region 294. 
A plausible scenario is that M. africanum is adapted to infect the human 
genotypes that are predominant in West Africa. A recent study has shown an 
association between lineage 5 (MAF1) and the Ewe ethnic group in Ghana 
434. Similarly, a retrospective study in the US showed reported a high 
prevalence of M. africanum among US-born African Americans 435. Co-
evolution of the MTBC with the human host is supported by striking 
topological resemblances between the phylogeny of the MTBC and the 
phylogeny of human mitochondrial genomes 423. 
The Cameroon clade has emerged as the dominant genotype in much of 
West Africa, particularly the eastern parts 436-440. The reasons for the 
selection and dissemination of this genotype in West Africa remain unclear, 
highlighting the need to investigate its evolutionary origins through WGS. In 
Ghana, the Cameroon clade was most likely introduced through the south of 
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the country, where a higher proportion of infection is associated with this 
clade than in the north 441. 
The Ghana genotype (or T1 lineage) is disseminated across almost all West 
African countries 294. The evolutionary origins of this genotype remain a 
mystery and its epidemiology is not well described. However, it is the most 
prevalent genotype in Guinea 442 and evidence from Ghana and Mali 
suggests that the Ghana genotype is associated with drug resistance 441,443. 
The Beijing clade is a globally disseminated lineage that is highly 
transmissible and is associated with drug resistance 428,444-446. Although the 
prevalence of the Beijing genotype in West Africa is generally low, its 
prevalence is increasing in some countries. For example, Beijing is the most 
common genotype causing human pulmonary in Benin 447. Similarly a high 
prevalence of Beijing strains has been recorded in Senegal 448: both 
countries host large international ports.  
The animal lineages of the MTBC are associated with a wide range of host 
species 284: 
x Mycobacterium bovis (cattle) 
x Mycobacterium caprae (sheep and goats) 
x Mycobacterium microti (voles) 
x Mycobacterium mungi (mongoose) 
x Mycobacterium pinnipedii (seals and sealions) 
x Mycobacterium orygis (antelope) 
M. bovis has been found to cause human pulmonary TB in West Africa 449,450. 
Patients infected with M. bovis need special treatment, because M. bovis 
isolates are intrinsically resistant to pyrazinamide 451, which is part of the 
recommended treatment regimen for drug-sensitive TB.  
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5.1.3 Multidrug-resistant tuberculosis (MDR-TB) 
Mycobacteria are intrinsically resistant to most commonly prescribed 
antibiotics due to a thick cell envelope that serves as a barrier and to 
intracellular mechanisms that evade or deactivate antibiotics 452. This means 
that TB is usually treated with drugs specific to management of this infection. 
However, mycobacteria are able to acquire resistance to anti-TB drugs, 
through chromosomal mutations in the drug target gene, the drug target 
promoter region and/or drug activation enzymes 452.  
Multidrug resistant tuberculosis (MDR-TB) emerges through the acquisition 
of resistance in the individual patient during treatment or through 
transmission of MDR-TB from patients with active pulmonary disease. Drug 
resistance emerges through spontaneous resistance mutations that are 
selected for during intermittent exposure to sub-lethal levels of drugs. Such 
sub-optimal levels arise due to poor adherence, poor drug quality or patient-
specific pharmacodynamics 290. However, in high-burden settings, inter-
patient transmission is the main source of MDR-TB infection 453. WGS can 
reliably trace the emergence MDR-TB during treatment and can identify  on 
going transmission chains 454,455.  
Early diagnosis of MDR-TB is instrumental in ensuring successful treatment. 
MDR-TB is confirmed by antimicrobial susceptibility testing. Culture-based 
phenotypic testing is the gold standard, but it is slow and laborious. The 
WHO now recommends rapid testing, at least for rifampicin resistance, at the 
time of diagnosis 292. Molecular based techniques such as Xpert® MTB/RIF 
(Cepheid Inc.) and the Hain-MTBDR-plus kit provide rapid early diagnosis of 
MDR-TB. Whole-genome sequencing is emerging as a useful tool for 
diagnosing and guiding treatment of MDR-TB by offering early detection of 
resistance to both first- and second-line drugs 456-458. 
It is recommended that MDR-TB cases be treated with individualized 
treatment regimens guided by drug susceptibility testing 459. Unfortunately 
the global success rate for treating MDR-TB is only about 50% 460. Moreover, 
a large number of cases go undetected or unreported: e.g. in 2012 only 2% 
of the estimated cases of MDR-TB in Nigeria were reported 460. 
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5.1.4 Rationale for the WATENAM study 
In the 2016 global TB report, the WHO highlights a major shortfall in the 
annual funding on TB research and development of TB treatment 292. This 
shortfall is profound in West Africa where 12 of the 15 countries are among 
the 42 least developed countries worldwide 461. Since the year 2000, only 
The Gambia, Ghana and Nigeria have reported surveillance on the 
prevalence of TB 292. There is a paucity of data on the prevalence of drug-
resistant TB in West Africa. The vast majority of health facilities in the region 
lack the facilities for handling Mycobacterium tuberculosis, a category 3 
pathogen.  
The West African Nodes of Excellence for Tuberculosis, AIDS and Malaria 
(WANETAM) project was set up in 2008, with the aim of tackling these three 
major public health problems through sub-regional collaboration. The TB 
nodes of excellence were set up in eight countries (The Gambia, Senegal, 
Guinea Bissau, Togo, Ghana, Burkina Faso, Mali and Nigeria) with two aims: 
x To provide capacity-building through training in mycobacterial culture 
and identification to prepare the sites for clinical trials 
x To estimate the burden of drug resistance through recruitment of 
patients at tertiary health facilities and antimicrobial susceptibility 
testing 
The WANETAM coordinators have provided numerous training opportunities, 
including courses in: 
x Good clinical and laboratory practice 
x Identification, culture, storage and transport of mycobacterial isolates 
x Molecular typing and rapid detection of mycobacteria 
x Data analysis and publishing 
x Introductory bioinformatics, taught by the author 
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5.1.5 Objectives and study rationale 
I wished to exploit whole-genome sequencing to study the epidemiology of 
TB and genetics of multi-drug resistance among patients with active 
pulmonary disease in West Africa. Due to limitations in time and money, it 
was not possible to sequence all the isolates from the WANETAM sites. I 
therefore undertook a pilot study of isolates from two West African countries:  
x Nigeria, where the high burden of drug resistance makes it an ideal 
setting to study the molecular mechanisms of MDR-TB in West Africa 
x Mali, which has a well-structured hierarchy of TB reference health 
care facilities in the capital Bamako. The WANETAM dataset 
presented the opportunity to study the epidemiology of the TB in this 
city 
I used whole genomes sequencing data to: 
x Understand the genomic epidemiology of MTBC in each country 
by reconstructing the phylogeny of MTBC and classifying strains into 
the global phylogenetic lineages and families 
x Investigate the existence of inter-patient transmission by 
searching for identical or closely related strains in different patients 
x Understand the molecular mechanisms that are driving the 
emergence of dug resistance by scanning the genomes for known 
resistance inducing mutations 
x Understand the evolution of drug resistance by studying the 
patterns of resistance mutations in the context of the phylogeny 
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5.2 Methods 
5.2.1 Study sites 
The WANETAM network has coordinated TB drug resistance surveys in nine 
sites across eight West African countries (Figure 5.2): 
1. Senegal, Laboratoire Bactériologie Virologie, Le Dantec, Dakar  
2. The Gambia, National Public Health Laboratory Services, Banjul  
3. Guinea-Bissau, National Institute for Public Health, Bissau 
4. Mali, SEREFO (HIV/TB Research and Training Center) Faculté de 
Médecine, de Pharmacie et d’Odento-Stamologie, University of 
Bamako, Bamako  
5. Burkina Faso, Centre Muraz and the National TB Program, 
Ouagadougou 
6. Ghana, Korle Bu Teaching Hospital, Accra 
7. Togo, Laboratoire National de Référence des Mycobactéries, Lome 
8. Nigeria, Nigerian Institute for Medical Research, Lagos 
9. Nigeria, College of Medicine, University of Ibadan, Ibadan 
Patients with confirmed active pulmonary TB based on WHO guidelines 462 
were recruited at the study sites. Mycobacteria were cultured on site and the 
pure isolates were sent to the MRCG for viability testing and antimicrobial 
susceptibility testing to first and second line anti-TB drugs. The Joint Gambia 
Government/MRC Ethics Committee and the relevant ethical bodies in other 
participating countries approved the study protocols.  
As noted, two countries were chosen for investigation in this study: Nigeria 
and Mali. Nigeria borders Cameroon, Chad, Niger and Benin and has a 
coastal region on the Gulf of Guinea. Nigeria has implemented WHO 
recommended DOTS (Directly Observed Treatment Short-Course) since 
1996. In recent years, Nigeria has increased use of Xpert® for early detection 
of rifampicin resistance 463. Despite these measures, Nigeria still has one of 
the highest burdens of TB globally and is among the six countries that 
 111 
account for 60% of the global TB burden 292. Nigeria also has the second 
largest population of HIV-positive individuals in the world 464. The rise of 
MDR-TB in Nigeria has disrupted efforts to eradicate TB.  
 
Figure 5.2 Map of West Africa highlighting the countries (in red) that participated in 
the WANETAM tuberculosis drug resistance survey. 
Nigeria was the only country in the WANETAM network with two study 
sites—Lagos and Ibadan—both in Southwest Nigeria. According to the most 
recent census figures, Lagos is the most populous city in Africa and Ibadan is 
the third most populous city in Nigeria 465. The Nigerian Institute of Medical 
Research in Lagos is the national TB reference laboratory. The Ibadan 
University College Hospital is a tertiary health care facility with designated 
facilities for culturing M. tuberculosis.  
The WANETAM survey in Nigeria revealed very high rates of MDR-TB 
(higher than WHO estimates), particularly among retreatment cases. This 
presented as an opportunity to perform an in-depth study on resistance 
mutations in this region. Furthermore patients recruited in Lagos were 
sample at multiple time points over the course of treatment. This gave us a 
rare opportunity to investigate the microevolution of the MTBC over the 
course of treatment.  
 112 
Mali is a large landlocked country that borders seven countries including 
Senegal, Algeria and Niger. Mali has a population of 15.3 million that 
consists of people from diverse ethnic backgrounds 466. The study 
participants from Mali were recruited in the capital city Bamako. Bamako is 
highly cosmopolitan and is one of the fastest growing cities in Africa. Bamako 
has a population of about 2 million people and is divided into six districts. 
Each district has a TB referral health centre, equipped with diagnosis and 
treatment facilities. Our isolates were collected at the University Teaching 
Hospital, which acts as the principal TB referral centre. Retreatment cases 
from across Mali are referred to the University Teaching Hospital for further 
investigation and treatment. The Malian Ministry of health reported that in 
2014 more than a third of all TB cases in Mali were managed in Bamako 467. 
The Mali dataset offered an opportunity to study the molecular epidemiology 
of the MTBC in Bamako since all the referral health centres report to the 
central teaching hospital. From the WANETAM survey the prevalence of 
MDR in Mali was low among new cases, but very high among retreatment 
cases. Through WGS we set out to study the on going transmission of TB 
between patients in Bamako and to establish whether MDR-TB among 
retreatment cases was associated with a particular genotype.   
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5.2.2  Study isolates and workflow 
Mycobacterial isolates were sent to the MRCG laboratories from Mali, Ibadan 
and Lagos (Table 5.1). Isolates were tested for viability and antimicrobial 
susceptibility testing to the first-line drugs isoniazid, rifampicin, ethambutol 
and streptomycin. MDR-TB strains were further tested for susceptibility to the 
second-line agents fluoroquinolones, kanamycin, capreomycin and 
ethionamide (Table 5.2). For whole genome sequencing isolates were sub-
cultured on Middlebrooks 7H9 liquid medium for 3-8 weeks and genomic 
DNA was extracted using the cetyl-trimethylammonium-bromide method 
(Section 2.2.2). Whole-genome sequencing was performed on the Illumina 
MiSeq using Nextera XT library kits. 
The datasets from Mali and Nigeria were analysed separately due to 
differences in sampling strategy. The datasets comprised of: 
x Seventy-five isolates (43 MDR and then 32 non-MDR) that were 
selected at random from 177 archived Nigerian isolates for whole-
genome sequencing. Sequencing failed for two isolates from Nigeria 
so only 73 isolates were followed up. These isolates had been 
recovered from 63 patients (21 and 42 from Ibadan and Lagos 
respectively), with some patients supplying multiple isolates (Tables 
5.3 and 5.4).  
x Seventy-eight isolates that were selected at random from 208 
archived Malian isolates for whole-genome sequencing (Tables 5.3 
5.5). All originated from distinct patients. Two sequenced isolates from 
Mali had no patient metadata or antimicrobial susceptibility profiles.  
Detailed methods are provided in Chapter 2 but the workflow for 
bioinformatics analyses is shown in Figure 5.3. This workflow included the 
characterisation of strains based on their phylogenetic lineage and 
genotypically predicted antimicrobial susceptibility profiles. For each dataset 
a detailed phylogenetic analysis was performed that probed for on going 
transmission and gave insights into the evolution of drug resistance in 
tuberculosis infection.  
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Table 5.1 Summary of patient information for isolates that were collected as part of 
the WANETAM drug resistance survey in Mali, Ibadan and Lagos. 
    Mali Nigeria Ibadan Nigeria Lagos 
    No. % No. % No. % 
 Total 208 - 57 - 120 - 
Treatment 
History 
New  150 72 13 23 28 23 
Retreatment 58 28 44 77 88 73 
Unknown 0 0 0 0 4 3 
Age 
0-14 4 2 3 5 1 1 
15-24 50 24 6 10 16 14 
25-34 78 38 21 37 45 39 
35-44 38 18 15 26 32 28 
45-54 21 10 8 14 12 10 
55-64 11 5 2 4 9 8 
65+ 6 3 2 4 1 1 
Unknown 0 - 0 - 4 - 
Sex 
Female 51 25 23 40 54 46 
Male 157 75 34 60 63 54 
Unknown 0 - 0 - 3 - 
HIV 
Negative 172 83 42 74 46 38 
Positive 29 14 4 7 27 23 
Unknown 7 3 11 19 47 39 
 
Table 5.2 Prevalence of MDR-TB in Mali and Nigeria (Ibadan and Lagos) from the 
WANETAM survey stratified by patient treatment history. 
Study Site Treatment history 
Total MDR 
 n %  
Mali 
All 208 39 19 
New 150 5 3 
Retreatment 58 34 59 
Nigeria Ibadan 
All 57 17 30 
New 13 0 0 
Retreatment 44 17 39 
Nigeria Lagos 
All 120 71 59 
New 28 9 32 
Retreatment 88 58 66 
unknown 4 4 100 
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Table 5.3 Patient data for all genome-sequenced isolates from Mali, Ibadan and Lagos. 
  
Mali Ibadan Lagos 
  
MDR Non-MDR MDR Non-MDR MDR Non-MDR 
Total 
 
12 64 6 15 30 12 
HIV Status 
Negative 11 51 6 15 21 8 
Positive 1 6 0 0 7 4 
Not Done 0 7 0  0 2 0 
Gender Female 2 19 4 3 11 6 
Male 10 45 2 12 18 6 
Treatment 
History 
New 3 58  0 8 4 4 
Retreatment 9 6 6 7 21 1 
Failure 0  0 0 0 2 3 
Relapse 0 0 0  0 2 4 
Age 
(years) 
0-15 1 2 0 1 1 1 
16-30 5 30 1 6 10 1 
Above 30 6 32 5 8 18 10 
 
Table 5.4 Metadata for MTBC isolates from Nigeria that were genome-sequenced. 
ID Site MDR preXDR XDR StudyCase HIV Age Sex Date 
NG46 IBADAN  R S S Retreatment -ve 35 F  1/8/2012 
NG64 IBADAN  R R S Retreatment -ve 23 F  3/8/2012 
NG68 IBADAN  R S S Retreatment -ve 42 M  7/8/2012 
NG70 IBADAN  R S S Retreatment -ve 47 M  1/8/2012 
NG44 IBADAN  R S S Retreatment -ve 34 F  7/8/2012 
NG45 IBADAN  R S S Retreatment -ve 49 F  1/8/2012 
NG88 IBADAN  S   New -ve 40 M  7/8/2012 
NG47 IBADAN  S   New -ve 38 F  7/8/2012 
NG62 IBADAN  S   New -ve 44 M  7/8/2012 
NG81 IBADAN  S   New -ve 25 F  7/8/2012 
NG82 IBADAN  S   New -ve 7 M  7/8/2012 
NG89 IBADAN  S   New -ve 33 M  7/8/2012 
NG84 IBADAN  S   New -ve 41 M  7/8/2012 
NG69 IBADAN  S   New -ve 77 M  7/8/2012 
NG61 IBADAN  S   Retreatment -ve 51 M  1/8/2012 
NG65 IBADAN  S   Retreatment -ve 29 F  1/8/2012 
NG80 IBADAN  S   Retreatment -ve 47 M  3/8/2012 
NG83 IBADAN  S   Retreatment -ve 17 M  1/8/2012 
NG85 IBADAN  S   Retreatment -ve 27 M  1/8/2012 
NG86 IBADAN  S   Retreatment -ve 28 M  3/8/2012 
NG67 IBADAN  S   Retreatment -ve 30 M  1/8/2012 
NG36 LAGOS R S S  NA    3/11/2012 
NG55 LAGOS R S S  NA   12/27/2011 
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NG6 LAGOS R S S Failure -ve 28 F 12/27/2011 
NG9 LAGOS R S S Failure -ve 58 M 12/27/2011 
NG12 LAGOS R S S New -ve 36 F 12/27/2011 
NG13 LAGOS R S S New -ve 12 F 12/27/2011 
NG25 LAGOS R S S New +ve 40 M  3/11/2012 
NG2 LAGOS R S S New -ve 28 M 3/26/2012 
NG10 LAGOS R S S Relapse +ve 18 F 12/27/2011 
NG16 LAGOS R S S Relapse +ve 41 M 12/27/2011 
NG42 LAGOS R S S Relapse -ve 31 M 12/27/2011 
NG1 LAGOS R S S Retreatment +ve 41 M 7/17/2013 
NG14 LAGOS R R S Retreatment -ve 30 F 7/17/2013 
NG18 LAGOS R S S Retreatment -ve 41 M 7/17/2013 
NG22 LAGOS R S S Retreatment -ve 30 M 7/17/2013 
NG23 LAGOS R S S Retreatment -ve 58 M  3/11/2012 
NG24 LAGOS R S S Retreatment -ve 36 M  3/11/2012 
NG26 LAGOS R R S Retreatment -ve 35 M  3/11/2012 
NG3 LAGOS R S S Retreatment -ve 30 M 7/17/2013 
NG31 LAGOS R S S Retreatment -ve 33 M 7/17/2013 
NG32 LAGOS R R S Retreatment -ve 26 F  3/11/2012 
NG54 LAGOS R R S Retreatment -ve 26 M  3/11/2012 
NG15 LAGOS R S S Retreatment +ve 35 M  3/11/2012 
NG30 LAGOS R S S Retreatment -ve 57 F 7/17/2013 
NG34 LAGOS R S S Retreatment -ve 57 F  3/11/2012 
NG35 LAGOS R S S Retreatment -ve 57 F  3/11/2012 
NG21 LAGOS R S S Retreatment -ve 30 M 7/17/2013 
NG17 LAGOS R S S Retreatment -ve 50 F 7/17/2013 
NG4 LAGOS R S S Retreatment +ve 41 M 7/17/2013 
NG43 LAGOS R S S Retreatment +ve 41 M  3/11/2012 
NG19 LAGOS R S S Retreatment NA 32 F 7/17/2013 
NG29 LAGOS R S S Retreatment -ve 28 M  3/11/2012 
NG28 LAGOS R S S Retreatment -ve 35 F  3/11/2012 
NG33 LAGOS R S S Retreatment +ve 45 M  3/11/2012 
NG37 LAGOS R S S Retreatment +ve 45 M  3/11/2012 
NG38 LAGOS R S S Retreatment -ve 23 M  3/11/2012 
NG5 LAGOS R S S Retreatment +ve 50 F  3/11/2012 
NG72 LAGOS S   Failure -ve 23 M 12/27/2011 
NG79 LAGOS S   Failure +ve 41 M 12/27/2011 
NG39 LAGOS S   Failure -ve 15 F 12/27/2011 
NG40 LAGOS S   Failure -ve 15 F 12/27/2011 
NG50 LAGOS S   New +ve 46 F 12/27/2011 
NG76 LAGOS S   New +ve 31 F 12/27/2011 
NG51 LAGOS S   New -ve 38 M 12/27/2011 
NG52 LAGOS S   New -ve 32 F 12/27/2011 
NG75 LAGOS S   Relapse +ve 38 F 12/27/2011 
NG77 LAGOS S   Relapse +ve 38 F 12/27/2011 
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NG78 LAGOS S   Relapse -ve 36 M 12/27/2011 
NG53 LAGOS S   Relapse -ve 45 M 12/27/2011 
NG71 LAGOS S   Relapse -ve 42 F 12/27/2011 
NG74 LAGOS S S S Relapse -ve 42 F 12/27/2011 
NG90 LAGOS S   Retreatment -ve 36 M  3/11/2012 
Footnote: Table sorted by Site, then MDR status (R = resistant, S = non-MDR) and then 
Study Case to make the table more intelligible. NA is not applicable or no result available. 
Date listed is the date that patients were enrolled into the study. 
Table 5.5 Metadata for MTBC Isolates from Mali that were genome-sequenced. 
ID MDR preXDR XDR StudyCase HIV Age Sex Date 
MA154         
MA272         
MA209 R S S New -ve 42 M 02/07/14 
MA240 R   New -ve 72 M 02/07/14 
MA026 R S S New +ve 40 M 05/07/14 
MA066 R S S Retreatment -ve 21 F 05/07/14 
MA249 R S S Retreatment -ve 20 F 02/07/14 
MA059 R S S Retreatment -ve 19 M 05/07/14 
MA078 R S S Retreatment -ve 27 M 05/07/14 
MA080 R R S Retreatment -ve 33 M 05/07/14 
MA086 R S S Retreatment -ve 57 M 05/07/14 
MA089 R S S Retreatment -ve 3 M 05/07/14 
MA100 R S S Retreatment -ve 35 M 05/07/14 
MA170 R   Retreatment -ve 21 M 16/07/14 
MA008 S   New -ve 43 F 05/07/14 
MA028 S   New -ve 24 F 05/07/14 
MA057 S   New -ve 35 F 05/07/14 
MA204 S   New -ve 35 F 02/07/14 
MA207 S   New -ve 45 F 02/07/14 
MA210 S   New -ve 26 F 02/07/14 
MA215 S   New -ve 14 F 02/07/14 
MA224 S   New -ve 23 F 02/07/14 
MA225 S   New -ve 27 F 02/07/14 
MA241 S   New -ve 27 F 02/07/14 
MA242 S   New -ve 22 F 02/07/14 
MA245 S   New -ve 45 F 02/07/14 
MA246 S   New -ve 40 F 02/07/14 
MA250 S   New -ve 4 F 02/07/14 
MA003 S   New -ve 37 M 05/07/14 
MA006 S   New -ve 43 M 05/07/14 
MA009 S   New -ve 34 M 05/07/14 
MA010 S   New -ve 57 M 05/07/14 
MA016 S   New -ve 20 M 05/07/14 
MA017 S   New -ve 26 M 05/07/14 
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MA018 S   New -ve 25 M 05/07/14 
MA019 S   New -ve 47 M 05/07/14 
MA020 S   New -ve 25 M 05/07/14 
MA036 S   New -ve 25 M 03/07/14 
MA050 S   New -ve 30 M 05/07/14 
MA056 S   New -ve 28 M 05/07/14 
MA129 S   New -ve 23 M 15/07/14 
MA148 S   New -ve 39 M 15/07/14 
MA153 S   New -ve 34 M 16/07/14 
MA202 S   New -ve 55 M 02/07/14 
MA205 S   New -ve 34 M 02/07/14 
MA206 S   New -ve 20 M 02/07/14 
MA208 S   New -ve 25 M 02/07/14 
MA213 S   New -ve 27 M 02/07/14 
MA214 S   New -ve 19 M 02/07/14 
MA218 S   New -ve 35 M 02/07/14 
MA219 S   New -ve 36 M 02/07/14 
MA220 S   New -ve 35 M 02/07/14 
MA221 S   New -ve 34 M 02/07/14 
MA222 S   New -ve 29 M 02/07/14 
MA227 S   New -ve 52 M 02/07/14 
MA228 S   New -ve 21 M 02/07/14 
MA239 S   New -ve 24 M 02/07/14 
MA247 S   New -ve 25 M 02/07/14 
MA248 S   New -ve 18 M 02/07/14 
MA230 S   New +ve 42 F 02/07/14 
MA231 S   New +ve 26 F 02/07/14 
MA243 S   New +ve 26 F 02/07/14 
MA027 S   New +ve 45 M 05/07/14 
MA034 S   New +ve 36 M 05/07/14 
MA048 S   New +ve 46 M 03/07/14 
MA237 S   New NA 20 F 02/07/14 
MA229 S   New NA 37 M 02/07/14 
MA233 S   New NA 32 M 02/07/14 
MA234 S   New NA 29 M 02/07/14 
MA235 S   New NA 58 M 02/07/14 
MA236 S   New NA 23 M 02/07/14 
MA238 S   New NA 25 M 02/07/14 
MA058 S   Retreatment -ve 34 F 05/07/14 
MA067 S   Retreatment -ve 38 M 05/07/14 
MA069 S   Retreatment -ve 78 M 05/07/14 
MA070 S   Retreatment -ve 31 M 03/07/14 
MA087 S   Retreatment -ve 20 M 05/07/14 
MA096 S   Retreatment -ve 60 M 03/07/14 
Footnote: Columns were sorted by MDR status, then Study Case, then HIV status. 
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5.2.3 Workflow and bioinformatics analysis 
 
 
Figure 5.3 A schematic summary of the bioinformatics analysis for the two MTBC 
datasets from Nigeria and Mali 
WANETAM
WGSSection 2.2
Nigerian = 73
PhylogenyMapping
TransmissionInter-patient
Micro-evolutionIntra-patient
Mali n = 78
PhylogenyAssembly
TransmissionClusters
MDR-TB evolutionGhana clade
Lineage and resistanceSection 2.3.5
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5.3 Results 
5.3.1 Phylogenetic analysis of Nigerian isolates 
Sequencing reads were mapped to the H37Rv reference genome with an 
average genome coverage of 50 X (range 23 to 78). Variants were called 
from the core genome after excluding known repeat regions (Section 2.4.5.1 
and Appendix 5.1). The maximum likelihood was reconstructed from 8430 
variable sites in the core genome using RAxML with a general time reversible 
model for substitution. The phylogenetic lineage of each isolate was inferred 
by uploading the sequencing reads to kvarq, PhyResSE and TBprofiler. 
KvarQ only assigned strains into the seven global lineages while TBProfiler 
and PhyResSE assigned strains to the sub-families and clades within the 
seven global lineages. There was generally very good agreement in the 
lineage assignments of PhyResSE and TBprofiler. I noticed only two 
discrepancies: 
1. TBprofiler failed to assign strains to the Ghana genotype 
2. PhyResSe failed to assign strains to the Uganda genotype 
Consequently, the assignments of Ghana genotype are based on PhyResSE 
and the Uganda genotype assignments are based on TBprofiler. 
Lineage 4 was the dominant lineage in the dataset (56/63 cases, 88%) 
(Table 5.6 and Appendix 5.2). Within lineage 4 the Cameroon clade was the 
most common genotype (37/63 cases, 57%). The Cameroon clade strains 
clustered on a recently diverged clade, with an average pairwise distance 
within the clade of 97 SNVs in the core-genome (range: 1-195) (Appendix 
5.3). Short branch lengths within the Cameroon clade were suggestive of 
clonal expansion (Figure 5.4).  
Within the Cameroon clade, four putative inter-patient transmission events 
were identified (3 MDR and 1 non-MDR). Inter-patient transmission was 
defined based on the presence of near-identical genomes (a difference of 3 
SNVs or fewer) in two patients. Among the eight patients involved in putative 
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transmission events, six were retreatment cases, one had succumbed to 
treatment failure and only one was a new case.  
The Haarlem, X-type, Ghana, TUR, LAM, Uganda and H37Rv-like genotypes 
of lineage 4 were collectively associated with 20 cases of TB (32%). There 
was no indication that these genotypes were involved in  on going 
transmission. The closest indication of transmission was in two TUR 
genotype MDR strains from different patients that differed by 18 SNVs.  
The M. africanum sub-lineage 1 (MAF1) was isolated from six patients: five 
were MDR and one was non-MDR. Two closely related MAF1 strains that 
differed by 11 SNVs were isolated from two retreatment cases from Lagos 
and Ibadan. Although this is not definitive evidence of direct transmission 
between the two patients, it suggests that MAF1 is involved in transmission 
of MDR in this setting. The high prevalence of MDR MAF1 is probably 
because we sampled patients at referral centres where severe cases are 
managed. One patient was infected with the animal lineage M. bovis.  
Table 5.6 The prevalence of MTBC lineages and genotypes among MDR and non-MDR 
cases in Nigeria. 
Lineage Clade Total MDR Non-MDR 
M. bovis Bovis 1  1 
Lineage 4 
Cameroon 37 19 18 
Uganda 6 2 4 
Ghana 2 2  
X-type 1 1  
H37Rv 1 1  
Haarlem 3 2 1 
LAM 4 2 2 
TUR 2 2  
Lineage 5 West Africa 1 6 5 1 
 Grand Total 63 36 27 
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Figure 5.4 Phylogeny of 73 MTBC strains from Nigeria showing patient metadata and 
inter-patient transmission events. Branches are coloured based by lineage and tips are 
coloured based on the clade/family. Heatmap shows MDR/pre-XDR status, presence of 
fluoroquinolone resistance mutations (FQ), study case/treatment status and HIV status. 
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5.3.2 Microevolution of drug resistance in Nigeria 
To study the microevolution of drug resistance we compared resistance 
profiles of identical/near-identical strains, which formed flat branches in the 
phylogenetic tree (Figure 5.5). These included genomes recovered from the 
same patient over the course of treatment as well as those isolated from 
different patients, which I have cited as putative transmission events. Six 
patients had isolates from two time points during treatment genome-
sequenced and two patients had isolates from three time points genome-
sequenced. Three instances were observed where microevolution influenced 
the susceptibility profiles of strains: 
x NG9 and NG23; two patients enrolled in Lagos in 2011 and 2012. 
Both were MDR strains, but NG23 isolate acquired katG mutation 
L587P 
x NG1 and NG31; two patients from Lagos. Both MDR, with canonical 
mutations in embB. NG1 acquired a mutation in the embA promoter, 
so became ethambutol resistant, while NG31 was ethambutol 
susceptible 
x NG16, NG43, NG4 were from the same patient on treatment. All were 
MDR, but fluoroquinolone-susceptible on phenotypic testing. However 
the most recent isolate, NG4, acquired a low-level fluoroquinolone-
resistance mutation in the gyrB gene 
To confirm whether the samples were from the same patient or different 
patients the lab numbers of these strains were sent to our collaborators at 
the National Institute for Medical Research in Lagos for confirmation. Due to 
patient confidentiality the patient names are not presented as part of this 
thesis. NG39 and NG40 were isolated from the same patient at different time 
points. Both strains were susceptible to all first-line drugs by phenotypic 
testing. However, both strains bore katG and rpoB mutations that confer 
isoniazid and rifampicin respectively. It is unclear why this discrepancy was 
observed but a sample mix-up cannot be ruled out. 
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Figure 5.5 Microevolution of MTBC strains from Nigeria within patients during treatment and between patients during putative transmission. 
Phylogeny is shown in the context of antimicrobial susceptibility profiles.
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5.3.3 Molecular basis of resistance in Nigeria 
Phenotypic testing identified 39 cases as MDR, five of them pre-XDR (Figure 
5.4). Almost all isoniazid-resistant strains carried a mutation in katG or inhA; 
mutations at codon 315 of katG were the commonest cause of isoniazid 
resistance, but mutations in the aphC and inhA promoter regions also 
contributed. All rifampicin-resistant isolates carried at least one resistance 
mutation in rpoB. In two cases, a mutation in rpoB was complemented by an 
apparent epistatic mutation in rpoC (Figure 5.6). 
A clonally expanding sub-clade within our Cameroon clade was associated 
with a synonymous SNP at codon 241 of the katG gene (codon change 
CCC/CCG; katG P241P), which we have included in our analysis of potential 
resistance-associated mutations 468 (Figure 5.6). However, this mutation was 
present in both isoniazid-resistant and sensitive strains and, so, although 
epidemiologically informative, it is unlikely to be causally associated with 
resistance. However, it is worth noting that some MDR isolates lack any 
other mutations in katG, suggesting that there may be cryptic genotypic 
changes causing resistance.  
All pre-XDR strains were resistant to fluoroquinolone due to mutations in 
gyrA. Three MDR strains were susceptible to fluoroquinolone by phenotypic 
testing, but bore mutations in gyrA or gyrB. One strain had the ttyl N236K 
and the gyrA D94H resistance mutations, suggesting XDR-TB. However, this 
strain was susceptible to both second-line agents on phenotypic testing.  
In this dataset, accumulation of mutations in the embCAB operon led to 
phenotypic resistance to ethambutol. However, mutations at codons 306, 497 
and 406 in embB were detected in both ethambutol-resistant and 
ethambutol-sensitive isolates. Curiously, only 12 out of 29 (41.4%) cases of 
streptomycin resistance were associated with a known resistance mutation. 
Phenotypic resistance profiles are presented alongside predicted genotypic 
resistance profiles for all strains in Appendix 5.4. 
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Figure 5.6 The molecular mechanisms of isoniazid and rifampicin resistance among 
Nigerian MTBC strains in the context of phylogeny. Phylogenetic tree linked to a 
heatmap showing the phenotypic resistance profiles and the presence/absence of known 
resistance mutations. 
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5.3.4 Phylogenetic analysis of Malian isolates 
SPAdes assemblies from each strain were mapped against the H37Rv 
genome and placed in a multiple sequence alignment. Using custom Perl 
scripts, variants were called from the core genome after excluding repeat 
regions (Full a alignment Appendix 5.5). The maximum likelihood phylogeny 
was reconstructed from 8508 variant core genome sites. All the modern 
human-associated lineages of MTBC (2,3 & 4) were detected among patients 
from Mali (Table 5.7) (Lineage assignments Appendix 5.6).  
The dominant lineage was the Euro-American super lineage, Lineage 4. 
Within lineage 4, the Cameroon lineage was the most prevalent genotype 
(25.6%). Strains within the Cameroon clade, including a MDR-TB strain, 
formed three distinct clusters. Notably, 44% of patients were infected with 
strains belonging to the related genotypes Ghana, Haarlem and X-type. 7/12 
MDR-TB strains belonged to the Ghana genotype. The LAM genotype was 
recovered from 6 patients but none were MDR-TB. 
Six patients were infected with MAF2 strains, but none were MDR. Five 
patients were infected with strains belonging to the Beijing clade. These 
strains formed a tight cluster with short branches. Four patients were infected 
with EAI strains but the long branches separating these strains suggest that 
the EAI strains were not epidemiologically linked. 
Table 5.7 The prevalence of MTBC lineages and genotypes among MDR and non-MDR 
cases in Mali. 
Lineage Clade Total MDR Non-MDR 
Not 
tested 
2 Beijing  5 1 3 1 
3 EAI  4 1 3 
 
4 
 Cameroon  20 2 18 
 Ghana  16 7 9 
 H37Rv  2 1 1 
 Haarlem  10 0 10 
 LAM  6 0 6 
  Uganda  1 0 1 
 X-type  8 0 8 
 6 MAF2 6 0 5 1 
 
Total  78 12 64 2 
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5.3.5 Transmission clusters in Mali 
In the absence of patient epidemiological data it was not possible to 
reconstruct chains of transmission. However, it was possible to detect 
clusters of strains that were likely to be part of a transmission network based 
on genomic similarity. Transmission clusters were defined as five or more 
strains that clustered in a clade characterised by short branches and a highly 
conserved core genome (on average <25 SNVs difference between strains) 
(Appendix 5.7). The phylogenetic tree suggested that there were three 
transmission clusters within the dataset (Figure 5.7): 
x A sub-clade of 13 Ghana clade strains clustered on a recently 
divergent branch. On average, strains within this cluster differed by 12 
core-genome SNVs. The most divergent pair of strains within this 
cluster differed by 24 core genome SNVs. Within this transmission 
cluster there was an MDR sub-cluster and a non-MDR sub-cluster 
x Eight non-MDR Cameroon clade strains formed a cluster on a recently 
divergent branch. The average pairwise distance for strains within this 
cluster was 7 core genome SNVs and the most divergent strains 
differed by 13 core genome SNVs. This cluster represented the most 
conserved transmission cluster in this dataset 
x The five Beijing strains formed a monophyletic clade with a within-
clade pairwise distance of 21 core-genome SNVs. The pairwise 
distance between strains within this cluster ranged from 11 to 30 core 
genome SNVs. The Beijing cluster was less conserved than the 
Ghana and Cameroon genotype clusters  
Two sporadic cases of inter-patient transmission involving non-MDR strains 
were noted (Figure 5.7): 
x Identical LAM genotype strains were isolated from two new cases 
(MA245 & MA246)  
x Identical Cameroon clade strains were recovered from two new cases 
(MA242 & MA243). They differed from a third strain MA224 by six 
core genome SNVs 
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Figure 5.7 Phylogenetic tree for the Malian the MTBC dataset showing patient 
metadata and highlighting transmission clusters. Tree is linked to a heatmap showing 
MDR status, study case/treatment status and HIV status. Transmission clusters are 
highlighted in a grey oval. Branches are coloured by lineage and tips were coloured by 
clade. 
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5.3.6 Evolution of MDR in the Ghana clade 
To understand the evolution of drug resistance among Ghana genotype 
strains the phylogeny of the Ghana genotype transmission cluster was 
visualized in the context of the antimicrobial susceptibility profiles (Figure 
5.8). PhyResSE predicted resistance to anti-TB drugs based on the presence 
of known resistance mutations (Appendix 5.8). The phylogenetic topology of 
strains within the transmission cluster suggests that the MDR sub-cluster 
emerged from the non-MDR sub-cluster and then evolved through clonal 
expansion.  
The ancestral clone of the MDR sub-cluster probably acquired the katG 
S315T isoniazid resistance mutation, since it was conserved in all strains 
within the MDR sub-cluster. Moreover, within the MDR sub-cluster MA058 
was resistant to isoniazid but susceptible to rifampicin. Other strains in the 
MDR sub-cluster developed rifampicin and ethambutol resistance through 
acquisition of different resistance mutations. Within the non-MDR cluster only 
MA016 was mono-resistant to rifampicin, the other strains were susceptible 
to all first-line anti-TB drugs and MA250 & MA248 were identical. 
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Figure 5.8 The evolution of MDR-TB among Ghana genotype strains in Mail. The phylogeny of the Ghana genotype transmission cluster is shown in the 
context of antibiotic resistance profiles. 
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5.3.7 MDR risk factor analysis 
In the full Malian WANETAM dataset, 59% of the MDR strains were isolated 
from retreatment cases. This observation was significantly higher than the 
prevalence rate estimated by the WHO. In the dataset subjected to whole-
genome sequencing, 9 out of 12 MDR strains were recovered from 
retreatment cases. Seven of the twelve MDR strains belonged to the Ghana 
genotype; all but one of these were retreatment cases.  
To determine whether there was an association between the Ghana 
genotype and/or retreatment with MDR-TB in Mali, a regression analysis was 
performed using the Chi Squared test. The test evaluated whether the odds 
ratio of a strain being MDR if it belonged to the Ghana genotype was 
significant. The analysis was adjusted for age and study case. 
The results show that Ghana genotypes strains were 9 times more likely to 
be MDR than other genotypes in this setting (Table 5.8). After adjusting for 
age and study case it was estimated that Ghana genotype strains were still 6 
time more likely to be MDR. Retreatment cases were approximately 30 times 
more likely to be MDR compared to new cases. The number of retreatment 
cases was low (15/78), which probably explains why the confidence intervals 
for the retreatment odds ratio are so wide. 
 
Table 5.8 Risk factor analysis for MDR-TB in Mali. Regression analysis showing the 
relationship between MDR and Ghana genotype strains or retreatment cases by the Chi 
squared test. P value <0.05 = significant. 
 Factor Observation 
Odds 
ratio 
Standard 
Error P value 95% CI 
Cr
ud
e Genotype 
Other 1.00    Ghana 8.87 6.09 0.001 2.30 - 34.06 
Study 
case 
New 1.00    Retreatment 30 23.77 0.00 6.35 - 141.76 
Ad
ju
st
ed
 
Genotype Other 1.00    Ghana 5.77 5.03 0.044 1.05 - 31.86 
Study 
case 
New 1.00    Retreatment 22.35 18.70 0.00 4.34 - 115.25 
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5.4 Discussion 
5.4.1 Diversity of TB: Nigeria versus Mali 
The Euro-American super-lineage was dominant in all our study sites. In 
Bamako, two other “modern” lineages, Beijing and EAI, were also detected. 
The M. africanum lineages MAF1 and MAF2 were detected in Southwest 
Nigeria and Bamako respectively. The geographic restriction of these two 
lineages to West Africa has been documented 431. The animal lineage M. 
bovis has been previously reported in both Mali and Nigeria 449,450. We report 
one only case of M bovis infection that occurred in Ibadan. Prevalence of M. 
bovis is higher in regions where cattle are more widespread. All our study 
sites were in urban cities where contact with cattle is minimal.  
Our data shows that the diversity of MTBC isolates in Bamako, towards the 
northwest of the West African region, is greater that the diversity in Ibadan 
and Lagos, towards the Gulf of Guinea. This is in line with the most recent 
analysis on the phylogeography of the MTBC in West Africa by Gehre et. al. 
294. Furthermore, in Southwest Nigeria evidence of  on going transmission 
and clonal expansion was found only in the Cameroon clade. However, in 
Bamako there was evidence of  on going spread not just of Cameroon-clade 
strains but also of the Ghana genotype and Beijing strains.  
As its name suggests, the Cameroon clade is believed to have emerged in 
Cameroon and has now spread throughout much of West Africa 439: it has 
been reported as the most dominant genotype in Nigeria, Ghana, Burkina 
Faso, Chad and Cameroon 436,438,440,469,470. Nigeria is probably the largest 
reservoir of the Cameroon clade genotype 439. However, our data suggests 
that the prevalence of the Cameroon clade in Bamako is increasing rapidly. A 
recent survey based on strains collected between 2006-2010 estimated the 
prevalence of Cameroon strains to be 10% 443. This figure has more than 
doubled based on our dataset. The reasons for the selection and 
dissemination of the Cameroon clade in West Africa remain unclear, but 
perhaps will become clearer with additional WGS studies. 
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Although the Ghana genotype, also known as the T1 clade, has been 
replaced by the Cameroon clade as the most abundant genotype in Bamako 
443, it remains comparable in prevalence. Our data confirms previous reports 
that the Ghana genotype is associated with MDR-TB 440,443. Among our 
isolates, this association appears to have been driven by emergence of a 
sub-clade of the Ghana genotype, carrying the katG S315T isoniazid-
resistance mutation. In Lagos, an MDR Ghana-genotype isolate acquired a 
fluoroquinolone-resistance mutation over the course of treatment. As more 
strains belonging to this genotype are genome-sequenced, the evolutionary 
mechanisms driving its association with drug resistance will be unravelled. 
There is a paucity of data on the prevalence of Beijing strains in sub-Saharan 
Africa. Reviews published from the 2000s suggest that the Beijing strains 
were rarely found in sub-Saharan Africa 471. In 2008, two cases of TB in 
Bamako were due to unrelated Beijing strains 472. Our data shows that 
Beijing strains are on the rise in Bamako through clonal expansion of drug 
susceptible strains. Introduction of Beijing strains in Cape Town was followed 
by a rapid increase in prevalence 473,474. Similarly, recent evidence shows 
that the Beijing strain was introduced in Afghanistan during the Soviet 
invasion in the 1980’s and has continued to evolve and spread with human 
migration since 475. It is imperative to closely monitor the rise in prevalence of 
Beijing strains in Bamako and other parts of West Africa, given this clade’s 
propensity for increased virulence, high transmissibility and resistance. 
Despite reports of a diminished presence in Cameroon 476 M. africanum is 
still an important cause of TB in West Africa 294,439,440,477. Although we have 
not found any recent inter-patient transmission events involving MAF1 in 
Nigeria, our findings do suggest that multidrug resistant MAF1 isolates have 
been transmitted in this setting during the recent past. There was no 
evidence of direct transmission of MAF2 strains isolated from patients in 
Bamako and none of the strains were MDR. The high prevalence of MDR 
among MAF1 strains from Nigeria (5/6) is probably because we sampled 
patients from retreatment centres in a high MDR-TB burden setting. 
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5.4.2 Impact of MDR transmission on TB control 
Globally the burden of MDR-TB is increasing, especially in low-resource 
settings 292. This increase is driven largely by the transmission of MDR-TB 
especially in high-TB-burden regions 453. Effective TB control strategies 
deliver prompt identification of cases and adequate treatment 478. Correct 
administration of treatment renders the patient non-contagious and 
completion of treatment results in a high cure rate 478. It is encouraging to 
see a decrease in the prevalence of MDR-TB in countries that have 
implemented effective TB control programs 479 
In Bamako, retreatment cases are referred to the central teaching hospital for 
antimicrobial susceptibility testing and adequate treatment. However, it is 
unclear whether the peripheral health facilities are equipped to perform 
antimicrobial susceptibility testing. Failing to diagnose MDR would lead to 
treatment failure on the standard regimen for drug-susceptible TB.  
In Nigeria, culture facilities are also scarce, in part because of the stringent 
biosafety requirements. Funding and resources need to be directed to 
provide adequate diagnostic facilities in low-resource settings where the 
burden of B is highest. Measures need to be taken to stem the spread of 
MDR-TB in West Africa. Policy makers are encouraged to consider social 
intervention such as sensitisation campaigns, improved affordable housing 
and improved sanitation. 
5.4.3 Usefulness of rapid molecular testing for drug 
resistance in high burden settings 
Early diagnosis of MDR-TB can be instrumental in ensuring treatment 
success. The WHO recommends rapid testing, at least for rifampicin 
resistance, at the time of diagnosis 292. The implementation of Xpert® 
MTB/RIF (Cepheid Inc.) for rapid detection of Mycobacterium tuberculosis 
complex (the MTBC) and rifampicin resistance has been intensified in Nigeria 
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to good effect 463,469. However, Xpert® probably needs to be complemented 
with additional resistance testing 480.  
The Hain MTBDR plus kit is a rapid tool for early detection of drug resistance 
in the MTBC using molecular probes. In Bamako, the Hain kit would be 
adequate for detecting the MDR Ghana genotype cluster since it has probes 
for detecting the katG S315T isoniazid-resistance mutations. In Nigeria, the 
Hain kit is unlikely to be sufficient to rule out isoniazid resistance due to the 
presence of rare isoniazid resistance mutation in the katG gene and in gene 
promoter region. In Nigeria, there appears to be an emerging pre-XDR TB 
problem driven by fluoroquinolone resistance. The Hain kit also offers early 
detection of fluoroquinolone. 
5.4.4 Need for genomic surveillance of TB across 
West Africa 
West African health authorities may wish to consider a move towards routine 
in situ use of bacterial WGS for characterisation of TB isolates. WGS offers 
early detection of resistance to both first- and second-line drugs, making it 
useful for diagnosing and guiding treatment of MDR-TB 457,481,482. User-
friendly web tools such as PhyResSe and TBProfiler are available for 
inferring the phylogenetic lineages and drug-resistance profiles of the MTBC 
isolates directly from WGS data 314,315. WGS boasts superior discriminatory 
power in delineating human-to-human transmission and it differentiates 
strains that appear identical by conventional genotyping techniques (e.g. 
spoligo typing, MIRU VNTR and IS6110 typing) 455,483. Moreover WGS offers 
insights into the evolutionary mechanisms that drive important process like 
transmission and drug resistance.  
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5.4.5 Limitations 
The samples in the WANETAM dataset were collected from patients 
recruited at tertiary referral centres. This is likely to present a sampling bias 
since strains belonging to hypervirulent lineages that are prone to resistance 
are more likely to cause chronic cases of tuberculosis disease that warrant 
referral. Consequently these samples are likely not to be an accurate 
representation of the true genomic epidemiology of MTBC in Mali and 
Nigeria. Due to the lack of patient epidemiology and social network data it 
was not possible to conclusively infer the routes of inter-patient transmission. 
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6 CHAPTER SIX: CONCLUSIONS 
6.1 The varieties of bacterial evolution 
My work has involved three bacterial species that evolve in quite different 
ways. Through genomics, I have gained valuable insights into the 
epidemiology and antimicrobial resistance patterns of each pathogen. Some 
insights have a clear and present translational impact e.g. unravelling the 
cause of a meningitis outbreak and illuminating the mechanisms of antibiotic 
resistance in MDR-TB. Others, like the evolutionary history of S. aureus in 
monkeys in The Gambia, satisfy the curiosity, but have a less direct impact 
on public health.  
The mode and tempo of evolution are known to vary between different 
bacterial species 190 and this applies to the three species studied in this 
thesis: 
x Staphylococcus aureus readily undergoes horizontal gene transfer, 
resulting in changes in the accessory genome that contribute 
significantly to its evolution 337,338. However, this data demonstrates 
the distinction between the core genome and accessory genome is 
somewhat arbitrary, as shown by the conservation of accessory 
genome components within clonal lineages. Evolution within the core 
genome of S. aureus is driven mainly by point mutations, although 
there is evidence for recombination between distantly related strains. 
Recombination events can lead to the emergence of epidemic clones 
of S. aureus e.g. a recombination event between ST8 and ST30 is 
believed to be the origin of the ST239 “hybrid lineage”, which evolved 
into a methicillin-resistant lineage 378,484. However, the full functional 
implications of recombination in S. aureus remain unclear 485. Point 
mutations in the core genome were key to reconstructing the 
phylogenetic tree and in inferring the approximate dates for host 
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species jumps. These inferences hinged on the assumption of a 
neutral evolutionary rate and a uniform mutation rate. This approach 
can be criticised for not considering the effect of variable mutation 
rates in different lineages. Nonetheless it provides a reasonable 
estimate for the timescales of the jumps from one host species to 
another. 
x Streptococcus pneumoniae is also known for its promiscuity in 
terms of acquiring foreign DNA, but also experiences very high rates 
of homologous recombination that shape its evolutionary landscape 
178. Homologous recombination proved to be the main driving force 
behind the emergence of the novel clade that drove the meningitis 
outbreak described here—over two hundred mutations were 
introduced into this lineage through recombination. These 
recombination blocks overlapped with genes that are associated with 
fitness and virulence. In S. pneumoniae, antibiotic resistance is 
mediated through point mutations as well the acquisition of genes via 
horizontal gene transfer 406. Although antibiotic resistance genes were 
detected in the novel clade, no accessory genes are conserved in this 
clade yet absent in the West African ST303 and ST217 strains. 
x Mycobacterium tuberculosis is a genetically monomorphic lineage 
devoid of horizontal gene transfer and homologous recombination 203. 
Instead, evolution within this species is driven by point mutations and 
large genomic deletions. Novel insights have emerged into the 
phylogeny of the M. tuberculosis complex in West Africa, highlighting 
inter-patient transmission and microevolution of strains within and 
between patients. Point mutations are the underlying mechanism of 
resistance to anti-TB drugs. A vast repository of known resistance 
mutations exists and resistance mutations are confirmed by 
convergent evolution in different lineages. I characterised antibiotic 
resistance in my datasets based on the presence/absence of known 
resistance mutations. This gave valuable insights into the mechanisms 
behind the emerging MDR-TB and pre-XDR-TB threat in West Africa 
293. 
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6.2 Novel insights 
Whole-genome sequencing has identified a novel clade of S. aureus, which 
colonizes Green Vervet monkeys in The Gambia. Analysis of gene 
repertoires points to gene loss as a major contributor to adaptation of the 
bacterium to a new host, the monkeys. Genomic epidemiology points 
towards to humans as the source of S. aureus in monkeys in The Gambia 
with recent anthroponotic transmission of human-associated genotypes to 
monkeys. The novel clade is believed to well before the advent of recent 
industrialisation and urbanisation. 
Quantitative PCR (qPCR) was instrumental in revealing the aetiological 
agent of the meningitis outbreak in Ghana. However, WGS went beyond 
qPCR and standard genotyping to unveil a novel serotype 1/ST303 genotype 
lineage that showed features of an outbreak strain: high clonality, low 
sequence divergence and geographic clustering in the epicentre. Comparing 
the outbreak serotype strains to previously sequenced serotype 1 strains 
from West Africa confirmed the novelty of the novel clade. This novel clade 
has probably emerged because of rapid evolution through homologous 
recombination. Genomic evidence confirmed that strains in the novel clade 
have undergone capsular switching. A likely scenario is that the novel clade 
had acquired selective traits that enhanced its dissemination among the 
unvaccinated older population. 
WGS has highlighted the gravity of the MDR-TB burden in Nigeria. MDR 
strains belonging to almost all the major genotypes of the Euro-America 
super lineage were detected in Nigeria. This widespread emergence of MDR-
TB should be treated as a public health emergency and measures must be 
taken to prevent Nigeria from becoming a reservoir for MDR-TB. This 
situation could ominously deteriorate into an XDR-TB problem. 
In Mali, the emerging MDR-TB problem appears to be driven by the Ghana 
genotype. Authorities should work towards enhancing diagnostic capacities 
across the Bamako area, so that patients are treated appropriately. Currently 
only retreatment cases are referred to the tertiary tuberculosis referral 
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hospital in Bamako. It is important that new cases are also referred for 
antimicrobial susceptibility testing to place patients on the right treatment 
regimen from the start. Mali also appears to face a rising threat from Beijing 
strains. This is a concern, given the highly virulent nature of this genotype 
and its predilection for drug resistance 486. 
My results show that MDR transmission is an  on going phenomenon in our 
setting. The confirmation of microevolution of MTBC during treatment should 
be a wake up call to health-care officials, showing the devastating 
consequences of sub-optimal treatment: worsening, now-resistant infection 
that poses an imminent threat to the public.  
6.3 Advances in microbial genomics 
It is worth pausing to consider the breathless pace of progress in this field 
that has taken place while the work described in this thesis was  on going. 
Since enrolling for my PhD in October 2013, microbial genomics has become 
increasingly accessible. The prediction of anti-TB drug resistance from the 
genome has become increasingly easier. For example, at the time of my 
upgrade in 2014, I reviewed two major studies that identified drug resistance 
mutations in MTBC through custom pipelines that detected homoplastic 
mutations in multiple lineages 156,487. I put on a brave face at the time, as the 
prospect of me reproducing a similar feat from The Gambia was farfetched. 
But today there are several publicly available user-friendly tools that can 
predict drug resistance from the tuberculosis genome, including kvarq, 
PhyResSE, TBProfiler and Mykrobe 304,313-315 and such approaches have 
now become part of routine clinical practice in Public Health England. 
The nullarbor pipeline from Torsten Seeman exemplifies the ideal approach 
for clinical and research microbiologists with basic computational skills. It can 
characterise a number of bacterial species from the sequencing reads. This 
data includes speciation, genotyping, resistance predictions, phylogenetic 
analysis and pan genome analysis. This data can then be fed into 
downstream analysis pipelines.  
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Similar considerations apply to the analysis of pan-genomes. I recall building 
my first pan-genome in 2012, which included 50 genomes of S. pneumoniae 
serotype 1. This was a painstaking experience, as I manually curated 
comparisons of each strain with the growing pan genome to build the 
accessory genome. But now ROARY has made pan genome analysis very 
accessible. All you need to do is feed it annotated genomes and it has tools 
for visualising output and for comparing sets of sequences within your 
dataset. 
Access to computational facilities has been facilitated by the advent of cloud 
computing, particularly the environment made available by the Cloud 
Infrastructure for Microbial Bioinformaticians (CLIMB) project 300. With 
CLIMB, you can now fire up a genome virtual lab that is preloaded with the 
basic bioinformatics tools you need. This circumvents the onerous task of 
setting up a Linux or Ubuntu workstation from scratch and installing a myriad 
of programs and dependencies. All you need is a stable Internet connection 
to log in from anywhere in the world and perform your analysis. 
6.4 Future prospects 
Our aim at the MRC Unit in The Gambia is to develop our unit into a regional 
centre of excellence for genomics and bioinformatics. We recently 
established a bioinformatics core platform at the unit to serve the growing 
need for big data analysis. Our genomics focus group has successfully 
lobbied MRCG leadership to invest in an Illumina Miseq and a high 
performance computer server. By 2017, we aim to perform whole genome 
sequencing and bioinformatics analysis on site in The Gambia.  
The insights gained from analysing 15 outbreak strains of S. pneumoniae 
have opened up new avenues of investigation. We are now collaborating with 
the WHO to carry out a carriage surveillance of S. pneumoniae in Ghana to 
investigate the effect of PCV-13 on the diversity of S. pneumoniae. I will be 
part of a team that analyses 3000 S. pneumoniae genomes from The 
Gambia and West Africa through the Gates pneumococcal sequencing 
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project. Through these collaborative efforts we hope to gain insights into the 
genomic epidemiology of S. pneumoniae to guide intervention strategies 
towards the elimination of this deadly pathogen as a public health problem.  
The analysis reported here of MTBC in Mali and Nigeria has paved the way 
for a more ambitious programme of research. During this PhD, I have 
created a biobank: I have barcoded and stored 400 MTBC isolates from 
across West Africa together with associated genomic DNA samples. We aim 
to create a comprehensive database for these isolates that combines 
phenotypic drug susceptibility profiles with genomic data. This database will 
be a useful tool in testing novel diagnostic tools to assess how suited they 
are for use in West Africa. Moving forward, I am keen to devote effort 
towards understanding the evolutionary origins of genotypes and lineages 
that are endemic to West Africa. The Cameroon and Ghana genotypes are 
on the rise and urgent intervention is needed to curb their rise. 
Colleagues at the MRCG continue to work on S. aureus, incorporating 
detailed studies on this dynamic pathogen into their PhD projects, using 
WGS to assess the impact of azithromycin treatment during labour on 
antibiotic resistance or to reconstruct perinatal transmission chains for S. 
aureus. 
Finally, I hope that I have convinced the reader that West Africa is now 
poised to embrace microbial genomics as a key weapon in the arms race 
between man and microbe. We Africans stand ready to turn the tide on 
infection, harnessing the force of reason and the progress of science against 
our most fearsome—but far from invincible—microbial adversaries. The 
struggle continues! A luta continua!  
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APPENDIX 
The appendix is presented on a DVD that is attached to this thesis due to the 
size of the files. If the DVD is not attached or you cannot access the 
appendix please contact me on msenghore@mrc.gm or 
madikaysenghore@gmail.com. 
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